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A B S T R A C T
Background
The burden of asthma on patients and healthcare systems is substantial. Interventions have been developed to overcome difficulties
in asthma management. These include chronic disease management programmes, which are more than simple patient education,
encompassing a set of coherent interventions that centre on the patients’ needs, encouraging the co-ordination and integration of health
services provided by a variety of healthcare professionals, and emphasising patient self-management as well as patient education.
Objectives
To evaluate the effectiveness of chronic disease management programmes for adults with asthma.
Search methods
Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Effective Practice and Organisation of Care (EPOC) Group
Specialised Register, MEDLINE (MEDLINE In-Process and Other Non-Indexed Citations), EMBASE, CINAHL, and PsycINFO
were searched up to June 2014. We also handsearched selected journals from 2000 to 2012 and scanned reference lists of relevant
reviews.
Selection criteria
We included individual or cluster-randomised controlled trials, non-randomised controlled trials, and controlled before-after studies
comparing chronic disease management programmes with usual care in adults over 16 years of age with a diagnosis of asthma. The
chronic disease management programmes had to satisfy at least the following five criteria: an organisational component targeting
patients; an organisational component targeting healthcare professionals or the healthcare system, or both; patient education or self-
management support, or both; active involvement of two or more healthcare professionals in patient care; a minimum duration of
three months.
Data collection and analysis
After an initial screen of the titles, two review authors working independently assessed the studies for eligibility and study quality; they
also extracted the data. We contacted authors to obtain missing information and additional data, where necessary. We pooled results
using the random-effects model and reported the pooled mean or standardised mean differences (SMDs).
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Main results
A total of 20 studies including 81,746 patients (median 129.5) were included in this review, with a follow-up ranging from 3 to more
than 12 months. Patients’ mean age was 42.5 years, 60% were female, and their asthma was mostly rated as moderate to severe. Overall
the studies were of moderate to low methodological quality, because of limitations in their design and the wide confidence intervals for
certain results.
Compared with usual care, chronic disease management programmes resulted in improvements in asthma-specific quality of life (SMD
0.22, 95% confidence interval (CI) 0.08 to 0.37), asthma severity scores (SMD 0.18, 95% CI 0.05 to 0.30), and lung function tests
(SMD 0.19, 95% CI 0.09 to 0.30). The data for improvement in self-efficacy scores were inconclusive (SMD 0.51, 95% CI -0.08 to
1.11). Results on hospitalisations and emergency department or unscheduled visits could not be combined in a meta-analysis because
the data were too heterogeneous; results from the individual studies were inconclusive overall. Only a few studies reported results on
asthma exacerbations, days off work or school, use of an action plan, and patient satisfaction. Meta-analyses could not be performed
for these outcomes.
Authors’ conclusions
There is moderate to low quality evidence that chronic disease management programmes for adults with asthma can improve asthma-
specific quality of life, asthma severity, and lung function tests. Overall, these results provide encouraging evidence of the potential
effectiveness of these programmes in adults with asthma when compared with usual care. However, the optimal composition of asthma
chronic disease management programmes and their added value, compared with education or self-management alone that is usually
offered to patients with asthma, need further investigation.
P L A I N L A N G U A G E S U M M A R Y
Chronic disease management for asthma
Asthma is a chronic (long-term) airway (breathing) disease affecting about 300 million people worldwide. People with asthma have
many symptoms, such as wheezing, coughing and shortness of breath. The aim of a chronic disease management programme for asthma
is to improve the quality and effectiveness of asthma care by creating a programme that is centred on patient’s needs, encourages the
co-ordination of the health services provided by healthcare professionals such as doctors and nurses, who should work together, and
focuses on helping the patients to manage their illness themselves as well as providing them with information to help them understand
their illness.
This review found 20 studies that compared the effects of chronic disease management programmes in adults with asthma with the
effects of usual care. The average age of the patients was 42.5 years, 60% were women, and they had moderate to severe asthma. Overall
the evidence that was found was of moderate to low quality.
Chronic disease management programmes for adults with asthma probably improve patients’ quality of life, reduce the severity of
the asthma, and improve breathing as demonstrated by improved performance in lung function tests after 12 months. It is unclear
whether chronic disease management programmes improve the patients’ abilities to manage their own asthma or decrease the number
of hospitalisations or emergency visits.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Chronic disease management compared with usual care for adults with asthma
Patient or population: adults with asthma
Settings: 7 studies in primary care practices, 3 in outpatient hospital departments, 3 in pharmacies, 2 in health maintenance organisations (HMOs), 5 in mixed settings
Intervention: chronic disease management
Comparison: usual care
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Usual care Chronic disease man-
agement
Asthma-specific quality
of life score
Measured on different
scales in different stud-
ies. Higher scores indi-
cate higher quality of life.
Follow-up: 3 to 12
months
The mean asthma-spe-
cific quality of life score
ranged across control
groups from
3.8 to 5.3 1
The mean asthma-spe-
cific quality of life score
in the intervention groups
was
0.22 standard deviations
higher
(0.08 to 0.37 higher)
1627
(8 studies)
⊕⊕⊕©
moderate2
A SMD of 0.22 repre-
sents a small improve-
ment in quality of life. On
the AQLQ scale, it repre-
sents a mean difference
of 0.31 (0.11 to 0.53).
MCID of AQLQ = 0.53,4
Number of hospitalisa-
tions per patient - not re-
ported
The mean number of
hospitalisations per pa-
tient ranged across con-
trol groups from 0.06 to
1.23
The mean number of hos-
pitalisations per patient
ranged across interven-
tion groups from 0.02 to
0.4
Not estimable - Not assessed;see com-
ment
Data too heterogeneous
to perform meta-analysis
Number of emergency
room or unscheduled
visits - not reported
The mean number of
emergency room or un-
scheduled visits per pa-
tient ranged across con-
trol groups from 0.02 to
1.4
The mean number of
emergency room or un-
scheduled visits per pa-
tient ranged across inter-
vention groups from 0.02
to 1.9
Not estimable - Not assessed; see com-
ment
Data too heterogeneous
to perform meta-analysis
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Asthma exacerbations -
not measured
Not assessed Not assessed Not estimable - Not assessed;see com-
ment
No data available for
meta-analysis
Self-efficacy score5
Measured on different
scales in different stud-
ies. Higher scores indi-
cate higher self-efficacy
Follow-up: 3 to 12
months
5 The mean self-efficacy
score in the intervention
groups was
0.51 standard deviations
higher
(0.08 lower to 1.11
higher)
642
(5 studies)
⊕⊕©©
low6,7
A SMD of 0.51 represents
a moderate improvement
in self-efficacy3,8
Asthma severity score5
Measured on different
scales in different stud-
ies. Higher scores indi-
cate lower severity
Follow-up: 6-12 months
The mean asthma sever-
ity score in the interven-
tion groups was
0.18 standard deviations
higher
(0.05 to 0.3 higher)
1330
(6 studies)
⊕⊕©©
low6,9
A SMD of 0.18 represents
a small improvement in
asthma severity<BR/>3,8
Days off work - not mea-
sured
Not assessed Not assessed Not estimable - Not assessed;see com-
ment
No data available for
meta-analysis
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Values correspond to the AQLQ scores only
2 Downgraded because majority of studies were at high or unclear risk of bias
3 As a rule of thumb: SMD <0.40 = small effect, SMD 0.40 to 0.70 = moderate effect, SMD >0.70 = large effect
4 The score was estimated using a SD of 1.43 (control group of Gallbreath’s study)
5 No assumed risk presented for usual groups because too much variation in the instruments or scales used
6 Downgraded because of clinical, statistical and measurement heterogeneity
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7 Wide 95% CIs
8 Back-transformation was not performed because all studies used another instrument or scale
9 Downgraded because three studies were at high risk of bias
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B A C K G R O U N D
Description of the condition
Asthma is a chronic inflammatory disorder of the airways, affecting
an estimated 300 million people worldwide (GINA 2012). The
prevalence of asthma in adults is up to 10% in developed countries,
and is currently rising (Asher 2006; Braman 2006; Masoli 2004).
Despite being a common chronic disease, it does not rank among
the 15 first projected causes of mortality or disability-adjusted life
years (Mathers 2006). Nevertheless, asthma places a substantial
burden on affected people and healthcare systems, with morbidity,
mortality, and economic burdens that have been increasing during
the last 40 years (Braman 2006).
In order to achieve effective asthma control, the Global Initiative
for Asthma (GINA) has been providing, since 2002, an evidence-
based global strategy for asthma management and prevention (
GINA 2012). However, despite the existence of effective therapies
and the development of evidence-based guidelines, there are still
significant practice variations and gaps between recommended care
and current practice (Klomp 2008; Vermeire 2002). Asthma could
be controlled, but its management remains suboptimal (Leuppi
2006; Vermeire 2002).
The difficulties in asthma management are multiple, including
poor implementation of treatment guidelines, suboptimal patient
education and self-management, poor patient adherence to treat-
ment and lifestyle modifications, neglect of preventive care, and
lack of co-ordination between healthcare providers, among oth-
ers (Latry 2008; Mäkinen 1999; Pacheco 1999; Vermeire 2002).
A variety of individual interventions have been used to address
these issues and systematically assessed. For instance, a Cochrane
review showed that self-management programmes in adult asth-
matics reduced healthcare utilisation, the number of days off work
or school, nocturnal asthma, and improved quality of life (Gibson
2003). In contrast, limited patient education (information only)
did not (Gibson 2002). Similarly, two other systematic reviews
examining the effectiveness of written asthma action plans did not
find evidence of benefit (Powell 2003; Toelle 2004). Neverthe-
less, given that the included studies were small and of low power,
experts still recommend the use of written action plans (GINA
2012; NAEPP 2007). Finally, provider level interventions such as
continuing medical education, reminder systems, or audit with
feedback yielded inconsistent results across chronic diseases (Davis
1995; Davis 1999; Weingarten 2002). The combination of all
these types of interventions is proposed in chronic disease man-
agement programmes.
Description of the intervention
Chronic disease management (CDM) was developed during the
1990s as a means of reorganising healthcare systems and medical
treatment for chronic diseases such as heart failure, diabetes, de-
pression, and chronic lung diseases. Its purpose is to enhance the
quality and cost-effectiveness of care for chronic diseases. CDM
is centred on patients’ needs, fosters the co-ordination and inte-
gration of health services provided by various professionals who
should work together (multidisciplinary care), and emphasizes pa-
tients’ self-management as well as education and empowerment.
CDM is also based on formal evidence of effectiveness and pro-
motes continuous improvement processes through quality control
(DMAA Definitions 2009; Ellrodt 1997; Epstein 1996; Faxon
2004; Hunter 1997; Kesteloot 1999; Pilnick 2001; Weingarten
2002).
Several definitions of CDM, which differ by the number and vari-
ety of elements that they integrate, have been published (DMAA
Definitions 2009; Ellrodt 1997; Epstein 1996; Faxon 2004;
Hunter 1997; Kesteloot 1999; Pilnick 2001; Weingarten 2002).
In addition, the American Heart Association’s Disease Manage-
ment Taxonomy Writing Group developed a system of classifi-
cation intended to help categorise and compare disease manage-
ment programmes (Krumholz 2006). Recently, to facilitate the
understanding and communication about the concept of CDM,
Schrijvers 2009 proposed a tentative definition of chronic dis-
ease management based on the elements found in the literature:
“[CDM] consists of a group of coherent interventions designed
to prevent or manage one or more chronic conditions using a sys-
tematic multidisciplinary approach potentially employing multi-
ple treatment modalities. The goal of chronic disease management
is to identify persons at risk for one or more chronic conditions,
to promote self-management by patients and to address the illness
or conditions with maximum clinical outcome, effectiveness and
efficiency regardless of treatment setting(s) or typical reimburse-
ment patterns” (Schrijvers 2009). Because CDM programmes
are adapted to the regional healthcare, social, and political con-
texts, they vary in terms of treatment modalities, frequency, inten-
sity, and duration. Nevertheless, several systematic reviews have
shown that CDM programmes are effective, at least for some out-
comes and some chronic diseases such as diabetes (Egginton 2012;
Elissen 2013; Knight 2005; Norris 2002; Pimouguet 2011), de-
pression (Badamgarav 2003; Neumeyer-Gromen 2004), chronic
heart failure (Gohler 2006; Gonseth 2004; McAlister 2001;
Roccaforte 2005), and chronic obstructive pulmonary disease
(COPD) (Adams 2007; Kruis 2013; Lemmens 2013; Niesink
2007; Peytremann-Bridevaux 2008), or across chronic conditions
(de Bruin 2011; Ofman 2004;Ouwens 2005; Tsai 2005). As such,
they are supported by an increasing number of healthcare sys-
tems (Busse 2004; Gogovor 2008;Montague 2007; Steuten 2007;
Stock 2006) and have been implemented throughout Northern
American and European countries during the past decade (NCSL
DMP descriptions).
Why it is important to do this review
6Chronic disease management programmes for adults with asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Asthma presents all characteristics described as mandatory for
CDM suitability (Mechanic 2002; Velasco-Garrido 2003). In-
deed, asthma CDM programmes have yielded positive results in
some studies and are considered a promising way to improve
asthma management and reduce costs (Blaiss 2005; Durbin 1997;
Steuten 2007a). Still, the effectiveness of CDM for adults with
asthma has yet to be systematically and comprehensively assessed.
One systematic review evaluating CDM programmes for patients
with asthma found that these programmes reduced resource utili-
sation and improved some aspects of self-management and organi-
sation of care, but had almost no impact on asthma symptoms and
lung function (Steuten 2007a). However, it only included studies
published betweenDecember 2005 and December 2006 and con-
sidered both adults and children with asthma. The authors also
showed that while process and outcome measures were more ap-
propriately chosen than before, structure indicators were lacking.
Two other systematic reviews published in 2009 (Lemmens 2009;
Maciejewski 2009) provided further information. The Lemmens
2009 review showed that CDM programmes targeting adults with
asthma or COPD improved quality of life and decreased the risk of
hospitalisation, especially when the interventions included three
components, but did not have any effect on emergency visits. The
authors of the other review on CDM programmes, targeting only
adults with asthma, decided not to conduct meta-analyses because
of heterogeneity andmissing information; they concluded that the
quality of studies was not optimal and that it was not possible to
decide whether CDMwould or would not be beneficial to patients
with asthma (Maciejewski 2009).
O B J E C T I V E S
Primary objective
To assess the effectiveness of chronic disease management pro-
grammes for adults with asthma.
Secondary objectives
To assess the effectiveness of chronic disease management pro-
grammes for adults with asthma according to the intensity of the
intervention (e.g., more intensive versusminimal interventions, in
terms of number of intervention components and types of compo-
nents, such as mainly centred on the patient versus on healthcare
professionals).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Eligible studies were randomised controlled trials (RCTs), non-
randomised controlled trials (NRCTs), controlled before-after
studies (CBAs), and interrupted time series studies (ITSs), allo-
cating patients or clusters. According to the guidance from the Ef-
fective Practice and Organisation of Care (EPOC) Review group
(EPOC 2013), CBA studies were eligible only if the pre- and post-
intervention periods for the study and control sites were the same;
if the study and control sites were comparable with respect to the
dominant reimbursement system, level of care, setting of care, and
academic status; and if there were aminimum of two interventions
and two control sites. ITS studies were eligible only if there was
a clear, time-defined beginning of the intervention and if there
was a minimum of three measurement points available before and
after the intervention.
The rationale for including study types other than RCTs was that
it can be difficult to implement RCTs assessing complex disease
management programmes. Additionally, this is a relatively new
research area with few RCTs.
Types of participants
We included adult participants (over 16 years of age) with a di-
agnosis of asthma. We excluded studies in which patients with
other significant pulmonary chronic disease (like moderate or se-
vere COPD or bronchiectasis) represented a significant propor-
tion of participants, unless subgroup analysis was available. In the
same way, trials including both adults and children were included
only if the majority of participants were over 16 years or if the
adult subgroup was analysed independently.
Types of interventions
Based on several definitions of disease management (DMAA
Definitions 2009; Ellrodt 1997; Epstein 1996; Faxon 2004;
Hunter 1997; Kesteloot 1999; Pilnick 2001; Weingarten 2002),
we considered the following five criteria for our operational defi-
nition of CDM:
1. at least one organisational component (i.e., elements that
interfere with the care process or that aim to improve continuity
of care) targeting patients (Steuten 2007a; Weingarten 2002);
2. at least one organisational component targeting healthcare
professionals (e.g., physicians, nurses, etc.), the healthcare
system, or both;
3. presence of a patient education or self-management support
component, or both;
4. active involvement of two or more healthcare professionals
in patient care; and
5. minimum duration of three months (or 12 weeks) for at
least one component.
Therefore, we only included CDM programmes that entirely met
the above operational definition of chronic disease management
(that is, all five criteria are compulsory). Below are listed the types
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of components that are usually proposed in CDM programmes,
adapted to asthma patients. They directly relate to the above-
mentioned five criteria.
1. At least one organisational component targeting patients (each
of the following was considered as an independent component):
• case management (defined as explicit allocation of co-
ordination tasks to a case manager or a small team who takes
responsibility for guiding the patient through the care process in
the most efficient, effective, and acceptable way);
• structured follow-up (e.g., telephone calls, regular clinic
visits, etc.) or encouragement for regular follow-up;
• home or outreach visits;
• discharge planning in the case of hospitalisation;
• advice or assistance, or both, if needed (e.g., a telephone
hotline);
• smoking cessation programmes recommended or proposed,
or both; and
• other (other components deemed compatible by all the
review authors).
2. At least one organisational component targeting primarily
healthcare professionals (for example physicians, nurses, etc.) or
the healthcare system, or both, such as:
• explicit teamwork and collaborative processes between
healthcare providers;
• physicians’ education and training (any format) or other
healthcare professionals’ education and training, or both;
• other quality improvement processes (e.g., reminder
systems, clinical pathways, routine reporting, feedback loops,
etc.);
• integration of care (i.e., continuity of care between primary,
secondary, and tertiary care);
• financial incentives;
• information technology (e.g., computerised medical
records, reminders or prompts, etc.);
• explicit use of evidence-based medicine supports (e.g., use
of evidence-based clinical practice guidelines, etc.);
• process and outcome measurements (at the patient level);
• evaluation of CDM programmes (at the group level); and
• other (other components deemed compatible by all the
reviews authors).
3. Presence of a patient education or self-management support
component, or both. Patient education was defined as giving the
patients information (materials, instructions, or both) regarding:
• asthma;
• management of the disease, its exacerbations, or both;
• prevention of exacerbations (trigger recognition and
reduction strategies);
• smoking cessation;
• exercise or physical activity.
The types of educational sessions included, for example:
• distribution of published or printed material;
• educational groups or meetings;
• one-on-one educational sessions during visits (physician,
nurses, etc.).
Self-management support was defined as helping patients acquire
the skills and knowledge to manage their own illnesses, providing
self-management tools, and routinely assessing their problems and
accomplishments (Ouwens 2005). The types of self-management
support included, for example:
• the availability of an action plan;
• so-called supervised reinforcement sessions;
• regular checks of inhalation technique.
4. Two or more healthcare professionals actively involved in the
patient care, such as:
• general or family practitioners (GPs), primary care
physicians, and general internists;
• pulmonary care physicians;
• respiratory care nurses (nurses with training in asthma
management);
• non-specialised nurses;
• physiotherapists;
• pharmacists; and
• other healthcare professionals (for example social workers).
5. Minimal duration of three months (12 weeks) for at least one
component.
CDM programmes targeting chronic diseases require long lasting
interventions, and should not be merely considered as another
treatment modality but rather as a newway to organise care imple-
mented from a long-term perspective. Therefore, they needed to
have at least one component from criteria one to three that lasted
three months or more (arbitrary cut-off point).
We compared CDM to standard care (varying from usual care to
usual care including limited CDM components).
Types of outcome measures
Throughout the text, we use the term outcome in its broad sense
to refer to the notion of dependent variable. Under that term, we
considered clinically relevant effect measures (such as patient out-
comes), process of care and intermediate measures, as well as struc-
ture indicators. These were based and adapted from a consensus
of clinically relevant outcomes of an asthma patient management
model (Clark 1994). Indicators relating to the implementation of
CDM programmes, per se, were not considered. We divided our
outcomes into two main groups: organisational and patient level
outcomes. The list of possible outcomes, as well as the 10 out-
comes selected as primary outcomes (specified in brackets) that
were considered in the analyses, are shown below. We included
7 of these 10 primary outcomes in the Summary of findings for
the main comparison, based on their clinical importance: quality
of life, hospitalisation, emergency or unscheduled visits, asthma
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exacerbations, self-efficacy, asthma severity, and days off school or
work absences.
Organisational level outcomes
• Organisation of care outcomes: participation rate for CDM
programme; healthcare professionals’ satisfaction with
programme.
• Process outcomes: use of an action plan (primary);
compliance with treatment schedule; prescription of inhaled
corticosteroids; check of appropriate inhalation techniques; and
smoking cessation advice or support, or both.
• Healthcare utilisation outcomes: asthma-related or all-cause
hospitalisation, or both, defined as any inpatient hospital stay
(primary); asthma-related or all-cause unscheduled visits, or
both, defined as urgent visits to hospital emergency departments
(ED) or unscheduled physicians visits (primary); GP visits,
defined as routine (scheduled) ambulatory care visits to a GP or
family physician; and healthcare costs (direct and indirect, if
available).
Patient level outcomes
• Quality of life: an asthma-specific quality of life instrument
(primary) such as the St-George Respiratory Questionnaire
(Jones 1991), Living with Asthma Questionnaire (LWAQ)
(Hyland 1991), Asthma Quality of Life Questionnaire (AQLQ)
(Juniper 1992); a generic quality of life instrument such as the
Short Form 36 (SF-36) (Ware 1992), SF-12 (Ware 1996), EQ-
5D (EuroQol Group 1990), or self reported subjective health.
• Symptoms and activity level: asthma exacerbations (defined
as prompting hospitalisation, ED visit, unscheduled medical
visit, or rescue systemic glucocorticoids) (primary); asthma
severity and symptoms (primary) (subjective measures that
include asthma symptoms or severity scores, or both) (e.g., the
Asthma Control Test (Nathan 2004), the Asthma Therapy
Assessment Questionnaire (ATAQ) (Vollmer 1999)); days off
school or work absences (due to asthma or other causes, or both)
(primary); nights disturbed by asthma (sleep interruptions due to
asthma or nights with asthma symptoms); days of restricted
activity; use of rescue ß2-agonists; and all-cause mortality.
• Self-management: patients’ asthma knowledge score; trigger
recognition and reduction strategies; measures of self-efficacy
and self-management (primary).
• Pulmonary function tests: forced expiratory volume in 1
second (FEV1); peak expiratory flow rate (PEF); a combined
measure of lung function, defined as either FEV1 or PEF
(primary).
• Patient satisfaction with care: measures of patient
satisfaction (or experiences) with care (primary).
To define the timing of outcomes measurements, we grouped
time points in three arbitrary intervals to represent short-term,
medium-term, and long-term outcomes (from 0 to 6 months, 6
to 12 months, and over 12 months).
Studies were excluded if none of the primary outcomes were re-
ported.
Search methods for identification of studies
Electronic searches
M Fiander, Trials Search Co-ordinator (TSC) for the EPOC re-
view group, developed search strategies in consultation with the
authors. The TSC searched the Cochrane Database of System-
atic Reviews and the Database of Abstracts of Reviews of Effects
(DARE) for related systematic reviews and the databases listed be-
low for primary studies. Searches were conducted to June 2014;
exact search dates for each database are included in the search
strategies in Appendix 1; Appendix 2; Appendix 3; Appendix 4;
Appendix 5.
• Cochrane Central Register of Controlled Trials
(CENTRAL), OvidSP.
• Cochrane EPOC Group Specialised Register (to 2012).
• MEDLINE In-Process and Other Non-Indexed Citations
(1946 on), OvidSP.
• EMBASE (1947 on), OvidSP.
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature) (1980 to 2012) , EBSCOhost.
• PsycINFO (1806 on), OvidSP.
Search strategies were comprised of keywords, when available, and
controlled vocabulary such as MeSH (Medical Subject Headings).
Two methodological search filters were used to limit retrieval to
appropriate study designs: the Cochrane highly sensitive search
strategy (sensitivity- and precision-maximizing version, 2008 revi-
sion) (Higgins 2011) to identify RCTs, and an EPOC methodol-
ogy filter to identify non-RCT designs. Language restrictions were
not applied.
Searching other resources
We conducted handsearches of selected journals from 2000 to
2012. We also performed handsearching of reference lists of re-
trieved papers and relevant narrative or systematic reviews. To
identify new and ongoing trials, we searched www.clinicaltrials.org
and www.controlled-trials.com/mrct.
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Data collection and analysis
Selection of studies
We used a three-step study screening procedure. First, based on
titles only, one review author (CA, GG or IPB) excluded obviously
non-pertinent references. These excluded references were double-
checked by a second review author (CA, GG or IPB) to approve
the exclusions. Then, based on abstracts, two review authors (CA,
GG, POB or IPB) independently, and in duplicate, excluded pre-
viously retained articles if they represented a non-original study,
were obviously not focused on asthma, were obviously not on
chronic disease management, or were clearly on another topic. Fi-
nally, articles deemed potentially relevant by any review author had
their full texts assessed for eligibility by two review authors (CA,
GG, POB or IPB). Reasons for excluding studies based on the full-
text assessment are described in the Characteristics of excluded
studies table. Any disagreement about eligibility was resolved by
discussion between the review authors and with the involvement
of an arbitrator as necessary. Multiple published articles from a
single study were treated as a single intervention evaluation. Be-
cause chronic disease management programmes were developed
and first described in the early 1990s, studies from 1990 onwards
were selected. In addition, since we were interested in the effective-
ness of chronic disease management in adult asthmatic patients
(16 years and over), we selected studies involving adults. The latter
limit did not, however, exclude studies including both adult and
non-adult patients (< 16 years of age).
Data extraction and management
Two review authors (CA, GG or IPB) independently, and in du-
plicate, extracted data from selected studies using a tailored extrac-
tion form based on the generic Cochrane EPOC Review Group
data collection checklist (EPOC 2013a). Any disagreement was
resolved by discussion and if disagreement persisted an arbitrator
was involved, as necessary. Where required, we sought additional
information by contacting corresponding authors.
Asthma severity was determined by study self-report, examination
of FEV1 and PEF, or chronicity of asthma symptoms at baseline.
Patients were categorised as having severe asthma if they had a
mean FEV1 or PEF less than 0.6 of the predicted value, or if they
reported daily asthma symptoms (Bateman 2008).Whenever pos-
sible, we categorised study populations as ’moderate to severe’ if
asthmatics with severe asthma were enrolled in the study popula-
tion, and ’mild to moderate’ otherwise.
Assessment of risk of bias in included studies
Two review authors (CA, GG or IPB) independently assessed
the methodological quality of the included studies using the sug-
gested risk of bias criteria for EPOC reviews (EPOC2013b). Each
individual component (sequence generation, allocation conceal-
ment, blinding of outcome assessment, completeness of outcome
data, selective outcome reporting, baseline characteristics, base-
line outcomes measurements, protection against contamination,
and other sources of bias) was explicitly rated and categorised as
being at low, unclear, or high risk of bias. Any disagreement was
resolved by discussion or involvement of an arbitrator, or both. If
necessary, we contacted study authors for additional information
or clarification of the study methods. The same risk of bias table
was used for all study designs considered in the review.
For sensitivity analyses, a summary assessment of the risk of bias of
each study was done using one key domain of a study level entry
(allocation concealment) and one key domain of an outcome level
entry (incomplete outcome data) of the core Cochrane Collabo-
ration tool. Studies were considered to be at: low risk of bias (high
quality) if the two key domains were at low risk; at unclear risk of
bias (moderate quality) if at least one of the key domains was at
unclear risk and none at high risk; at high risk of bias (low quality)
if at least one of the key domains was at high risk of bias.
Measures of treatment effect
In trials reporting score outcomes, we considered the results of the
overall score if available.When not available, we selected one score
or dimension of the scale as the representative outcome or calcu-
lated the average score if possible. If authors reported outcomes
at more than one follow-up period, we selected the period of fol-
low-up that matched the end of the intervention. The direction
of the effect size was standardised so that a positive difference in-
dicated improvement in the intervention group. Results of count
data (that is, hospitalisations and ED or unscheduled visits) were
treated as rate ratios.
For RCTs and NRCTs, we reported results of dichotomous out-
comes as odd ratios (OR) and results of continuous outcomes as
mean differences (MD) or standardised mean differences (SMD)
if outcomes related to scores, using post-intervention (follow-up)
values. We used the latter because there were more studies re-
porting these values and corresponding standard deviations (SD)
compared to change from baseline values. In addition, because the
number of patients at baseline and follow-up were often not the
same, change scores for individual studies could not be calculated
by hand. Sensitivity analyses, using change from baseline values
and change from baseline SDs, were conducted to assess the ro-
bustness of results according to the choice of MD estimates if data
permitted.
Standardised effect sizes, which were calculated for continuous
measures by dividing the difference in mean scores between the
intervention and comparison group in each study by an estimate
of the (pooled) SD, result in a ’scale free’ estimate of the effect
for each study. This can then be interpreted and pooled across
studies regardless of the original scale of measurement used in each
study (Laird 1990). We re-expressed SMDs using rules of thumb
(SMD < 0.4 = small effect, 0.4 to 0.7 = moderate effect , > 0.7 =
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large effect) or using the most commonly used instrument (back-
transformationof the effect size) to havemeasures that are clinically
useful in daily practice, following the method described in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). If available, we related the results to the minimal clinically
important difference (MCID) of the instrument considered.
For CBA studies, we planned to report results of dichotomous
outcomes as risk ratio (RR) derived from statistical analyses adjust-
ing for baseline measures (such as logistic regressions) and results
of continuous outcomes as MD or SMD derived from statistical
analyses adjusting for baseline measures (such as linear regression
models, mixed models, or hierarchical models). If adjusted results
were not available, study data were excluded from the analyses.
Unit of analysis issues
Cluster-randomised trials
Some cluster-randomised trials might have a unit of analysis er-
ror, when the trial has not adjusted for data clustering. This error
implies that confidence intervals and standard errors of effects are
smaller (more precise) than they should be (Ukoumunne 1999).
We noted the method of randomisation and unit of analysis for
each included cluster trial and corrected the sample size by dividing
it by the design effect, according to the guidance in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
If the intraclass correlation coefficient or the number of clusters
was not reported and attempts to contact the authors were unsuc-
cessful, study data were excluded from the analyses.
Cross-over trials
In cross-over trials, only data before cross-over were considered to
avoid any unit of analysis issues.
Studies with multiple treatment groups
In studies with one control group and two or more intervention
groups that satisfied our CDM criteria, we combined the interven-
tion groups to create a single pair-wise comparison to avoid unit
of analysis errors. For dichotomous outcomes, both the sample
size and the number of patients with events were summed across
groups. For continuous outcomes, means and SDs were combined
using the formulae presented in table 7.7.a of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011).
Dealing with missing data
We contacted corresponding authors to request missing informa-
tion whenever the published information did not allow us to de-
cide whether to include or exclude a study.We also contacted them
to get missing data (for example, SDs) in order to appropriately
describe the study results or perform a meta-analysis, or both.
In cases where SDs and change from baseline SDs were not re-
ported by the authors, we computed them from reported standard
errors, P values, or confidence intervals. If none of these values
were reported, we imputed the SD (or change from baseline SD)
by calculating the mean SD (or change from baseline SD) of the
other studies included in the meta-analysis using the same scale
(following the guidance of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011)). The method of impu-
tation for each relevant study is described in the forest plot foot-
notes. The potential impact of missing data was addressed in the
sensitivity analysis.
Assessment of heterogeneity
As suggested in Pigott 2013, we considered heterogeneity in terms
of substantive features of complex interventions, methodological
and procedural features of studies, as well as research character-
istics and reporting context. These sources are included in what
others categorise as clinical, methodological, and statistical hetero-
geneity (Gagnier 2012; Gagnier 2013). Statistical heterogeneity
among trials was specifically examined with Cochran’s Q test and
by calculating the I2 statistic, which describe the proportion of
variability in the summary estimate that is due to heterogeneity
rather than by chance.
We conducted subgroup analyses to explore clinical heterogeneity
in meta-analyses including at least nine studies, according to the
following planned study characteristics (unless specified as post
hoc).
• Comprehensiveness of the programme
We defined a comprehensive programme as including at least the
median number of independent components of included studies
(that is, eight components).
• Dominant component of the programme
Two review authors (CA, IPB) independently, and in duplicate, se-
lected a dominant component of the programme out of the follow-
ing threemain categories, which are linked to the first three criteria
of the operational definition of CDM: organisational component
targeting patients, organisational component targeting healthcare
professionals or system, or educational component. It was done
based on the number of various components present in each cate-
gory, themain aim of the intervention, and the relative importance
of the different components. If we could not determine one dom-
inant component, we classified the CDM programme as mixed.
Any disagreement was resolved by discussion.
• Presence of limited CDM components in the control group
(which were considered as usual care in the specific context of
single studies) (post hoc)
We did not perform meta-regression because there were less than
10 studies in our meta-analyses.
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Assessment of reporting biases
We assessed the presence of publication bias by means of funnel
plots. This was done for exploratory purposes only, as the number
of studies included in the meta-analyses (less than 10) was insuf-
ficient to reach a conclusive result.
Data synthesis
Where possible, we conducted meta-analyses using the Cochrane
ReviewManager software (ReviewManager 2014) to calculate the
overall effect size for all relevant primary outcomes. We pooled re-
sults of the RCTs and NRCTs separately using the random-effects
model (DerSimonian 1986) to incorporate some level of expected
heterogeneity among pooled studies. All results were expressed
with 95% confidence intervals. Baseline-adjusted results for CBA
studies were also combined separately, if available. For primary
outcomes that could not be incorporated in a meta-analysis, we
provided a brief description of the results in the main text.
We presented the most important outcomes of the review in the
Summary of findings for the main comparison, which includes
an overall grading of the evidence using the GRADE approach,
according to the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011). This approach specifies four levels of
quality (high, moderate, low, very low) for each outcome sepa-
rately. The highest quality rating is for RCT evidence, but it can be
downgraded depending on the presence of the following five fac-
tors: study limitations in the design and implementation suggest-
ing high likelihood of bias; indirectness of evidence (indirect popu-
lation, intervention, control, outcomes); unexplained heterogene-
ity or inconsistency of results (including problems with subgroup
analyses); imprecision of results (wide confidence intervals); and
high probability of publication bias. Sound observational studies
are generally rated as low quality but the following factors can in-
crease the quality of evidence: large magnitude of effect; all plausi-
ble confounding would reduce a demonstrated effect; and a dose-
response gradient.
Sensitivity analysis
We explored the influence of the following characteristics on effect
size: excluding studies at high risk of bias; excluding studies with
imputed SDs; excluding studies using instruments of unknown
validity; using change from baseline measures; and using the fixed-
effect model instead of random-effects model.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
See: Figure 1.
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Figure 1. Flow diagram.
We identified a total of 10,593 records to June 2014. We screened
the full texts of 425 potentially relevant articles. Of these, we ex-
cluded 395 articles, classified 3 articles (corresponding to 2 stud-
ies) under ongoing studies and retained 20 studies (from 27 arti-
cles) that met all our inclusion criteria.
Included studies
Design and setting
An overview of the characteristics of the included studies is pro-
vided in Table 1.
Fifteen studies were RCTs. Out of these 15 studies, one study was
a cross-over trial (Cambach 1997) and two studies were cluster-
RCTs with the unit of allocation being the provider in Petro 2005
and the pharmacy in Armour 2007. The other studies included
were one NRCT (Herborg 2001) with a cluster design (unit of
allocation: pharmacy) and four CBAs (Feifer 2004; Landon 2007;
Weng 2005;Windt 2010)with at least two sites in both the control
and intervention groups.
Nine studies recruited patients from primary care clinics or phar-
macies (Armour 2007; Charrois 2006; Couturaud 2002; Herborg
2001; Landon 2007; Martin 2009; McLean 2003; Petro 2005;
Schatz 2006). Two studies enrolled patients from respiratory care
clinics (Cambach 1997; Huang 2009), three other studies re-
cruited hospital inpatients (Castro 2003; Kokubu 2000; Mayo
1990), and four studies enrolled patients from the general popu-
lation (Feifer 2004; Weng 2005; Wilson 2010; Windt 2010). The
remaining two studies enrolled patients frommore than one pool:
Smith 2005 enrolled patients from both primary care and respi-
ratory care clinics; and Galbreath 2008 recruited patients from
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the general population, primary care clinics and respiratory care
clinics.
Three studies took place in pharmacies (Armour 2007; Herborg
2001; McLean 2003), seven in primary care practices (Cambach
1997; Feifer 2004; Galbreath 2008; Landon 2007; Martin 2009;
Petro 2005; Windt 2010), three in outpatient hospital depart-
ments (Couturaud 2002; Huang 2009; Mayo 1990), and two in
health management organisations (HMOs) (Schatz 2006; Wilson
2010). The remaining studies took place in mixed settings: inpa-
tient andoutpatient hospital departments (Castro 2003), inpatient
hospital department and patients’ home (Kokubu 2000), pharma-
cies and primary care practices (Charrois 2006), and outpatient
hospital departments and primary care clinics (Smith 2005;Weng
2005).
Ten studies were carried out in North America, six in Europe,
three in Asia, and one in Australia.
Study population
A total of 10,846 patients were included in 19 studies (between 37
and 4042 patients per study, median 111) when the CBA study
reporting data from 70,900 patients from a health insurance com-
pany database was excluded (Feifer 2004). The mean age in the
intervention and control groups varied between 28.0 and 57.3
years old (median 42.0) and the percentage of women between
22% and 85% (median 59%). Asthma severity in the 13 studies
reporting it was rated as moderate-severe in all except one study,
where it was mild-moderate (Cambach 1997). The baseline pre-
dicted FEV1 varied between 22.5% and 89% (median 69%) in
eight studies where it was reported. The percentage of patients
using inhaled corticosteroids was reported to be between 13.3%
and 100% (median 78%) in six studies.
Interventions
See: Figure 2.
Figure 2. Description of intervention components by study.
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All the programmes met the predefined five CDM criteria: at least
one organisational component targeting patients, at least one or-
ganisational component targeting healthcare professionals or the
healthcare system, patient education or self-management support
or both, the active involvement of two or more healthcare profes-
sionals in patient care, and a minimum duration of three months
for at least one component. The number of independent compo-
nents per programme ranged from 6 to 15 (mean 8.4; median 8).
Eleven programmes comprising eight or more components (that
is, including at least the median number of components) were de-
fined as comprehensive programmes (Armour 2007; Castro 2003;
Charrois 2006; Galbreath 2008; Herborg 2001; Kokubu 2000;
Landon 2007; Schatz 2006; Smith 2005; Weng 2005; Wilson
2010), and the remaining nine, comprising seven or fewer com-
ponents, were defined as less comprehensive.
The dominant component was ’educational’ in eight studies, ’or-
ganisational targeting healthcare professionals or the healthcare
system’ in four studies, and ’organisational targeting patients’ in
two studies. We could not determine the dominant component
in the remaining six studies, which were classified as mixed.
The most frequently assessed educational component was individ-
ual educational sessions (n = 19), followed by providing an action
plan for self-management support (n = 12), and verification of
inhalation technique (n = 9). The most frequently assessed organi-
sational component targeting patients involved structured follow-
up (n = 16), followed by having assistance and advice on demand
via, for example, a hotline (n = 6). Themost frequently assessed or-
ganisational component targeting healthcare professionals or the
healthcare system involved explicit teamwork and collaborative
processes between the healthcare providers (n = 15), followed by
education and training of providers (n = 10), and explicit use of
evidence-based medicine supports (n = 9).
The duration of the programmes ranged from 3 months to more
than 12 months (median 8.5 months).
Three studies assessed two intervention groups that fulfilled our
CDM inclusion criteria (Galbreath 2008; Huang 2009; Wilson
2010). In these studies, we combined the two intervention arms
and analysed them as a single intervention group.
Outcome (dependent variable) measures
A wide variety of outcomes were reported in the included studies
(see Characteristics of included studies for all available outcomes).
Here we describe briefly the outcomes reported in at least three
studies. The a priori primary outcomes we defined in the protocol
are the only ones we analysed. They are described in more detail
in the section presenting the effects of the interventions.
Five studies reported patient participation rates in the programme
and four reported the percentage of patients who received the
intervention or components, or both. Five studies reported the
percentage of patients with an action plan. Six studies reported
prescription rates of inhaled corticosteroids andnine reported rates
for prescription of other types of medication.
Fifteen studies reported healthcare utilisation outcomes: four re-
ported on any healthcare use (hospitalisation or unscheduled visit,
or both), and seven reported asthma-related or all-cause hospital-
isations and asthma-related or all-cause unscheduled visits sepa-
rately. Five studies reported cost data.
Fourteen studies reported asthma-specific quality of life scores.
Asthma severity scores were reported in nine studies and the num-
ber of symptomatic days in four studies. Three studies reported
the number of days off work or school due to asthma. Ten stud-
ies reported the patients’ actual use of medication. The reported
self-management outcomes included patients’ asthma knowledge
scores in seven studies, self-efficacy scores in six studies, and com-
pliance with treatment in four studies.
Pulmonary function tests such as FEV1, FEV1/FVC and PEF rate
were reported in seven, four, and six studies, respectively.
Missing data
We attempted to contact the authors of 15 of the included studies
to request additional data or information. We sent e-mails to 10
authors as we were unable to identify the correct e-mail address
for the authors of the other five studies. Nine authors responded
and five provided additional data. We imputed missing SDs for
seven studies (Couturaud 2002; Galbreath 2008; Herborg 2001;
Huang 2009; Kokubu 2000; Mayo 1990; McLean 2003).
Excluded studies
We excluded 395 studies after having assessed the full article (see
Figure 1). We excluded 211 studies because the intervention did
not meet the inclusion criteria of our CDM operational defini-
tion. We also excluded studies that used a design not included in
our predefined list, for example a before-after study with only one
site for the intervention and control groups, even if they met or
possibly met the inclusion criteria for our operational definition
of CDM (n = 66). We also excluded studies for the following rea-
sons: inappropriate target population (for example, only children
included; n = 13); insufficient information to determine eligibility
(n = 25); publication date before 1990, as the first CDM pro-
grammes were implemented after that date (n = 4); not primary
studies (for example, editorials, comments, reviews; n = 58); and
patients without asthma or from a mix of chronic diseases (n =
9). One study fulfilled our eligibility criteria but did not report
appropriate outcomes. The primary reason for excluding studies
that seemed to meet the eligibility criteria and could be consid-
ered relevant by some readers, but were not eligible after further
inspection, are listed under Characteristics of excluded studies.
Risk of bias in included studies
The full details of risk of bias judgements by study are described in
the Characteristics of included studies table. Figure 3 and Figure
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4 summarise these. Using GRADE (see Summary of findings for
the main comparison) the quality of the evidence was rated as
moderate or low depending on the outcome.
Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 4. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Ten of the 15 RCTs reported the use of a computerised randomi-
sation programme or a random number table to generate the al-
location sequence and were thus considered to be at low risk of
bias (Cambach 1997; Castro 2003; Charrois 2006; Couturaud
2002; Galbreath 2008; Huang 2009; Kokubu 2000; Schatz 2006;
Smith 2005; Wilson 2010). The process of sequence generation
was unclear for four studies, which stated that the study groups
were randomly allocated (Armour 2007; Martin 2009; McLean
2003; Petro 2005). The remaining RCT was judged to have a
high risk of bias because a quasi-randommethod of allocation (last
digit of hospital number) was used (Mayo 1990). In the NRCT
and CBAs, allocation was judged to be at high risk of bias because
of absence of randomisation (Herborg 2001; Landon 2007) and
retrospective allocation (Feifer 2004; Weng 2005; Windt 2010).
Allocation concealment was reported in nine of the randomised
studies but was unclear in the other six (Huang 2009; Kokubu
2000; Martin 2009; Mayo 1990; Petro 2005; Schatz 2006). Al-
location was judged as not having been done in the other studies
included (NRCT and CBAs).
Unit of allocation issues
Two of the three studies with a cluster design analysed the data
taking into account the clustering effect (Armour 2007; Herborg
2001) and were included in our analyses. The third study (Petro
2005) analysed the data at the patient level, which artificially in-
creases the precision of the statistical tests and can lead to inappro-
priate conclusions. The results of this study were excluded from
all analyses because we were unable to determine the number of
clusters in the study and therefore could not adjust the results.
Blinding
Six studies were at low risk of performance and detection bias be-
cause claims data were used or the assessors were blinded (Armour
2007; Feifer 2004; Galbreath 2008; Huang 2009; Wilson 2010;
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Windt 2010). Two studies were judged to be at high risk (Castro
2003; Smith 2005) and the risk for the remaining 12 studies was
unclear.
Incomplete outcome data
Outcome data were considered complete when 80% or more of
randomised patients were included in the analyses, when reasons
for attritionwere similar across groups, andwhen dropouts did not
differ from the patients analysed.Thesewere reported innine stud-
ies (Armour 2007; Cambach 1997; Castro 2003; Charrois 2006;
Huang 2009; Martin 2009; Smith 2005; Wilson 2010; Windt
2010). Outcome data were considered incomplete in three studies
because less than 80% of randomised patients were analysed and
no reasonswere given for themissingdata (Herborg 2001;McLean
2003; Schatz 2006). In the remaining eight studies, the number
of patients or clusters lost to follow-up was unclear or information
was missing for us to fully assessed attrition bias (Couturaud 2002;
Feifer 2004; Galbreath 2008; Kokubu 2000; Landon 2007; Mayo
1990; Petro 2005; Weng 2005).
Selective reporting
Only one study published an article on the design of the trial,
reporting the outcomes to be measured in the trial (Charrois
2006), and was considered at low risk of reporting bias. All other
studies were categorised as having an unclear risk of reporting bias
because of missing information.
None of the exploratory funnel plots appeared asymmetrical.
Other potential sources of bias
Baseline measurement of the outcome of interest was reported in
all studies except three (Castro 2003; Couturaud 2002; Galbreath
2008). In 10 of the studies reporting baseline measures, study
groups were comparable at baseline for the outcomes (Feifer 2004;
Huang 2009; Kokubu 2000; Martin 2009; Mayo 1990; Schatz
2006; Smith 2005;Weng 2005;Wilson 2010;Windt 2010); while
in one study important differences were reported (Armour 2007),
it was unclear if the differences in baseline measurements of the
outcomes between groups were important in five studies. Finally,
in one study (Petro 2005) there were important differences at
baseline for the secondary outcomes but not the primary outcome
(marked as unclear risk of bias).
All studies except two (McLean 2003; Petro 2005) reported pa-
tients’ characteristics at baseline allowing an assessment of base-
line heterogeneity between study groups. Four studies reported
important differences between groups (Armour 2007; Cambach
1997; Charrois 2006; Martin 2009) (at high risk of bias), 13 stud-
ies reported no important differences (at low risk of bias), and
one study (Landon 2007) reported important differences for some
characteristics (at unclear risk).
Two studies (Charrois 2006; McLean 2003) were considered at
high risk of contamination: trained pharmacists saw both the
control and intervention patients. In five studies (Armour 2007;
Castro 2003; Couturaud 2002; Martin 2009; Mayo 1990) it was
unclear whether patients in the control groups had received more
than usual care, which could have improved the care they had re-
ceived and their outcomes. The other 13 studies were considered
at low risk of contamination.
While no further bias was detected in 13 studies, five studies were
considered at high risk and two at unclear risk for other bias.
In four studies (Armour 2007; Couturaud 2002; McLean 2003;
Schatz 2006) there was a risk of recruitment bias due to the design
of the study (for example, selection of patients by pharmacist after
allocation, low recruitment rate). In two other studies (Charrois
2006; Galbreath 2008) the intervention was poorly implemented
with patients allocated to the intervention group completing only
parts of the intervention, resulting in potential bias. Finally, in two
studies (McLean 2003; Petro 2005) there was a high risk of bias
due to analysis errors (unit of analysis error, cluster randomisation
but analyses performed with patient level data).
Effects of interventions
See: Summary of findings for the main comparison Chronic
disease management compared with usual care for adults with
asthma
We reported the results using the 10 primary outcomes as pre-
defined in our protocol, followed by the results of subgroup and
additional sensitivity analyses. Data from one RCT (Petro 2005)
could not be included in the meta-analyses because we were un-
able to calculate the design effect due to missing information on
the number of clusters (unit of analysis error). Also, we were un-
able to include the four CBA studies in the meta-analyses in this
report because data provided by authors were either insufficient
or unadjusted.
Asthma-specific quality of life
Fourteen of the 20 studies selected for inclusion in this review
measured asthma-specific quality of life using three validated in-
struments: the Asthma Quality of Life Questionnaire (AQLQ) or
mini-AQLQ in nine studies; the Living with Asthma Question-
naire (LWAQ) in four studies; and the Chronic Respiratory Dis-
ease Questionnaire (CRDQ) in one study. However, only nine of
these studies provided data at follow-up and could be included
in the main meta-analysis. Of these, two had missing SDs, which
were estimated from the study data using the same instrument.
One study using the mini-AQLQ was excluded from the meta-
analysis because follow-up values were not available, due to copy-
right issues according to the corresponding author (Martin 2009).
In this study, the intervention group had improved asthma quality
of life compared with the control group after six months of follow-
up. Another study using the LWAQ (Petro 2005) was excluded
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from the meta-analysis as data could not be adjusted for unit of
analysis error. The study using the CRDQ (Cambach 1997) and
one study using the LWAQ (Kokubu 2000) only provided data on
change from baseline. They were excluded from the main meta-
analysis but we included them in the sensitivity analysis using
change from baseline data. Feifer 2004, using the mini-AQLQ,
was excluded from the meta-analysis because it was a CBA study
and data were available only for the intervention group.
The main meta-analysis included eight RCTs (Armour 2007;
Castro 2003; Couturaud 2002; Galbreath 2008; McLean 2003;
Schatz 2006; Smith 2005; Wilson 2010) with a total population
of 1627 patients with a follow-up of 3 to 12 months (see Figure
5; Analysis 1.1). The pooled SMD was 0.22 in favour of CDM
(95% confidence interval (CI) 0.08 to 0.37), with a moderate
degree of heterogeneity (I2 = 43%). The clinical significance of
this SMDwas low since, as a rule of thumb, a SMD lower than 0.4
indicates a small effect. In addition, the corresponding difference
on the AQLQ scale after back-transformation (0.30) was lower
than the minimal clinically important difference (MCID) of the
AQLQormini-AQLQ,which is 0.5 according to the developers of
the instrument (http://www.qoltech.co.uk/miniaqlq.html). The
SMD for theNRCT (Herborg 2001), including 413 patients, was
larger than the pooled SMD of RCTs (SMD 0.46, 95% CI 0.27
to 0.66) (see Figure 5; Analysis 1.1).
Figure 5. Forest plot of comparison: 1 Chronic disease management programme versus usual care,
outcome: 1.1 Asthma-specific quality of life score (post-intervention measurements).
Excluding the two RCTs at high risk of bias (McLean 2003; Schatz
2006) from themeta-analysis reduced the SMD (SMD0.17, 95%
CI 0.05 to 0.28) and the heterogeneity (I2 = 1%).
Subgroup analysis by quality of life instrument used
To determine if the heterogeneity of the results was due to the
use of different instruments, we analysed the results from each
instrument separately. This allowed us: i) to assess the effect of
using a single instrument with its specific properties, and ii) to
analyse theMD instead of the SMD. Seven studies including 1543
patients used the AQLQ, and one study including 84 patients used
the LWAQ (Analysis 1.5). Subgroup analysis of the studies using
the AQLQ scale showed a non-clinically significant MD of 0.32
(clinical significance 0.5 or more) in favour of CDM (95% CI
0.12 to 0.52), while results of the study using the LWAQ scale were
inconclusive (MD 0.02, 95% CI -0.16 to 0.20). Heterogeneity
was not improved by restricting the analysis to studies using the
same instrument (I2 = 42%).
Hospitalisations
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Nine studies reported hospitalisation data specifically. However,
we could not performameta-analysis because the datawere skewed
and heterogeneous, with wide variability in terms of length ofmea-
surement (hospitalisations within the last 1, 6, 8, or 12 months)
and reasons for hospitalisation (due to asthma or any cause).
Three RCTs reported a reduction in hospitalisation for asthma in
the intervention group compared with the control group. While
Castro 2003 reported a 56% reduction in readmissions for asthma
in the intervention group compared with the control group over
12months (MD-0.5, 95%CI -1.0 to 0.0), Kokubu 2000 reported
an 83% reduction in hospitalisations among patients at high risk
for hospitalisations in the intervention group after 6 months com-
pared with the control group (MD -0.29, 95% CI -0.49 to -0.09),
andMayo 1990 reported a 67%reduction in hospital readmissions
for acute exacerbation in the intervention group after 8 months
compared with the control group (MD -0.83, 95% CI -1.10 to -
0.56).
In contrast, two RCTs (Galbreath 2008; McLean 2003) and one
NRCT (Herborg 2001) did not report any differences between
groups. However, the number of hospitalisations per patient dur-
ing follow-up was lower in these studies than in the RCTs report-
ing a reduction: the mean number of hospitalisations per patient
was 0.12 during the 12 months of follow-up in Galbreath 2008,
0.12 during one month of follow-up in McLean 2003, and 0.04
during the 12 months of follow-up in Herborg 2001; compared
with 0.64, 0.21, and 0.85 in Castro 2003, Kokubu 2000, and
Mayo 1990. In Petro 2005 there were no hospitalisations in the
intervention group during the 12 months of follow-up compared
with 10% in the control group.
In the CBA study that assessed the impact on hospitalisation in
both the intervention and control groups, the number of hospi-
talisations per patient after 12 months did not differ between the
groups (Weng 2005).
Two RCTs (Charrois 2006; Schatz 2006) and two CBA studies
(Landon 2007; Windt 2010) that reported the number of hospi-
talisations and ED visits as one outcome did not report any im-
portant differences between groups in the number or percentage
of hospitalisations or ED visits during the study follow-up.
Emergency department (ED) or unscheduled visits
Nine studies reported the number of EDor unscheduled visits. We
could not perform a meta-analysis because the data were skewed
and heterogeneous, with wide variability in means and rates at
baseline; length of follow-up from 1 to 12 months; data treated
as continuous data, rate or count; and studies including ED or
unscheduled visits for asthma only versus for any reason.
Only one RCT (Kokubu 2000) showed a reduction in daytime
ED visits per patient in the intervention group compared with the
control group during the six month follow-up, but no difference
in night ED visits was observed.
The results from four RCTs and one NRCT did not show any dif-
ference between groups for the number of ED or unscheduled vis-
its for asthma per patient during 12 months of follow-up (Castro
2003; Couturaud 2002; Galbreath 2008; Herborg 2001) and 1
month of follow-up (McLean 2003). Another RCT showed no
difference in the percentage of patients with at least one unsched-
uled visit after six months of follow-up (Huang 2009).
In the CBA study that assessed the impact on ED or unscheduled
visits in both the intervention and control groups, there was no
important reduction between groups in the number of ED visits
per patient after 12 months (Weng 2005).
Asthma exacerbations
Asthma exacerbations, which we defined as prompting hospital-
isation, an ED or unscheduled medical visit, or systemic rescue
glucocorticoids, were not often reported as such in the included
studies. We were therefore unable to perform a meta-analysis due
to the lack of data.
Couturaud 2002 and Mayo 1990 reported the number of un-
scheduled visits for asthma exacerbation and the number of hos-
pitalisations for asthma exacerbation, respectively. In Couturaud
2002 the number of unscheduled visits for asthma exacerbation
were comparable between groups, and in Mayo 1990 the number
of readmissions for asthma exacerbation per patient for the inter-
vention group was less than for the control group. We could not
consider the other studies reporting healthcare use as they did not
specify whether the use was for asthma exacerbations.
Finally, five studies reported oral corticosteroids use (Charrois
2006; Couturaud 2002; Herborg 2001; Kokubu 2000; Schatz
2006) but did not specify whether the use was for asthma exacerba-
tion and data were too diverse and heterogenous to be combined.
In all studies except one (Couturaud 2002), no important differ-
ences between the intervention and control groups were observed.
In Couturaud 2002 the percentage of days of oral steroid intake
was higher in the intervention group at follow-up (P = 0.01).
Asthma self-efficacy
Six studies reported on asthma self-efficacy, using five differ-
ent instruments: the Perceived Control of Asthma Questionnaire
(PCAQ) in Armour 2007 and Smith 2005, the Asthma Self-effi-
cacy Scale in Huang 2009, the Chicago Initiative to Raise Asthma
Health Equity Asthma Self-Efficacy Scale in Martin 2009, open-
ended questions measuring self-management ability in Couturaud
2002, and specific questions measuring self-management skills in
Feifer 2004. The first three instruments have been formerly vali-
dated but the questions used in Couturaud 2002 and Feifer 2004
have not. Data from Feifer 2004 were excluded from this meta-
analysis because the study was a CBA and data were only available
for the intervention group.
The five studies (Armour 2007; Couturaud 2002; Huang 2009;
Martin 2009; Smith 2005) in the meta-analysis shown in Figure 6
20Chronic disease management programmes for adults with asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
and Analysis 1.7 included a total population of 642 patients, with
a follow-up of 3 to 12 months. The pooled SMD was 0.51 (95%
CI -0.08 to 1.11) but this difference could not be established, as
a negative effect or no difference, could not be ruled out. Pooling
indicated a high degree of heterogeneity (I2 = 91%).
Figure 6. Forest plot of comparison: 1 Chronic disease management programme versus usual care,
outcome: 1.7 Self-efficacy score (post-intervention measurements).
Removing the study that used a non-validated instrument (
Couturaud 2002) did not modify the overall result (no difference
between groups) or reduce the heterogeneity (pooled SMD 0.52,
95% CI -0.21 to 1.26; I2 = 93%). No studies were at high risk
of bias in this meta-analysis. Removing the study with the most
positive results (Huang 2009) decreased the pooled result (SMD
0.14, 95% CI -0.04 to 0.32) and reduced the heterogeneity (I2 =
0%).
Days off school or work absences
Three studies reported the impact of the intervention on days off
school or work absences. Couturaud 2002 reported comparable
percentages of days off work in the control and intervention groups
after 12 months of follow-up. In McLean 2003 the mean change
from baseline in number of days off school or work did not differ
between the intervention and control groups after 12 months of
follow-up. Feifer 2004 reported the number of productivity-loss
days among employed and unemployed patients in the interven-
tion group only. These data were not pooled because of their het-
erogeneous formats.
Asthma severity
Seven studies reported asthma severity scores, using the Asthma
Control Questionnaire (ACQ) (Charrois 2006), the Lara Asthma
Symptom Scores (LASS) (Galbreath 2008), the asthma morbidity
index (Herborg 2001), the Asthma Control Test (Huang 2009),
the Asthma Therapy Assessment Questionnaire (ATAQ) (Wilson
2010), and asthma symptom scores based on different question-
naires (McLean 2003; Smith 2005). All instruments except those
used in McLean 2003 and Smith 2005 had undergone validation.
We adapted the instruments so that higher scores corresponded to
less severe asthma for all measures.
The main meta-analysis included six RCTs (Charrois 2006;
Galbreath 2008;Huang 2009;McLean 2003; Smith 2005;Wilson
2010) with a total population of 1330 patients and a follow-up
of 6 to 12 months (see Figure 7; Analysis 1.8). The pooled SMD
was 0.18 in favour of CDM (95% CI 0.05 to 0.30) representing
a small effect clinically (SMD < 0.4). Pooling showed a low level
of heterogeneity (I2 = 13%). The SMD for the NRCT (Herborg
2001), including 409 patients, was higher than the pooled SMD
of the RCTs (SMD 0.47, 95% CI 0.27 to 0.66) (see Figure 7;
Analysis 1.8).
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Figure 7. Forest plot of comparison: 1 Chronic disease management programme versus usual care,
outcome: 1.8 Asthma severity score (post-intervention measurements).
Removing the two studies that used instruments that had not been
formally validated (McLean 2003; Smith 2005) or the study at
high risk of bias (McLean 2003) from the meta-analysis had little
impact on the point estimate (pooled SMD 0.20, 95% CI 0.04 to
0.37; and SMD 0.17, 95% CI 0.01 to 0.33, respectively).
Two other studies measured the percentage of patients having se-
vere asthma (Armour 2007) and the percentage of patients with-
out various respiratory symptoms (Petro 2005). In Armour 2007
the multilevel logistic regression model found that the odds ra-
tios (OR) for patients to change from the ’severe’ category to the
’not severe’ category (’moderate’ or ’mild’) were almost three times
higher in the intervention group than in the control group (OR
2.68, 95% CI 1.64 to 4.37). In Petro 2005, after 12 months of
follow-up, themedian percentage of patients not presenting severe
symptoms remained similar in the control group (from 44% to
46%) but increased from 46% to 81% in the intervention group.
Use of an action plan
Five studies reported the percentage of patientswith an actionplan,
but only two studies (Landon 2007; Martin 2009) provided data
for both the intervention and control groups. In the first study,
the percentage of patients with an asthma management plan was
higher in the intervention group (27%) than in the control group
(12%) at follow-up (P < 0.001) (Landon 2007). In the second
study, a greater percentage of patients in the intervention group
had received an asthma action plan after 3 months of follow-up
(control group 18%; intervention group 45%) but this difference
did not remain after 6 months of follow-up (control group 23%;
intervention group 20%; P = 0.17) (Martin 2009).
Patient satisfaction
Three studies reported outcomes on patient satisfaction. In
Herborg 2001 andMcLean 2003, patients in the intervention and
control groups had similar high satisfaction scores at the end of
the study. Only patients in the intervention group completed the
satisfaction survey in Kokubu 2000, therefore the impact of the
intervention could not be assessed.
Lung function
Nine studies reported outcomes on lung function: six reported the
mean per cent of predicted FEV1 value (% of predicted value)
(Armour 2007; Charrois 2006; Couturaud 2002;Galbreath 2008;
Huang 2009; Wilson 2010) and five reported the PEF rate, re-
ported as L/min in three studies (Herborg 2001; Huang 2009;
McLean 2003) and as per cent of predicted value in two studies
(Galbreath 2008; Kokubu 2000).
We combined data from the eight RCTs in onemeta-analysis using
the SMD, including a population of 1559 patients, with a follow-
up of 6 to 12 months (Analysis 1.9). Overall, the pooled SMD
for lung function was 0.19 in favour of CDM (95% CI 0.09 to
0.30). This SMD (small effect size if SMD < 0.4) corresponded
to a difference, on the predicted FEV1 % scale, of 5.0%. There
was no heterogeneity (I2 = 0%). In the FEV1 subgroup, the SMD
was 0.16 (95% CI 0.05 to 0.27). In the PEF (L/min) and PEF
(% predicted) subgroups, which only included one study each, the
SMD was 0.30 (95% CI 0.03 to 0.56) and 0.53 (95% CI -0.01
to 1.06), respectively.
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Removing the study at high risk of bias (McLean 2003) from the
meta-analysis did not affect the SMD (SMD 0.18, 95% CI 0.06
to 0.29).
We also looked at the impact of CDM on these three different
measures of lung function in three separatemeta-analyses (Analysis
1.10; Analysis 1.11; Analysis 1.12), allowing us to use the MD.
For FEV1, theMD for the predicted value was 2.81% in favour of
CDM (95% CI 0.99 to 4.64). For PEF, the pooledMDwas 33.52
L/min in favour of CDM (95% CI 11.38 to 55.65) for RCTs and
the MDwas 30.52 L/min (95% CI 7.46 to 53.58) for the NRCT.
For PEF in predicted % values, the MD was 8.68% in favour of
CDM (95% CI 3.73 to 13.63).
Subgroup analyses
We performed subgroup analyses for two outcomes with sufficient
studies: asthma-specific quality of life (Analysis 1.2; Analysis 1.3;
Analysis 1.4) and lung function (Analysis 1.13; Analysis 1.14;
Analysis 1.15). The results from these analyses did not show any
differences in the impact of the intervention as a function of its
comprehensiveness, the dominant component of the intervention,
or the presence of limited CDM components in the control group.
Additional sensitivity analyses
Similar results were observed when a fixed-effect model rather
than a random-effects model was used, and when studies with
imputed SDs (Couturaud 2002; Kokubu 2000;McLean 2003) or
SDs estimated from a graph (Wilson 2010) were excluded.
The available data allowed us to analyse the change from base-
line measurements instead of post-intervention measurements for
asthma-specific quality of life (Analysis 1.6). The pooled SMD
from the seven RCTs including 1547 patients (SMD 0.30, 95%
CI 0.18 to 0.43) was higher than in the meta-analysis with post-
intervention measures, although it did not reach clinical signifi-
cance (SMD < 0.4), and heterogeneity (I2 = 25%) was lower. The
SMD for the NRCT including 413 patients was similar to the
pooled SMD of RCTs (SMD 0.37, 95% CI 0.18 to 0.57).
D I S C U S S I O N
Summary of main results
We reviewed the results from 20 studies that assessed the effec-
tiveness of chronic disease management for adults with asthma.
Results from the meta-analyses showed that CDM programmes
probably improve asthma-specific quality of life (SMD 0.22, 95%
CI 0.08 to 0.37), asthma severity scores (SMD 0.18, 95% CI
0.05 to 0.30), and lung function tests (SMD 0.19, 95% CI 0.09
to 0.30) but the results were inconclusive for self-efficacy (SMD
0.51, 95% CI -0.08 to 1.11).
We could not combine data for hospitalisations and ED or un-
scheduled visits in a meta-analysis because the data were skewed
and too heterogenous; overall, the results from the individual stud-
ies were inconclusive. In addition, the data for the effectiveness
on asthma exacerbations, days off work or school, use of an action
plan, and patient satisfaction were sparse and meta-analyses could
not be performed. Although there were many different secondary
outcomes in the included studies, only one study reported data on
adverse events or mortality (Mayo 1990). In this study, during the
eight months of follow-up, there were no asthma-related deaths in
the intervention group but one patient died from asthma in the
control group.
We did not observe any differences for the effectiveness of the in-
tervention as a function of three pre-specified features of the in-
tervention: comprehensiveness of the intervention, the dominant
component of the intervention, and presence of limited CDM
components.
The seven clinically most important primary outcomes are sum-
marised in the Summary of findings for the main comparison.
Overall completeness and applicability of
evidence
We can reasonably consider that the results of this systematic re-
view reflect what has been published on the effectiveness of CDM
programmes in asthma. The 20 studies included in this review
were identified after applying a comprehensive search strategy de-
signed to identify interventions that met all five criteria of an op-
erational definition of chronic disease management (that is, in-
cluding at least one organisational component targeting patients,
at least one organisational component targeting healthcare pro-
fessionals or the healthcare system, patient education or self-man-
agement support, active involvement of two or more healthcare
professionals in patient care, and a minimum duration of three
months).
We pre-specified the 10 most relevant outcomes for people with
asthma as primary outcomes for this systematic review. The stud-
ies all reported at least one of these 10 primary outcomes (average
of seven primary and secondary outcomes per study) and a meta-
analysis could be performed for 4 out of these 10 outcomes, guar-
anteeing the relevance of our results. However, since the number
of studies included in each meta-analysis was rather low, except
for the outcomes asthma-specific quality of life and lung function
(eight studies each), we were unable to conduct appropriate sub-
group analyses or meta-regression.
However, although we included study designs other than RCTs
(that is, NRCTs, CBAs, and ITS), 49 studies had to be excluded
because their design was considered to be at high risk of bias (for
example, several CBA studies with only one control or interven-
tion site rather than at least two control and two intervention sites
as specified by the EPOC review group methodology). In addi-
tion, none of the four included CBAs with two control and two
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intervention groups could be included in the meta-analyses be-
cause available data were incomplete or inappropriate. Although
these excluded studies were not considered to be relevant in the
assessment of the effectiveness of CDM programmes, it might be
useful to investigate what data these studies could contribute to
the development of CDM programmes, in terms of understand-
ing which key components bring most benefits or in improving
our knowledge about the contexts and settings where these pro-
grammes have been implemented.
The results of this review should be considered with caution since
we observed statistical, clinical, and methodological heterogene-
ity. This heterogeneity was taken into account in the choice of
statistical models used and in the assessment of the level of the
evidence.
Quality of the evidence
We included 20 studies, 15 of which were RCTs, in this review,
and included up to eight studies and 1627 patients in the meta-
analyses. Sensitivity analyses based on study quality (excluding
studies at high risk of bias or with imputed SDs) did not change the
direction, significance, or magnitude of the observed effectiveness.
Following the GRADE approach, we specified the levels of quality
of the evidence (high, moderate, low, and very low) for the seven
most important primary outcomes presented in our Summary
of findings for the main comparison. This was done taking into
account the study design, indirectness of the evidence, unexplained
heterogeneity or inconsistency of the results, imprecision of the
results, and high probability of publication bias.
Overall, the quality of the evidencewasmoderate to lowdespite the
fact that studies for which ameta-analysis could be performedwere
mostly RCTs. This was due mainly to study design limitations,
which resulted in either unclear or high risk of bias in most cases,
and in wide confidence intervals, therefore explaining why the
level of evidence was downgraded by one or two levels depending
on the outcomes.
Potential biases in the review process
Weattempted tominimise biases in our reviewprocess by firstly us-
ing an explicit and detailed operational definition of what we con-
sidered asCDMtoovercome the absence of a consensual definition
of chronic disease management and help the reader understand
which types of programmes were considered in this review. This
definition included more than the traditional education and self-
management components evaluated previously in primary studies
and a few systematic reviews. Secondly, we restricted study designs
to those recommended by the EPOC Review Group methodol-
ogy (EPOC 2013), which meant that CBA studies had to assess
two intervention and two control groups. Finally, we performed a
comprehensive search for primary studies.
The results of this systematic review should be interpreted consid-
ering the following limitations. As with most systematic reviews
targeting complex interventions, such as CDM, several sources of
heterogeneity must be acknowledged. In addition to methodolog-
ical and statistical heterogeneity, the biggest source of heterogene-
ity was clinical heterogeneity due to context, settings, patients,
and interventions, which differed across studies. We attempted to
limit this clinical heterogeneity by having a clear operational def-
inition and only including comprehensive interventions. In addi-
tion, heterogeneity was taken into consideration in the statistical
analyses by using random-effects models and in the quality evalu-
ation of the studies, which resulted in downgrading in some cases.
Despite this, a high level of unexplained statistical heterogene-
ity remained in the self-efficacy meta-analysis, which was mainly
due to one study (Huang 2009) that included a higher propor-
tion of men than the other studies. However, as other outcomes
from this study did not stand out in the other meta-analyses it
is unlikely that the large positive results of this study were due
to intervention or population characteristics. The atypical result
for Huang 2009 could also be due to the self-efficacy instrument
used in this study, which was different from the other studies. De-
spite having included 20 studies in the review, only eight at most
could be included in the meta-analyses because of missing infor-
mation and the wide range of outcomes reported in the different
studies, which were too heterogeneous to be combined in some
cases. Further, three of the outcomes (quality of life, self-efficacy,
asthma severity) were self-reported by patients. However, patient
reported outcome measures are increasingly being measured in
evaluations of CDM programmes, because they are important to
patients. Most instruments used in the included studies have been
validated. Only two of the four studies that used an instrument
that had not been validated contributed data to a meta-analysis,
and sensitivity analyses excluding these two studies did not mod-
ify the pooled estimate. Finally, there was often little information
about the components of the interventions, their frequency and
intensity for example, as well as the specific setting and context
in which they were implemented, making their reproducibility in
other settings difficult. However, this is inherent to CDM and,
more generally, other quality improvement interventions, which
are complex and context-dependent (Davidoff 2009).
Agreements and disagreements with other
studies or reviews
This review updates three previous systematic reviews assessing
the effectiveness of CDM programmes in patients with asthma
(Lemmens 2009; Maciejewski 2009; Steuten 2007a). The main
differences between our review and the previous reviews are that
i) our search strategy was more comprehensive and detailed, and
did not have any restrictions for publication year, as did Steuten
2007a, thus giving a broader coverage of the intervention over
time and more potential articles to screen, ii) the use of an a priori
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proposed operational definition of CDM, defined in the published
protocol, which enabled the criteria for selecting studies to be
clearer, and iii) the study designs considered in the current review
included all those recommended by the EPOC group as being able
to minimise potential bias (EPOC 2013). However, despite these
differences, our results are consistent with previous reviews, that
is small overall effects, improved quality of life (Lemmens 2009),
no effect on emergency department (ED) visits (Lemmens 2009),
and limited impact on lung function (Lemmens 2009; Steuten
2007a).
There are several explanations why we found little effect of CDM
programmes in patients with asthma. First, the ’usual care’ ad-
ministered to the control group may have differed between studies
and may have included some asthma education initiatives; since
this has been considered as standard care of patients with asthma
for a long time and reflects a good level of clinical management.
Therefore, it may be difficult to demonstrate a difference of ef-
fect between a CDM programme and what is described as usual
care. Second, the CDM programmes assessed in this systematic
review were quite heterogeneous, therefore constituting a hetero-
geneous pooled intervention group that was compared with usual
care, which was also heterogeneous, resulting in pooled odds ra-
tios (ORs) tending towards a null effect. Third, the prevalence
of asthma varies between countries, and heterogeneity in its di-
agnosis, severity, and phenotypes has been reported (Eder 2006).
CDM could therefore be effective for only a subgroup of patients
with asthma. Fourth, the length of key components and follow-
up periods may have been too short to allow the effects of long-
term interventions to be detected. Finally, demonstrating differ-
ences for outcomes that are not so frequent in the daily life of
patients with asthma, such as hospitalisation and emergency or
unscheduled visits, may be difficult.
The results of this review, showing trends towards some ben-
efits for patients with asthma, are consistent with those from
other systematic reviews assessing CDM programmes for differ-
ent chronic diseases such as COPD (Kruis 2013; Lemmens 2013;
Niesink 2007; Peytremann-Bridevaux 2008), diabetes (Elissen
2013; Knight 2005; Norris 2002; Pimouguet 2011), heart failure
(Gohler 2006; Gonseth 2004; McAlister 2001; Roccaforte 2005),
and depression (Badamgarav 2003; Neumeyer-Gromen 2004).
CDM programmes seem to be less effective in asthma patients,
however. In addition to the factors which may have led to under-
estimation of the effect of CDM in our analysis discussed above,
other methodological issues could explain little effectiveness. As
previously reported (Lemmens 2009), the quality of the studies
assessing the effect of CDM for patient with asthma is suboptimal,
and RCTs can be difficult to conduct in the community, a setting
where patients with asthma often receive their care. Also, evalua-
tion measures were often not pertinent and focused on outcomes
rather than processes or structuremeasures (Steuten2007a).Other
explanations for a smaller effect in asthma, compared with other
chronic diseases, may relate to the disease itself or its treatment
since, comparedwith other common chronic diseases, asthma gen-
erally affects younger and otherwise healthy patients; and is ob-
served as respiratory symptoms only. It could therefore be hy-
pothesised that interventions limited to education or self-man-
agement, or both, which primarily target the appropriate use of
drugs and avoidance of triggers and which were frequently offered
in the control groups of this review may be sufficient. However,
there have been few published systematic reviews assessing the ef-
fectiveness of education or self-management interventions despite
there being a large number of primary studies. These interven-
tions have been shown to greatly vary and be insufficiently docu-
mented (Sudre 1999). However, it is generally accepted that while
patient education programmes limited to information only do not
improve health outcomes (Gibson 2002), self-management edu-
cation programmes associated with regular practitioner review do
(Gibson 2003). In our review, results of the exploratory subgroup
analyses on the dominant component and the comprehensiveness
of the implemented interventions were inconclusive. For patients
with asthma, it is unknown if implementing interventions such
as CDM programmes provides more benefit than education and
self-management support only.
The effects of CDM programmes for asthma can be contrasted to
the effects of those programmes targeting patients with COPD,
an obstructive disease characterised by respiratory symptoms and
systemic consequences of chronic inflammation that affects older
patients, where recent good quality evidence has confirmed the
benefits of CDM programmes in terms of quality of life, hospital-
isation, and exercise tolerance (Kruis 2013).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our systematic review provides moderate to low evidence that
CDM programmes have a clinically small but positive effect on
asthma-specific quality of life and asthma severity, which are
among the main objectives of asthma management and are the
most crucial outcomes for the everyday life of patientswith asthma.
Our results also showed that lung function tests (FEV1 and PEF)
were slightly improved with the CDM programmes.
Despite the moderate to low level of evidence, we can consider,
overall, that the results of this systematic review represent encour-
aging evidence for the effectiveness of CDMprogrammes in adults
with asthma. The development of CDM programmes must be
with evidence of their benefits since the programmes are resource
consuming and usually require organisational restructuring. Our
data seem to be encouraging for further investment in the pro-
motion, development, and evaluation of CDM programmes in
asthma, a condition with a substantial burden for patients and
healthcare systems. However, the optimal composition of asthma
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CDM programmes still needs further investigation, especially in
terms of the specific components and the level of complexity. It
seems very important to assess the benefits of CDM programmes
with those from education or self-management, or both, alone
since the latter are usually offered to patients with asthma and rep-
resent usual care for a majority of healthcare professionals taking
care of patients with asthma. Thismay be difficult since education,
self-management, and CDM programmes are not always readily
distinguishable.
Implications for research
We suggest that researchers planning future studies on the effec-
tiveness of chronic disease management for patients with asthma
consider the following issues.
1. Investigate the most responsive patients to determine
whether a particular subpopulation of patients with asthma
benefit more from CDM programmes than others. Future trials
could categorise patients into subgroups according to disease
severity or other criteria.
2. Describe the CDM programme in detail to identify which
of the CDM components are more beneficial than others to
patients with asthma, and assess if complex or intensive
programmes are needed, and what components could be added
to the current patient education and self-management support
provided. Hence, future trials should report and assess the
components of the CDM programmes in detail, including their
frequency and intensity. Future trials should also try to compare
education and self-management support with CDM
programmes directly, or to compare different types of CDM
programmes, in terms of comprehensiveness and intensity, for
example rather than comparing with usual care.
3. Assess the impact of CDM on hospitalisations and
emergency department or unscheduled visits more fully.
4. Consider not only outcome of care indicators but also
structure and process of care indicators. Since outcome
indicators do not seem to be greatly improved, emphasis should
be put on the assessment of structure and process of care
indicators to better interpret the outcome results.
5. Improve the quality and reporting of studies to increase the
level of evidence and confidence in the results. It is crucial to
improve both the quality of pragmatic studies assessing the
effectiveness of these programmes and the quality of their
reporting. Future trials describing methods and data collection
more completely would increase the quality of the evidence for
the results of systematic reviews.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Armour 2007
Methods C-RCT, unit of allocation: pharmacies (n = 57), patient recruitment: patients or clients
of primary care clinic or pharmacy
Setting: Rural and urban pharmacies, New SouthWales, Victoria, Queensland Australia
Participants Control patients: n = 205 (186 at follow-up (f/u)), women: 60.5%, mean age: 50.4,
smoking: 23%, moderate-severe asthma (according to symptoms), FEV1: 22.5%, ICS
use: 81%
Intervention patients: n = 191 (165 at f/u), women: 67.5%, mean age: 47.5, smoking:
20.9%, moderate-severe asthma, FEV1: 22.8%, ICS use: 85.3%
Interventions Name and duration of programme: Pharmacy Asthma Care Program during 6 months
Intervention group components
Organisational - patients: structured follow-up; adherence assessment; detection of drug-
related problems
Organisational - healthcare professionals/system: pharmacist education and training;
referral to a GP as appropriate (e.g. for a change of medication or dose); programme
development based on national guidelines
Patient education: one on one education on targeted counselling and education on the
condition, medication and lifestyle issues (e.g. trigger factors)
Self-management support: review of inhaler technique; goal setting and review
Frequency: baseline, 1 month, 3 months (optional), 6 months
Healthcare professionals involved: GPs, pharmacists
Control group components
Usual care (which includes risk assessment and spirometry training for pharmacists)
Number of components and dominant component: 8, education and self-manage-
ment
Outcomes Organisational level
Organisation of care: participation rate; number of interventions per patient; % inter-
vention patients receiving intervention components
Process: % patients referred to GP; % patients with action plan; % patients with pre-
scription of reliever; % patients with prescription of preventer + reliever
Patient level
Quality of life: AQLQ score
Asthma symptoms and activity level: asthma severity (% patients with mild, moderate
and severe asthma) (primary); mean daily dose of salbutamol
Self-management: CQ score; PCAQ score; BMQ score; % patients adherent to preventer
medication; % patients with correct inhaler technique
Pulmonary function: mean FEV1; mean FEV1/FVC
Time of outcome measurement: at 6 months
Notes Unit of analysis error (pharmacies randomised, patients analysed) taken into account in
analyses presented in article (change from baseline). We also used the unadjusted data
sent by authors for final values. We adjusted the sample size for the design effect (= 1.
03) based on the study’s ICC (0.006)
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Armour 2007 (Continued)
CQ: consumer asthma knowledge score; PCAQ: perceived control of asthma question-
naire; AQLQ: asthma-related quality of life questionnaire; BMQ: brief medication ques-
tionnaire
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”randomly allocated“
Allocation concealment (selection bias) Low risk Central allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Pharmacists were not informed as to group
allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT for primary outcome; for secondary
outcomes, no significant differences be-
tween patients who were recruited and
those who completed the study
Control patients: 205 - 19 loss to follow-
up = 186 (90.7%)
Intervention patients: 191 - 26 loss to fol-
low-up = 165 (86.4%)
Control pharmacies: 28 - 4 with no patient
recruitment = 24 (85.7%)
Intervention pharmacies: 29 - 3 with no
patient recruitment = 26 (89.7%)
Selective reporting (reporting bias) Unclear risk Protocol unavailable
Other bias High risk Potential recruitment bias, as pharmacies
recruited patients after allocation
unclear when FEV1 is measured
Outcomes at baseline similar? High risk Higher proportion of patients with severe
asthma in intervention group than in con-
trol group (88% versus 71%, P < 0.001)
Characteristics at baseline similar? High risk Higher proportion of previous smokers (P
= 0.05) and patients with other lung dis-
ease (P < 0.001) in control patients than
intervention patients
Adequate protection against contamina-
tion?
Unclear risk Allocation by cluster but questionnaires at
baseline could contribute to education
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Cambach 1997
Methods RCT (cross-over), patient recruitment: patients or clients of respiratory care clinic
Setting: Local physiotherapy practices, Netherlands
Participants Control patients: n = 21, women: 66.7%, mean age: 53, mild-moderate asthma (ac-
cording to FEV1), FEV1: 84%, dyspnoea score (CRDQ): 18, ICS use: not reported
Intervention patients: n = 22, women: 81.8%, mean age: 40, mild-moderate asthma
(according to FEV1), FEV1: 89%, dyspnoea score (CRDQ): 18, ICS use: not reported
Interventions Name and duration of programme: rehabilitation programme run in local physiother-
apy practices during 3 mo before cross-over
Intervention group components
Organisational - patients: recreational activities
Organisational - healthcare professionals or system: course on pulmonary rehabilitation
for physiotherapists
Patient education: group sessions on normal or pathological respiration, medication
treatment, inhalation technique and sanitation or resources; one on one education on
techniques of breathing retraining and evacuation of mucus; exercise training; group
sessions on relaxation techniques
Frequency: 2 individual sessions of 45minonbreathing retraining andmucus evacuation;
group sessions: 6 sessions of 45 min on education, exercise training 2 times/week for
90 min; recreational activities 1 time/week for 45 minutes; 6 relaxation sessions of 45
minutes
Healthcare professionals involved: physiotherapists; nurses
Control group components
Usual care
Number of components and dominant component: 6, organisational - patients
Outcomes Patient level
Quality of life: CRDQ score: fatigue, emotion, mastery, and dyspnoea scores
Asthma symptoms and activity level: mean endurance time during cycling at 75%Wmax;
mean cardiac frequency during cycling at 60% Wmax; mean walking distance
Time of outcome measurement: at 3 months
Notes First 3 months considered only (before cross-over)
CRDQ: Chronic Respiratory Disease Questionnaire
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation procedure with
closed envelopes
Allocation concealment (selection bias) Low risk Block randomisation procedure with
closed envelopes
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No indication in text
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Cambach 1997 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Total of 99 patients - 10 dropouts = 89 ran-
domised - 23 loss to f/u (9 Iintervention
and 14 control patients) = 66 patients in-
cluded (74%)
Baseline characteristics of 33 dropouts not
significantly different from 66 completed.
Similar rates of dropouts between groups
Selective reporting (reporting bias) Unclear risk No protocol
Other bias Low risk No other bias detected
Outcomes at baseline similar? Unclear risk No statistical test for asthma subgroup
Characteristics at baseline similar? High risk Significant difference between groups for
age and FEV1
Adequate protection against contamina-
tion?
Low risk Unlikely that control group received inter-
vention before cross-over
Castro 2003
Methods RCT, patient recruitment: hospital inpatients admitted for dyspnoea
Setting: inpatient and outpatient setting, Barnes-Jewish Hospital, Missouri, USA
Participants Control patients: n = 46, women: 85%, mean age: 38, moderate-severe asthma (accord-
ing to FEV1), FEV1: 58%, ICS use: not reported
Intervention patients: n = 50, women: 80%, mean age: 35, moderate-severe asthma
(according to FEV1), FEV1: 57%, ICS use: not reported
Interventions Name and duration of programme: Use of an asthma nurse specialist to provide a
multifaceted approach to asthma care for “high-risk” inpatients, tailored to patients,
during 6 months
Intervention group components
Organisational - patients: psychosocial support and screening for professional coun-
selling; consultation with social services to facilitate discharge planning; provision of
outpatient follow-up through phone contact and home visits as necessary; assessing need
for allergy skin testing
Organisational - healthcare professionals/system: teamwork and collaborative processes
between providers (suggestion by nurse to GP regarding current regimen, flow sheet as
direct communication between nurse and GP); explicit use of EBM for care (regimen in
accordance with National Asthma Education and Prevention Program II); daily ’asthma
care’ flow sheet
Patient education: one on one education on management of the disease, prevention of
exacerbation, smoking cessation, use of spacer, medication delivery technique, peak flow
monitoring
Self-management support: asthma self-management plan
Frequency: tailored to patients
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Castro 2003 (Continued)
Healthcare professionals involved: GPs; respiratory care nurses
Control group components
Usual care (which includes asthma education as well as inhaler technique and peak flow
monitoring by respiratory therapist and nurse in hospital)
Number of components and dominant component: 10, mixed (organisational - pa-
tients, organisational - healthcare professionals or system)
Outcomes Organisational level
Healthcare utilisation: asthma-related hospitalisations (absolute number, mean num-
ber per patient) (primary); non-asthma-related hospitalisations (absolute number, mean
number per patient); GP visits (absolute number, mean number per patient); ED visits
(absolute number, mean number per patient); asthma-related hospital days (absolute
number, mean number per patient); non-asthma-related hospital days (absolute number,
mean number per patient); mean time to readmission; mean healthcare costs per patient
Costs: total healthcare costs per patient
Patient level
Quality of life: AQLQ score: overall, activity, symptom, emotional, and environmental
scores
Time of outcome measurement: at 6 mo
Notes AQLQ: Asthma Quality of Life Questionnaire
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”study patients were randomly assigned in
a blind selection procedure using a pre-ran-
domised assignment in a sealed letter“
Allocation concealment (selection bias) Low risk See supra
Blinding (performance bias and detection
bias)
All outcomes
High risk Data were collected by asthma nurses who
knew allocation status
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data on all randomised patients
Selective reporting (reporting bias) Unclear risk No protocol
Other bias Low risk No other bias detected
Outcomes at baseline similar? Unclear risk No measurement of primary outcome at
baseline. ED visits at baseline: 4.8 versus 5.
6, but not significant
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Castro 2003 (Continued)
Characteristics at baseline similar? Low risk ”both groups were well balanced with re-
spect to all baseline characteristics, and
therewas no significant differences between
the groups“
Adequate protection against contamina-
tion?
Unclear risk Unclear if GP saw both intervention and
control patients
Charrois 2006
Methods RCT, patient recruitment: patients or clients of primary care clinic or pharmacy
Setting: community rural pharmacies and primary care practices, Alberta, Canada
Participants Control patients: n = 34, women: 53%, mean age: 38.7, moderate-severe asthma (ac-
cording to ACQ), ACQ score: 1.91, FEV1: not reported, ICS use: 76.5%
Intervention patients: n = 36, women: 53%, mean age: 35.7, moderate-severe asthma
(according to ACQ), ACQ score: 1.45, FEV1: not reported, ICS use: 69.4%
Interventions Name and duration of programme: Better Respiratory Education and Asthma Treat-
ment in Hinton and Edson (BREATHE), during 6 months
Intervention group components
Organisational - patients: structured follow-up; assessment of medication adherence;
optimisation of drug therapy (assessment of medications by pharmacist)
Organisational - healthcare professionals or system: teamwork and collaborative processes
between providers (referral to respiratory therapist or physician, or both, as needed)
; pharmacist training; quality improvement processes (routine reporting); explicit use
of evidence-based medicine for development of action plan and medication assessment
(Canadian asthma guidelines)
Patient education: distribution of printed material and one on one education on asthma,
management of the disease (asthma medication)
Self-management support: action plan; inhaler technique assessment or education
Frequency: reinforcement session at 1 week; phone call at 2 weeks; pharmacist visit at 1,
2, 4, 6 months; respiratory therapist visit at 2, 6 months
Healthcare professionals involved: pharmacists; respiratory therapists
Control group components
Usual care (which includes provision of asthma education booklet, general advice as
needed and assessment of inhaler technique; one referral to respiratory physiotherapist
for FEV1 measurement, and two follow-up visits to pharmacist
Number of components anddominant component: 11,mixed (organisational - health-
care professionals or system, education and self-management)
Outcomes Organisational level
Process: participation rate; % intervention patients with action plan; % intervention
patients with education at each visit (no data); % intervention patients with treatment
recommendation (no data); % patients with prescription of inhaled corticosteroids
Healtcare utilisation: number of ED visits or hospitalisation
Patient level
Asthma symptoms and activity level: ACQ score (primary); number of courses of oral
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Charrois 2006 (Continued)
steroids
Pulmonary function: mean FEV1
Time of outcome measurement: at 6 months
Notes ACQ: Asthma Control Questionnaire
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”The patient was randomised by an Inter-
net randomisation service trough an exter-
nal centre. Sealed envelopes were provided
for randomisation for sites without Inter-
net access“
Allocation concealment (selection bias) Low risk Central allocation and sealed envelopes:
compared with supra
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No indication in text
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data for 32/34 patients
in control group (94%) and 29/36 in in-
tervention group (81%), but ITT analyses
Selective reporting (reporting bias) Low risk Reported outcomes match planned study
outcomes published in design article
Other bias High risk Poor application of intervention: 2/3 with
complete f/u, 3/4 with action plan, 1/2
with education at each visit, 1/2 with treat-
ment recommendation
Outcomes at baseline similar? Unclear risk No statistical comparisons for primary
outcome. For one of the secondary out-
comes (unscheduled physician visit), sta-
tistically significant difference between the
two study groups at baseline
Characteristics at baseline similar? High risk ”Statistically significant differences be-
tween the two study groups with regards
to the results of previous pulmonary func-
tion tests, inhaler technique use, use of peak
flow meter“
Adequate protection against contamina-
tion?
High risk All pharmacists received training and they
saw both intervention and control patients
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Couturaud 2002
Methods RCT, patient recruitment: patients or clients of primary care clinic or pharmacy
Setting: outpatient clinic of two university hospitals, France
Participants Control patients: n = 36, women: 66.7%, mean age: 38.1, smokers: 8.3%, moderate-
severe asthma (according to GINA), FEV1: 85%, ICS use: 100%
Intervention patients: n = 36, women: 69.4%, mean age: 37.8, smokers: 16.7%, mod-
erate-severe asthma (according to GINA), FEV1: 83%, ICS use: 100%
Interventions Name and duration of programme: Educational programme in asthmatic patients
following treatment readjustment, during 12 months
Intervention group components
Organisational - patients: structured follow-up
Organisational - healthcare professionals or system: teamwork and collaborative processes
between providers (self-management plan sent to GP); nurse training
Patient education: one on one education on asthma, management of the disease (effects
and purpose of asthma drug), prevention of exacerbations
Self-management support: action plan; proper use of inhaler device; reinforcement ses-
sions
Frequency: 30-60 min sessions at 1, 2, 6, 9, 12 months
Healthcare professionals involved: respiratory care nurse; hospital physician; GP
Control group components
Usual care
Number of components and dominant component: 7, education and self-manage-
ment
Outcomes Organisational level
Healtcare utilisation: number of unscheduled visits (to GP, ED or MD, for asthma
exacerbation)
Patient level
Quality of life: AQLQ score
Asthma symptoms and activity level: absence of asthma symptoms (% symptom-free
days) (primary); % days of oral steroids intake; % days off work
Self-management: asthma knowledge score; self-management ability score; compliance
with medicine score (Morisky questionnaire)
Pulmonary function: mean FEV1
Time of outcome measurement: at 12 months
Notes AQLQ: Asthma Quality of Life Questionnaire
Supplementary data sought, but author replied data were unavailable
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised randomisation using a table of
permutations
Allocation concealment (selection bias) Low risk Centralised randomisation
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Couturaud 2002 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No indication in text
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 72 patients randomised - 18 dropouts = 54
completed (75%). No statistical difference
between dropouts and completed, but no
information on difference between drop-
outs in control and intervention groups
Selective reporting (reporting bias) Unclear risk No protocol
Other bias Unclear risk Patients were randomised after run-in pe-
riod, possibly selectingmore compliant pa-
tients
Outcomes at baseline similar? Unclear risk Not measured at baseline
Characteristics at baseline similar? Low risk No significant differences between groups
for clinical and demographical characteris-
tics
Adequate protection against contamina-
tion?
Unclear risk Patients in control group had to monitor
their PEF and record their daily symptoms,
possibly providing help for self-manage-
ment
Feifer 2004
Methods CBA, patient recruitment: general population (i.e. clients of health insurance)
Setting: practices in a US region covered by a specific health insurance company
Participants Control patients: n = 35,450, women: 56%, mean age: not reported, asthma severity:
not reported, FEV1: not reported, ICS use: not reported
Intervention patients: n = 35,450, women: 56%, mean age: not reported (5 to 17
yr: 27%; 18 to 44 yr: 27%; 45 to 64 yr: 24%; 65 plus yr: 22%), asthma severity: not
reported, FEV1: not reported, ICS use: not reported
Interventions Name and duration of programme: population-based asthma disease management
programme using broad-based educational interventions, during 12 months
Intervention group components
Organisational - patients: telephone counselling centre, refill reminders, compliance
reminders, pollen count alerts
Organisational - healthcare professionals/system: asthma management flow sheets
Patient education: distribution of educational material (5 workbooks, 2 newsletters) on
asthma therapy, self-management techniques, and trigger avoidance
Frequency: workbooks mailed at 2 month interval, newsletter at 6 month interval
Healthcare professionals involved: GP, pharmacists
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Feifer 2004 (Continued)
Control group components
Usual care
Number of components and dominant component: 7, mixed (organisational - health-
care professionals or system, education and self-management)
Outcomes Organisational level
Process: % patients who used one or more controllers; average number of controller
prescriptions dispensed per patient; average number of reliever prescriptions dispensed
per patient
For intervention group only: % patients with an action plan; a peak flow meter; a plan
for how to treat triggers
Healthcare utilisation (for intervention group only): % patients reporting 4 or more
outpatient visits; one or more emergency room (ER) visits; one or more hospitalisation
Quality of life (for intervention group only): mini-AQLQ score
Asthma symptoms and activity level (for intervention group only): productivity loss in
days
Self-management (for intervention group only): % patients who know how to use peak
flow meter; aware of triggers for asthma; aware of how medications can manage allergies
Time of outcome measurement: at 12 months
Notes AQLQ: Asthma-specific Quality of Life Questionnaire
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Retrospective allocation
Allocation concealment (selection bias) Unclear risk Retrospective allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Claims data
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Unclear risk No other bias detected
Outcomes at baseline similar? Low risk Matched control group
Characteristics at baseline similar? Low risk Matched control group
Adequate protection against contamina-
tion?
Low risk Contamination unlikely
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Galbreath 2008
Methods RCT, patient recruitment: general population, patients or clients of primary care clinic
or pharmacy, patients or clients of respiratory care clinic
Setting: University Medical Center and private primary practices, South Texas, USA
Participants Control patients: n = 143, women: 77.6%, mean age: 43.7, moderate-severe asthma
(according to GINA score), FEV1 (pre): 76.9
Leukotriene inhibitor use: 30.1%, inhaled corticosteroid (ICS) use (alone): 13.3%, ICS
use (alone or in combination): 65%
Intervention (a) patients: n = 143, women: 79.7%, mean age: 42.4, moderate-severe
asthma (according to GINA score), FEV1 (pre): 78.2 Leukotriene inhibitor use: 34.3%,
ICS use (alone): 13.3%, ICS use (alone or in combination): 66.4%
Intervention (b) patients: n = 143, women: 75.5%, mean age: 42.1, moderate-severe
asthma (according to GINA score), FEV1 (pre): 75.3 Leukotriene inhibitor use: 38.5%,
ICS use (alone): 20.3%, ICS use (alone or in combination): 72.7%
Interventions Name and duration of programme: The South Texas Asthma Management Project
(STAMP) comparing two national guideline-based asthma management strategies: tele-
phonic DM (CDM group), or telephonic DM plus in-home visits (augmented CDM
group), during 6 months
Intervention (a) group components (CDM)
Organisational - patients: structured follow-up; hotline if needed
Organisational - healthcare professionals or system: explicit teamwork betweenhealthcare
providers; explicit use of EBM supports for programme
Patient education: phone calls; topic of education: not clear
Self-management support: providing an action plan; supervised reinforcement sessions
Frequency: 6 to 7 phone calls by nurse
Healthcare professionals involved: GP; respiratory care nurse
Intervention (b) group components (augmented CDM)
Organisational - patients: intervention (a); home visits with home environment evalua-
tion
Organisational - healthcare professionals or system: intervention (a)
Patient education: intervention (a)
Self-management support: intervention (a); instruction on use of equipment
Frequency: intervention (a); 4 home visits at 1, 2, 3, and 6 months
Healthcare professionals involved: intervention (a); respiratory therapist
Control group components
Usual care
Number of components and dominant component: 9, mixed (organisational - pa-
tients, education and self-management)
Outcomes Organisational level
Organisational: % patients completing ≥ 80% of CDM intervention
Process: % patients who initiated controller therapy
Healthcare utilisation: time to first ED visit or inpatient hospitalisation for asthma
(primary); number of urgent office visits for asthma per patient per year (primary);
number of ED visits for asthma per patient per year (primary); number of inpatient
admissions for asthma per patient per year (primary)
Patient level
Quality of life: AQLQ score (primary)
Asthma symptoms and activity level: number of corticosteroids burst (no data); LASS
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Galbreath 2008 (Continued)
score
Pulmonary function: mean FEV1, FEV1/FVC, PEF
Time of outcome measurement: at 12 months
Notes AQLQ: Asthma Quality of Life Questionnaire; LASS: Lara Asthma Symptom Scale
The author identified 5 primary outcomes out of 7 outcomes. Only results of adult
population included in review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”using a sequence of randomly permuted
blocks generated with stata“
Allocation concealment (selection bias) Low risk ”the randomisation sequence was trans-
ferred to a series of consecutively num-
bered, sealed cardboard randomisation
boxes, packaged to ensure blindness from
sound or weight of box“
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinded research staff at randomisation;
blinded research staff administered study
questionnaires
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 99% of data for healthcare utilisation and
event. Around 60% of self-reported data
(similar rates across groups). Difference in
withdrawal (7 versus 2 versus 1) probably
not relevant
Selective reporting (reporting bias) Unclear risk PFT measured at each study visit but not
reported
Other bias Unclear risk 70% of study patients completed ≥ 80%
of intervention
Outcomes at baseline similar? Unclear risk Baseline data only available for 1 outcome
Characteristics at baseline similar? Low risk No significant differences
Adequate protection against contamina-
tion?
Low risk Unlikely that control patient received any
components of intervention group
50Chronic disease management programmes for adults with asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Herborg 2001
Methods C-NRCT, unit of allocation: pharmacy (n = 31), patient recruitment: patients or clients
of primary care clinic or pharmacy
Setting: Community pharmacies throughout Denmark
Participants Control patients: n = 236 (204 at 12 month f/u), women: 54.7%, mean age: 42.4,
moderate-severe asthma (according to study), FEV1: not reported, ICS use: not reported
Intervention patients: n = 264 (209 at 12 month f/u), women: 57.6%, mean age: 38.8,
moderate-severe asthma (according to study), FEV1: not reported, ICS use: not reported
Interventions Name and duration of programme: therapeutic outcomes monitoring (TOM) pro-
gramme, during 12 months
Intervention group components
Organisational - patients: structured follow-up; process and outcome measurement at
the patient’s level (PEFR, symptoms); identify and analyse drug therapy problems
Organisational - healthcare professionals or system: teamwork and collaborative processes
between providers (patient, physician, pharmacist partnership); pharmacist training;
routine reporting; meetings to discuss changes
Patient education: one on one education on asthma and management of the disease
Self-management support: regular checks of inhalation technique
Frequency: monthly visit to pharmacy
Healthcare professionals involved: GP; pharmacist
Control group components
Usual care
Number of components and dominant component: 9, organisational - patients
Outcomes Organisational level
Organisation of care: GP, physician and patient participation rates
Process outcomes: number of oral corticosteroid courses per patient; drug consumption
(mean defined daily dose (DDD) per user per day) for short-acting beta-agonists, long-
acting beta-agonists, total beta-agonists, inhaled adrenergic agonists, ICS, inhaled an-
ticholinergics, inhaled anti-allergics, oral beta-agonists and theophylline; drug therapy
problems
Healthcare utilisation: number of GP visits; number of GP phone contacts; number
of specialist visits; number of physician on call visits; number of ED visits; number of
hospital admissions; number of asthma clinic visits
Patient level
Patient satisfaction: DCPP score
Quality of life: LWAQ score; NHP score
Asthma symptoms and activity level: asthmamorbidity index; number of days of sickness
per patient
Self-management: asthma knowledge score; number of inhalation errors per patient
Pulmonary function: mean PEF
Time of outcome measurement: at 12 months
Notes Unit of analysis error (pharmacies randomised, patients analysed) taken into account in
analyses
DCPP: Danish College of Pharmacy Practice; LWAQ: Living with Asthma Question-
naire; NHP: Notthingham Health Profile
51Chronic disease management programmes for adults with asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Herborg 2001 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Not randomised
Allocation concealment (selection bias) High risk Not randomised
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk 20.8% dropped out in intervention group
and 13.6% in control group, but no reasons
were provided
Selective reporting (reporting bias) Unclear risk No protocol
Other bias Low risk Hierarchical structure of data taken into ac-
count in analyses
Outcomes at baseline similar? Unclear risk Differences at baseline, but no statistical
test provided
Characteristics at baseline similar? Low risk Characteristics appear well balanced (age,
sex)
Adequate protection against contamina-
tion?
Low risk Intervention pharmacies worked solely
with intervention patients
Huang 2009
Methods RCT, patient recruitment: patients or clients of respiratory care clinic
Setting: outpatient chest department of teaching hospital, Taiwan
Participants Control patients: n = 58, women: 22%, age (45 to 64): 40%, moderate-severe asthma
(according to GINA score), FEV1 (pre): 51.8, ICS use: not reported
Intervention (a) patients: n = 58, women: 35%, age (45 to 64): 43%, moderate-severe
asthma (according to GINA score), FEV1 (pre): 51.7, ICS use: not reported
Intervention (b) patients: n = 57, women: 24%, age (45 to 64): 39%, moderate-severe
asthma (according to GINA score), FEV1 (pre): 50.9, ICS use: not reported
Interventions Name and duration of programme: Individualised self-care education programmes
(with and without peak-flow monitoring) in older adults with moderate-to-severe
asthma, during 6 months
Intervention (a) group components (CDM)
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Huang 2009 (Continued)
Organisational - patients: structured follow-up; outcome measurement (day and night-
time asthma symptoms recorded by patients); involvement of family members
Organisational - healthcare professionals or system: explicit teamwork betweenhealthcare
providers
Patient education: distribution of material and one on one educational phone calls on
asthma, management of the disease, prevention of exacerbation, and physical activity
Self-management support: providing an action plan
Frequency: phone call once a week
Healthcare professionals involved: GP; non-specialised nurse
Intervention (b) group components (augmented CDM)
Organisational - patients: intervention (a)
Organisational - healthcare professionals/system: intervention (a)
Patient education: intervention (a); how to use a peak flow meter and manage asthma
based on values
Self-management support: intervention (a); use of peak flow meter
Frequency: intervention (a)
Healthcare professionals involved: intervention (a)
Control group components
Usual care (which includes routine asthma education programme with computer-aided,
self-learning video)
Number of components and dominant component: 6, education and self-manage-
ment
Outcomes Organisational level
Process: number of type of medications; % change of medication dose
Healthcare utilisation: number of unscheduled ED visits (MD, hospital, ED)
Patient level
Asthma symptoms and activity level: asthma control test score
Self-management: asthma self-care competence (knowledge and skills) score (primary);
asthma self-care behaviour score (primary); asthma self-efficacy score (primary)
Pulmonary function: mean FEV1, PEF, FVC, FEV1/FVC
Time of outcome measurement: at 6 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”used a computer-developed random table
to assign patients to intervention groups“
Allocation concealment (selection bias) Unclear risk ”allocation was concealed from recruiting
RA“ but no details provided
Blinding (performance bias and detection
bias)
All outcomes
Low risk ”RA collecting data and author who as-
sessed and analysed outcomes were blinded
to group assignment“
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Huang 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 173 randomised - 25 losses to follow-up
= 148 patients (85.5%). Similar rates and
reasons across groups (see figure 1)
Selective reporting (reporting bias) Unclear risk No protocol
Other bias Low risk No other bias detected
Outcomes at baseline similar? Low risk ”groups were well-balanced for lung func-
tion, asthma self-care competence, be-
haviours, self-efficacy“
Characteristics at baseline similar? Low risk ”groups were well-balanced for baseline de-
mographic characteristics“
Adequate protection against contamina-
tion?
Low risk Unlikely that nurse called control patients
Kokubu 2000
Methods RCT, patient recruitment: patients from hospital (n = 17)
Setting: hospital and patients’ home, Japan
Participants Control patients: n = 34, women: 56%, mean age: 47.3, asthma severity: not reported,
FEV1: not reported, ICS use: not reported
Intervention patients: n = 32, women: 62%, mean age: 49.9, asthma severity: not
reported, FEV1: not reported, ICS use: not reported
Interventions Name and duration of programme: asthma telemedicine system, during 6 months
Intervention group components
Organisational - patients: structured follow-up; telephone hotline
Organisational - healthcare professionals or system: explicit teamwork betweenhealthcare
providers; fax sent to physician; information technology
Patient education: one on one educational phone calls on asthma and management of
the disease
Self-management support: providing an action plan; regular checks of inhalation tech-
nique
Frequency: not clear
Healthcare professionals involved: pulmonary care physicians; respiratory care nurses
Control group components
Usual care
Number of components and dominant component: 8, organisational - healthcare
professionals or system
Outcomes Organisational level
Process: mean inhaled corticosteroid dose (puff/day)
Healthcare utilisation: hospitalisation rate (hospitalisation/patient/6 months); night ER
visits rate; daytime ER visits rate
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Kokubu 2000 (Continued)
Costs: direct and indirect cost savings
Patient level
Patient satisfaction: satisfaction survey
Quality of life: improvement in QoL score
Asthma symptoms and activity level: mean inhaled ß2-agonists dose (puff/day); mean
oral corticosteroid dose (tab/day)
Self-management: compliance with prescribed inhaled corticosteroids; compliance with
oral corticosteroids; compliance with daily PEF measurements
Pulmonary function: mean PEF
Time of outcome measurement: at 6 months
Notes We only used the data presented in the primary reference for the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Telephone registration randomisation
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not clear in the article
Selective reporting (reporting bias) Unclear risk No protocol
Other bias Unclear risk No other bias detected
Outcomes at baseline similar? Low risk No significant differences (see table 3 in the
article)
Characteristics at baseline similar? Low risk No significant differences (see table 3 in the
article)
Adequate protection against contamina-
tion?
Low risk Unlikely
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Landon 2007
Methods CBA, patient recruitment: patients/clients of primary care clinic or pharmacy
Setting: Community health centres throughout USA (n = 48)
Participants Control patients: n = not clear, women: 67.6%, mean age: 34.4, asthma severity: not
reported, FEV1: not reported, ICS use: not reported
Intervention patients: n = not clear, women: 63.5%, mean age: 28.4, asthma severity:
not reported, FEV1: not reported, ICS use: not reported
Total patients with asthma: n = 3392
Interventions Name and duration of programme: Health Disparities Collaboratives (each generally
including 20 or more community health centres) disseminating quality improvement
techniques developed by the Institute for Healthcare Improvement, during 4.5 years
Intervention group components*
Organisational - patients: community linkages component (access to resources (e.g.,
donated medical services) in the community for the benefit of patients in community
health centres; providing services to an entire community (e.g., “Diabetes Awareness
Day”))
Organisational - healthcare professionals or system: delivery system redesign compo-
nents (improvement of care management, missed-appointment follow-up, organisation
of the practice team; change of care delivery roles; patient visits planning); decision sup-
port component (guidelines, protocols, and prompts; providers education; facilitating
specialty and expert consultation); information support components (patient registry
systems; improving the collection or use of data for care management; providing perfor-
mance data to individual providers or to the group or organisation); health system organ-
isation component (increase administrators’ motivation and ability to improve care for
patients with chronic disease, increase providers’ motivation and ability to be involved
in such improvements, or improve the overall ability of the system or institution to en-
gage in co-ordinated quality improvement efforts); physician training; explicit teamwork
(creation of improvement teams)
Patient education and self-management support: self-care support component (provid-
ing education or care guidelines to patients, increase patient motivation for self-care,
assessment of self-care needs or abilities, providing support tools or resources to improve
self-care, collaborative decision making with patients)
Frequency: variable in the centres
Healthcare professionals involved: teams from community health centres
Control group components
Usual care
Number of components and dominant component: ≥11, organisational - healthcare
professionals or system
Outcomes Organisational level
Process outcomes: % patients with an action plan; % patients assessed for smoking
status and cessation advice; % patients assessed for exposure to smoke; % patients with
advice on smoking; % patients vaccinated for influenza; % patients assessed for asthma
severity; overall quality of care provided score (prevention and screening, monitoring
and treatment, outcomes)
Healthcare utilisation:%patientswith nourgent care, ERvisit, hospitalisation for asthma
Patient level
Asthma symptoms and activity level: % patients treated with anti-inflammatory medi-
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cation
Time of outcome measurement: at 2 to 3 years
Notes *The study evaluated a range of interventions that took place in 48 community health
centres. Each interventionhad to include at least 1 component of the 6major components
described above
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk No randomisation
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Unclear whether outcome assessment was
blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear whether all data were collected
Selective reporting (reporting bias) Unclear risk No protocol
Other bias Unclear risk No other bias detected
Outcomes at baseline similar? Unclear risk No P values provided for comparisons be-
tween groups
Characteristics at baseline similar? Unclear risk Significant differences between groups for
Charlson morbidity index, age and insur-
ance type
Adequate protection against contamina-
tion?
Low risk External control centres
Martin 2009
Methods RCT, patient recruitment: patients or clients of primary care clinic or pharmacy
Setting: primary care clinics, Chicago, USA
Participants Control patients: n = 22, women: 77%, mean age: 37, asthma severity: not clear, FEV1:
not reported, ICS use: 77%
Intervention patients: n = 20, women: 60%, mean age: 33, asthma severity: not clear,
FEV1: not reported, ICS use: 70%
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Interventions Name and duration of programme: A community-based intervention to improve
asthma self-efficacy in African American adults designed by the Chicago Initiative to
Raise Asthma Health Equity (CHIRAH), during 12 weeks
Intervention group components
Organisational - patients: home visits; financial incentive
Organisational - healthcare professionals/system: healthcare professionals training
Patient education: educational groups and outreach visits on asthma, management of the
disease, prevention of exacerbation, smoking cessation, physical activity, use of spacer,
inhalation techniques, symptom monitoring, and communicating with provider
Self-management support: providing an action plan; reinforcement sessions
Frequency: 4 group sessions and 6 home visits
Healthcare professionals involved: community health worker, social worker, member of
study team
Control group components
Usual care (which includes 2 mailings with asthma education information)
Number of components and dominant component: 7, education and self-manage-
ment
Outcomes Organisational level
Process: participation rate; % patients with action plan; % patients using spacer
Patient level
Quality of life: mini-AQLQ score
Asthma symptoms and activity level: number of symptomatic days; number of symp-
tomatic nights; number of times inhaled corticosteroids were used
Self-management: self-efficacy score (primary); asthma knowledge score; coping skills
score
Time of outcome measurement: at 6 months
Notes AQLQ: Asthma Specific Quality of Life Questionnaire
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”randomisation done in pairs“: pairwise
randomisation where each centre recruited
2 persons at a time (pair) and randomised
one to the intervention and one to the con-
trol group. But no description of the ran-
domisation method
Allocation concealment (selection bias) Unclear risk No description
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No description
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Martin 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up data missing for 2 intervention
and 4 control patients (14%) at 3 months
and 1 intervention and 3 control patients
(10%) at 6 months
Selective reporting (reporting bias) Unclear risk No protocol
Other bias Low risk No other bias detected
Outcomes at baseline similar? Low risk No statistical difference for primary and
secondary outcomes
Characteristics at baseline similar? High risk Statistical
difference for educational level, household
income, perceived general health
Adequate protection against contamina-
tion?
Unclear risk Not clear
Mayo 1990
Methods RCT, patient recruitment: hospital inpatients admitted for dyspnoea
Setting: hospital outpatient chest clinic, New York, USA
Participants Control patients: n = 57, women: 57.9%, mean age: 42, moderate-severe asthma (ac-
cording to study), FEV1: not reported, ICS use: not clear
Intervention patients: n = 47, women: 70.2%, mean age: 42, moderate-severe asthma
(according to study), FEV1: not reported, ICS use: not clear
Interventions Name and duration of programme: outpatient programme designed to reduce read-
missions for asthma exacerbations among adults with asthma, during 8 months before
partial cross-over
Intervention group components
Organisational - patients: structured follow-up; advice or assistance if needed
Organisational - healthcare professionals or system: teamwork and collaborative processes
between providers (nurse practitioner shared responsibilities with physician)
Patient education: one on one education on asthma and management of the disease
Self-management support: regular checks of inhalation technique; patients received
spacer device and peak flow meter
Frequency: 2 x 1 h visits, followed by≥ 30 min visits, depending on patient’s preferences
and level of asthma activity
Healthcare professionals involved: pulmonary care physician; respiratory care nurse
Control group components
Usual care
Number of components and dominant component: 6, education and self-manage-
ment
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Mayo 1990 (Continued)
Outcomes Organisational level
Healthcare utilisation: number of hospital admissions (mean and mean admissions per
patient); total hospitalisation days; hospitalisation days per patient
Patient level
Asthma symptoms and activity level: mortality rate
Time of outcome measurement: at 8 months
Notes We only considered results at 8 months, before part of the control patients were crossed
to the intervention group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Random allocation by last digit of hospital
number
Allocation concealment (selection bias) Unclear risk No description
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No description
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Ten patients lost to follow-up in inter-
vention group, no information on control
group
Selective reporting (reporting bias) Unclear risk No protocol
Other bias Low risk No other bias detected
Outcomes at baseline similar? Low risk No statistical difference
Characteristics at baseline similar? Low risk No statistical difference
Adequate protection against contamina-
tion?
Unclear risk Not clear if physician or nurse practitioner,
or both, saw both intervention and control
patients
McLean 2003
Methods RCT, patient recruitment: patients or clients of primary care clinic or pharmacy
Setting: community pharmacies, British Columbia, Canada
Participants Control patients: n = 214, women: 62.9%, mean age: not clear, asthma severity: not
clear, FEV1: not reported, ICS use: % not reported
Intervention patients: n = 191, women: 63.0%, mean age: not clear, asthma severity:
not clear, FEV1: not reported, ICS use: % not reported
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McLean 2003 (Continued)
Interventions Name and duration of programme: the British Columbia pharmacy asthma study in-
corporating an asthma care protocol provided by specially trained community pharma-
cists, during 12 months
Intervention group components
Organisational - patients:structured follow-up; outcome measurements at the patient’s
level (PEF reading); patients participation in decisions
Organisational - healthcare professionals/system: teamwork and collaborative processes
between providers (physicians informed or consulted regarding all results and interven-
tions); explicit use of EBM supports
Patient education: one on one education on asthma, management of the disease, pre-
vention of exacerbations, and use of peak flow meter
Self-management support: providing of action plan; calendars/diaries provided to record
PEF rate
Frequency: every 2 to 3 weeks for first 3 appointments, then every 3 months
Healthcare professionals involved: GP; pharmacists
Control group components
Usual care
Number of components and dominant component: 7, education and self-manage-
ment
Outcomes Organisational level
Healthcare utilisation: number of emergency visits per patient in previous month; num-
ber of hospital days per patient in previous month; number of medical visits per patient
in previous month; majors costs per month per patient
Patient level
Patient satisfaction: score on survey
Quality of life: Juniper score (+ 4 subscores)
Asthma symptoms and activity levels: total asthma symptoms score (+ 8 subscores);
number of days off school or work in previous month; dose/day of ß2-agonists; dose/
day of inhaled corticosteroids
Self-management: asthma knowledge score (+ 4 subscores)
Pulmonary function: mean PEF
Time of outcome measurement: at 12 months
Notes Juniper: asthma-specific quality of life questionnaire
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Procedure to assign patients not described
Allocation concealment (selection bias) Low risk Central randomisation
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
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McLean 2003 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow-up of pharmacies, pharma-
cists andpatientswithout reasons provided.
Control patients not included in analyses
Selective reporting (reporting bias) Unclear risk No protocol
Other bias High risk Possible recruitment bias by pharmacist;
clusters not taken into account in analyses;
not ITT because cross-over taken into ac-
count; patients in usual care completed di-
ary, were taught proper inhaler technique,
which may have improved care received
Outcomes at baseline similar? Unclear risk No statistical test provided
Characteristics at baseline similar? Unclear risk Not described
Adequate protection against contamina-
tion?
High risk Pharmacist sees control and intervention
patients
Petro 2005
Methods C-RCT, unit of allocation: providers (n = nc), patient recruitment: patients or clients of
primary care clinic or pharmacy
Setting: private primary practices, Germany
Participants Control patients: n = 55, women: 44.0%, mean age: 55.0, smokers: 28%, moderate-
severe asthma (according to study), FEV1: not reported, ICS use: not reported
Intervention patients: n = 56, women: 54.2%, mean age: 57.3, smokers: 22.9%, mod-
erate-severe asthma (according to study), FEV1: not reported, ICS use: not reported
Interventions Name and duration of programme: a disease management programme involving a case
manager who carries out patient instructions, evaluates symptoms and lung function
values on a daily basis and supervises treatment goals with the aid of predetermined
algorithms, during 12 months
Intervention group components
Organisational - patients: case management; outcome measurements at the patient level
Organisational - healthcare professionals or system: teamwork and collaborative processes
between providers (discussion between GP and case manager); case manager training;
quality improvement process (PulmAssist Plus), information technology (data transmit-
ted by modem)
Patient education: one on one education on themes linked to asthma
Frequency: daily monitoring of FEV and PEF
Healthcare professionals involved: GP; case manager
Control group components
Usual care
Number of components and dominant component: 7, organisational - healthcare
professionals or system
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Petro 2005 (Continued)
Outcomes Organisational level
Healthcare utilisation: % patients with asthma-related hospitalisations; cost difference
Patient level
Quality of life: FLA score (primary); EQ-5D score and VAS
Asthma symptoms and activity level: % patients without asthma symptoms
Pulmonary function: FEV1 (no data provided in article), PEFR (no data provided in
article)
Time of outcome measurement: at 12 months
Notes Unit of analysis error (provider randomised, patients analysed) were not taken into
account in the published analyses. The design effect can not be computed as the number
of clusters is unknown. Results were excluded from our meta-analyses
FLA: Fragebogen zür Lebensqualität bei Asthma, based on Living with Asthma Ques-
tionnaire; EQ-5D: descriptive system of health-related quality of life states consisting
of five dimensions (mobility, self-care, usual activities, pain and discomfort, anxiety and
depression)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description
Allocation concealment (selection bias) Unclear risk No description
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No description
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not clear for providers; for patients: 111
randomised - 8 losses to follow-up in in-
tervention group - 5 losses to follow-up in
control group = 98 (88%)
Selective reporting (reporting bias) Unclear risk No protocol
Other bias High risk Incorrect analysis (unit of analysis error:
cluster allocation but patient level analysis)
Outcomes at baseline similar? Unclear risk No statistical difference for primary out-
come, but statistical difference for EQ-5D
Characteristics at baseline similar? Unclear risk No statistical test provided (sex: 44%versus
54%)
Adequate protection against contamina-
tion?
Low risk Randomisation by provider
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Schatz 2006
Methods RCT, patient recruitment: patients or clients of primary care clinic or pharmacy
Setting: Kaiser Permanente Medical Care programme, San Diego, USA
Participants Control patients: n = 31, women: 54.8%, mean age: 45.4, smokers: 16.7%, moderate-
severe asthma (according to FEV1), FEV1: 69.2%, ICS use: % not reported
Intervention patients: n = 31, women: 32.3%, mean age: 45, smokers: 22.6%, moder-
ate-severe asthma (according to FEV1), FEV1: 66.7%, ICS use: % not reported
Interventions Name and duration of programme: A regular care manager follow-up in addition to an
initial intensive individualised educational visit and use of a potent controllermedication,
during 12 months
Intervention group components
Organisational - patients: structured follow-up; advice or assistance as needed; distribu-
tion of free inhalers; review of patient’s healthcare utilisation
Organisational - healthcare professionals or system: teamwork and collaborative processes
between providers (GP contacted if inadequate control)
Patient education: distribution of material and one on one education on asthma, man-
agement of the disease and inhalation technique
Self-management support: action plan; peak flow meter given with instructions; symp-
tom and peak flow diaries; review of inhalation technique
Frequency: initial visit with follow-up at 1, 6, and 12 months; phone calls 1/month
Healthcare professionals involved: GP, care manager
Control group components
Usual care (which includes distribution of free inhalers, distribution of material on
asthma and its management, action plan, peak flow meter given with instructions, and
symptom and peak flow diaries)
Number of components and dominant component: 11, mixed (organisational - pa-
tients, education and self-management)
Outcomes Organisational level
Process: prescription of oral steroids
Healthcare utilisation: % patients with any asthma-related hospitalisation or ED visit
Patient level
Quality of life: mini-AQLQ score (primary)
Asthma symptoms and activity level: number of symptom-free days; number of ß2-
agonists canisters
Self-management: asthma knowledge score
Time of outcome measurement: at 12 months
Notes Mini-AQLQ: Asthma Quality of Life Questionnaire
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”randomisation using a computer-gener-
ated list of random numbers“
Allocation concealment (selection bias) Unclear risk No description of concealment
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Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Electronic records used for some data; no
description if blinding for questionnaire
data
Incomplete outcome data (attrition bias)
All outcomes
High risk ”follow-up data were available on less than
half of the control group patients at 12
months“; 72 patients randomised - 17
losses to follow-up (1 in intervention, 16
in usual care) = 45 patients (72.5%)
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias High risk Low enrolment rate (7%) and significant
differences between enrolled and not en-
rolled for age, sex, inhaled steroids use, and
oral steroids
Outcomes at baseline similar? Low risk No significant differences for all outcomes
except one (inhaled steroids)
Characteristics at baseline similar? Low risk No significant differences
Adequate protection against contamina-
tion?
Low risk No risk of contamination (care manager
only for intervention patients)
Smith 2005
Methods RCT, patient recruitment: patients or clients of primary care clinic or pharmacy, patients
or clients of respiratory care clinic
Setting: hospital outpatient asthma clinics and general practices, Norfolk, Suffolk, UK
Participants Control patients: n = 45, women: 84%, mean age: 34.7, smokers: 17.4%, moderate-
severe asthma (according to study self-report), FEV1: not reported, ICS use: 100%
Intervention patients: n = 47, women: 62%, mean age: 38.2, smokers: 19.4%, moder-
ate-severe asthma (according to study self-report), FEV1: not reported, ICS use: 100%
Interventions Name and duration of programme: The Coping with Asthma Study (a home-based,
nurse led psycho-educational intervention for adults at risk of adverse asthma outcomes)
, during 6 months
Intervention group components
Organisational - patients: structured follow-up; advice and/or assistance as needed; in-
volvement of family members; liaison with health and social care professionals; home
visits
Organisational - healthcare professionals or system: teamwork and collaborative processes
between providers (GP and health psychologist available to nurse as supervisors if needed;
referral to specialist); manual to standardise delivery and general content of intervention
Patient education: distribution of material and one on one education on asthma, man-
agement of the disease, prevention of exacerbations, smoking cessation, exercise
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Self-management support: action plan; supervised reinforcement sessions; inhalation
technique; use of peak flow device; collaborative problem solving approach; workbook
with homework
Frequency: visits every 2 weeks for 2 months (~1 hour); phone calls every 2 weeks for 2
months then every month for 4 months
Healthcare professionals involved: respiratory care nurse; GP; health psychologist
Control group components
Usual care
Number of components and dominant component: 15, education and self-manage-
ment
Outcomes Patient level
Quality of life: LAQ score; SF-36 physical function score; SF-36 mental health score;
HADS anxiety score; HADS depression score; GHQ-12 psychiatric morbidity score
Asthma symptoms and activity level: asthma symptom control score (primary)
Self-management: % patients monitoring their peak flow; % patients using reliever
inhaler > 4 times/day; % patients currently smoking; % patients identifying additional
triggers; perceived control of asthma score; medication compliance score
Time of outcome measurement: at 12 months
Notes LAQ: Living with Asthma Questionnaire; SF-36: general health status assessed by the
Short Form 36; HADS: Hospital Anxiety and Depression Scale; GHQ-12: General
Health Questionnaire
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”randomisation by third party not involved
in patient care using open computer gen-
erated block randomisation“
Allocation concealment (selection bias) Low risk By third party not involved in patient care
Blinding (performance bias and detection
bias)
All outcomes
High risk ”no attempts were made to blind assess-
ment“
Incomplete outcome data (attrition bias)
All outcomes
Low risk ”small numbers of individual missing ques-
tionnaire items were replaced with ample
medians to allow calculation of total scores
for each scale“; 92 patients randomised -
8 losses to follow-up (”no clear differences
between these and patients completing the
study“) = 84 in ITT
Selective reporting (reporting bias) Unclear risk Protocol not available
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Other bias Low risk Random-effects model used to adjust for
hierarchical structure of data
Outcomes at baseline similar? Low risk Baseline imbalance adjusted for in analyses
Characteristics at baseline similar? Low risk Imbalance for sex, education, hospitalisa-
tion or ED visit but adjusted for in analyses
Adequate protection against contamina-
tion?
Low risk No risk of contamination (home visits)
Weng 2005
Methods CBA, patient recruitment: general population (i.e. clients of the National Health Insur-
ance)
Setting: Hospital outpatient clinics and primary care clinics run by the National Health
Insurance, Taiwan
Participants Control patients: n = 3188, women: 43%, mean age: not reported (18 plus yr: 72%),
asthma severity: not reported, FEV1: not reported, ICS use: not reported
Intervention patients: n = 854, women: 44.5%, mean age: not reported (18 plus yr:
71.4%), asthma severity: mild-moderate, FEV1: not reported, ICS use: not reported
Interventions Name and duration of programme: A government-sponsored outpatient-based disease
management programme for patients with asthma, during 12 months
Intervention group components
Organisational - patients: case management; structure follow-up
Organisational - healthcare professionals or system: explicit teamwork between primary
care physician and case manager; physician education and training; integration of care
(case manager assured communication between key departments); explicit use of guide-
lines
Patient education: one on one educational sessions on recognition of asthma triggers,
environmental control, symptoms and early warning signs, medication usage and side
effects, use of spacer devices and peak flow meters, and self-management of asthma
exacerbations
Self-management support: supervised reinforcement sessions
Frequency: reinforcement sessions every 3 months
Healthcare professionals involved: general physicians, selected specialists, registered
nurses, physician assistants
Control group components
Usual care
Number of components and dominant component: 8, education and self-manage-
ment
Outcomes Organisational level
Organisation of care: HC professional satisfaction
Healthcare utilisation: number of outpatient department visits; number of emergency
department visits; number of inpatient visits; length of stay
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Time of outcome measurement: at 12 months
Notes We only considered patients already diagnosed with asthma for inclusion in this review,
as patients newly diagnosed with asthma were very young and did not meet our inclusion
criteria for age
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Retrospective allocation
Allocation concealment (selection bias) High risk Retrospective allocation
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Claims data
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Unclear risk No other bias detected
Outcomes at baseline similar? Low risk Matched control group (compared with ta-
ble 3)
Characteristics at baseline similar? Low risk Matched control group
Adequate protection against contamina-
tion?
Low risk Contamination unlikely
Wilson 2010
Methods RCT, patient recruitment: general population (i.e. clients of health insurance)
Setting: Kaiser Permanente clinics, USA (n = 5)
Participants Control patients: n = 204, women: 57.4%, mean age: 45.1, smokers: 16.2%, moderate-
severe asthma (according to GINA), FEV1: ~70%, ICS use: % not clear
Intervention (a) patients: n = 204, women: 55.9%, mean age: 46.9, smokers: 16.2%,
moderate-severe asthma (according to GINA), FEV1: ~70%, ICS use: % not clear
Intervention (b) patients: n = 204, women: 56.4%, mean age: 45.7, smokers: 15.2%,
moderate-severe asthma (according to GINA), FEV1: ~70%, ICS use: % not clear
Interventions Name andduration of programme: the BetterOutcomes of AsthmaTreatment (BOAT)
study, involving asthma education and two in-person and three brief phone encounters,
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with or without shared decision making (SDM), where non-physician clinicians and pa-
tients negotiated a treatment regimen that accommodated patient goals and preferences,
during 9 months
Intervention (a) group components (CDM)
Organisational - patients: structured follow-up
Organisational - healthcare professionals or system: teamwork and collaborative processes
between providers (discussion of recommendations between caremanager and physician)
; healthcare professional training; explicit use of guidelines; quality control (audio taping
to ensure proper intervention delivery)
Patient education: distribution of material and one on one education on asthma, man-
agement of the disease, and instruction on inhaler technique
Self-management support: action plan
Frequency: session 1 at baseline (50 to 60 min), session 2 at 1 month (20 to 30 min),
phone call at 3, 6, 9 months
Healthcare professionals involved: GP, care manager (nurse, respiratory therapist, phar-
macist, or physician assistant)
Intervention (b) group components (augmented CDM)
Organisational - patients: intervention (a); shared decisionmaking for treatment regimen
Organisational - healthcare professionals or system: intervention (a)
Patient education: intervention (a)
Self-management support: intervention (a)
Frequency: intervention (a)
Healthcare professionals involved: intervention (a)
Control group components
Usual care (which includes referral to asthma care management programmes)
Number of components and dominant component: 9, mixed (organisational - patient,
education and self-management)
Outcomes Organisational level
Process: continuous medication acquisition index for ICS only, all asthma controller
(ICS, leukotriene modifiers, cromolyn sodium, theophylline), LABAs, and SABAs; %
patients dispensed a LABA
Healthcare utilisation: asthma-related visits, costs
Patient level
Quality of life: mini-AQLQ score
Asthma symptoms and activity level: ATAQ score
Pulmonary function: FEV1; FEV1/FEV6
Time of outcome measurement: at 24 months
Notes Mini-AQLQ: Asthma Quality of Life Questionnaire; ATAQ: Asthma Therapy Assess-
ment Questionnaire
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-based adaptive randomisation
algorithm was used
69Chronic disease management programmes for adults with asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wilson 2010 (Continued)
Allocation concealment (selection bias) Low risk Allocation was concealed from staff ran-
domising patients
Blinding (performance bias and detection
bias)
All outcomes
Low risk All study personnel, except for care man-
agers, were blinded to patient’s study as-
signment
Incomplete outcome data (attrition bias)
All outcomes
Low risk See figure 2: less than 20% loss to follow-
up, rate is similar across groups
Selective reporting (reporting bias) Unclear risk Trial registered on www.clinicaltrials.gov
but pre-determined outcomes not men-
tioned
Other bias Low risk No other bias detected
Outcomes at baseline similar? Low risk See figures 3, 4, 5
Characteristics at baseline similar? Low risk See table 1
Adequate protection against contamina-
tion?
Low risk Care managers of intervention group (a)
and intervention group (b) were trained
separately and worked independently
Windt 2010
Methods CBA, patient recruitment: general population (i.e. clients of health insurance)
Setting: primary care practices throughout Germany (region covered by one health
insurance company)
Participants Control patients: n = 317, women: 44.2%, mean age: 36.5, asthma severity: not re-
ported, FEV1: not reported, ICS use: not reported
Intervention patients: n = 317, women: 48.6%, mean age: 36.5, asthma severity: not
reported, FEV1: not reported, ICS use: not reported
Interventions Name and duration of programme: nationwide asthma disease management pro-
gramme (duration varies according to specific programme)
Intervention group components*
Organisational - patients: structured follow-up
Organisational - healthcare professionals or system: use of guidelines; information tech-
nology (electronic reports); feedback to physicians
Patient education: education sessions
Frequency: not clear
Healthcare professionals involved: not clear
Control group components
Usual care
Number of components and dominant component: ≥ 5, organisational - healthcare
professionals or system
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Outcomes Organisational level
Process: % patients with prescription of: ICS, ICS as single agent, ICS/LABA in a single
inhaler, controller to total medication ratio ≥ 0.5, oral corticosteroids, theophylline,
leukotriene receptor antagonists, cromolyn combined with LABA, LABAs without ICSs
Healthcare utilisation: % patients with emergency care (hospitalisations or ED visits)
, % patients doctor hopping (with an anti-asthmatic drug prescription from at least 3
different providers)
Time of outcome measurement: at 12 months
Notes *All patients in the intervention group were enrolled in a German disease management
programme, with the following obligatory elements; regular check-ups, education ses-
sions, use of guidelines, information technology (electronic reports), feedback to physi-
cians
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Retrospective allocation
Allocation concealment (selection bias) High risk Retrospective allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Claims data
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data on all patients
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Unclear risk No other bias detected
Outcomes at baseline similar? Low risk Matched control group (compared with ta-
ble 1)
Characteristics at baseline similar? Low risk Matched control group (compared with ta-
ble 1)
Adequate protection against contamina-
tion?
Low risk Contamination unlikely
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
[Advocate’s disease] 2003 CDM but inappropriate study design
[Asthma DM] 2005 CDM but inappropriate study design
[Asthma patients] 1998 Insufficient information
[Asthma project] 1999 CDM but inappropriate study design
[Integrated care] 1994 Insufficient information
[Population-based] 1998 Insufficient information
Afifi 2007 Not CDM according to operational definition
Allen-Ramey 2002 CDM but inappropriate study design
Bailey 1990 Not CDM according to operational definition
Bailey 1999 Not CDM according to operational definition
Baker 2003 Possibly CDM but inappropriate study design
Barbanel 2003 Not CDM according to operational definition
Bolin 2005 Possibly CDM but inappropriate study design
Bolton 1991 Not CDM according to operational definition
Brandao 2009 Possibly CDM but inappropriate study design
Buchner 1998 Not CDM according to operational definition
Burton 2001 Not CDM according to operational definition
Burton 2001a Not CDM according to operational definition
Carmo 2011 CDM but inappropriate study design
Chamnan 2010 Not CDM according to operational definition
Charlton 1990 Not CDM according to operational definition
Charlton 1992 Possibly CDM but inappropriate study design
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Choy 1999 Not CDM according to operational definition
Clark 2007 Not CDM according to operational definition
Clark 2010 Not CDM according to operational definition
Cordina 2001 Not CDM according to operational definition
Cote 1997 Not CDM according to operational definition
Cote 2000 Not CDM according to operational definition
Cote 2001 Not CDM according to operational definition
Cruz 2010 CDM but inappropriate study design
Curtin 1998 CDM but inappropriate study design
D’Souza 2000 CDM but inappropriate study design
Dall 2010 Not CDM according to operational definition
De Oliveira 1999 Not CDM according to operational definition
Delaronde 2002 Possibly CDM but inappropriate study design
Delaronde 2005 Not CDM according to operational definition
Donald 2008 Not CDM according to operational definition
Dozor 2011 Not target population
Dzyngel 1994 Not CDM according to operational definition
Emmerton 2003 CDM but inappropriate study design
Erhola 2003 CDM but inappropriate study design
Fardy 1999 Not CDM according to operational definition
Fireman 2004 CDM but inappropriate study design
Ford 1996 Not CDM according to operational definition
Gallefoss 1999 Not CDM according to operational definition
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Gallefoss 1999a Not CDM according to operational definition
Gallefoss 2000 Not CDM according to operational definition
Gallefoss 2000a Not CDM according to operational definition
Gallefoss 2001 Not CDM according to operational definition
Gallefoss 2002 Not CDM according to operational definition
Gallefoss 2003 Not CDM according to operational definition
Garrett 1994 Not CDM according to operational definition
Groban 1998 CDM but inappropriate study design
Haahtela 2006 CDM but inappropriate study design
Hartmann 2005 Possibly CDM but inappropriate study design
Heard 1999 Not CDM according to operational definition
Hertzman 2005 CDM but inappropriate study design
Hesselink 2004 Not CDM according to operational definition
Holton 2010 Not CDM according to operational definition
Hopman 1999 Not CDM according to operational definition
Horswell 2008 Insufficient information
Ignacio-Garcia 1995 Not CDM according to operational definition
Ignacio-Garcia 2002 CDM but inappropriate study design
Janson 2009 Not CDM according to operational definition
Johnson 2003 CDM but inappropriate study design
Jones 1995 Not CDM according to operational definition
Jounieaux 2003 Not CDM according to operational definition
Jowers 2000 CDM but inappropriate study design
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Kelso 1996 CDM but inappropriate study design
Kligler 2011 Not CDM according to operational definition
Knoell 1998 Not CDM according to operational definition
Kotses 1996 Not CDM according to operational definition
Lahdensuo 1996 Not CDM according to operational definition
Legorreta 2000 Not CDM according to operational definition
Lemaigre 2010 Not CDM according to operational definition
Licskai 2012 CDM but inappropriate study design
Lind 2006 CDM but inappropriate study design
Lindberg 1999 CDM but inappropriate study design
Lindberg 2002 CDM but inappropriate study design
Linden 2007 Not CDM according to operational definition
Lo 2006 CDM but inappropriate study design
Ludwig-Beymer 1998 Not CDM according to operational definition
Magar 2005 Not CDM according to operational definition
Maljanian 1999 CDM but inappropriate study design
Mangiapane 2005 CDM but inappropriate study design
Mehuys 2008 Not CDM according to operational definition
Mildenhall 1998 Not CDM according to operational definition
Morisky 2009 Not CDM according to operational definition
Moudgil 2000 Not CDM according to operational definition
Mu 2006 CDM but inappropriate study design
Mu 2008 CDM but inappropriate study design
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Munroe 1997 CDM and study design alright, but inappropriate outcomes
Narhi 2001 CDM but inappropriate study design
Narhi 2002 CDM but inappropriate study design
Park 2010 Not CDM according to operational definition
Patel 2004 CDM but inappropriate study design
Pauley 1995 CDM but inappropriate study design
Peretz 2012 Not target population
Pilotto 2004 Not CDM according to operational definition
Premaratne 1999 Not CDM according to operational definition
Rossiter 2000 Not CDM according to operational definition
Saini 2004 CDM but inappropriate study design
Saini 2008 CDM but inappropriate study design
Saini 2011 Not CDM according to operational definition
Schonlau 2005 Not CDM according to operational definition
Schott-Baer 1999 Not CDM according to operational definition
Schulz 2001 Not CDM according to operational definition
Scott 2009 Not target population
Shelledy 2009 Not CDM according to operational definition
Smith 2007 Not CDM according to operational definition
Sommaruga 1995 Not CDM according to operational definition
Souza-Machado 2010a CDM but inappropriate study design
Steuten 2006 CDM but inappropriate study design
Swanson 2000 Not CDM according to operational definition
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Tatis 2005 CDM but inappropriate study design
Thoonen 2003 Not CDM according to operational definition
Tinkelman 2004 CDM but inappropriate study design
To 2008 CDM but inappropriate study design
Treadwell 2009 CDM but inappropriate study design
Tschopp 2002 CDM but inappropriate study design
Tschopp 2005 CDM but inappropriate study design
Van Damme 1994 Possibly CDM but inappropriate study design
van der Meer 2009 Not CDM according to operational definition
van der Palen 2001 Not CDM according to operational definition
Wang 2011 Insufficient information
Weinberger 2002 Not CDM according to operational definition
Williams 2007 Possibly CDM but inappropriate study design
Yang 2010 Not CDM according to operational definition
Yawn 2008 Not CDM according to operational definition
Characteristics of ongoing studies [ordered by study ID]
Ahmed 2011
Trial name or title My asthma portal: a web-based self management intervention
Methods Design: Parallel multicentred 2-arm randomised controlled trial
Setting: pulmonary clinics in two tertiary care hospitals in Montreal, Canada
Participants Males and females, aged 18 to 69 years, with a confirmed asthma diagnosis, and classified as having poor
asthma control by their doctor
Interventions Intervention group: personalised web-based application that provides self-management support by combining
personal asthma health information with opportunities to self-monitor and receive feedback from the care
team using a web-based system. It includes tailored asthma education and aims to modify health behaviours
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related to medication adherence, action plan use, and physical activity
Control group: usual care (including an asthma nurse who provides education and follow-up as needed and
follow-up phone calls between visits by the asthma nurse)
Outcomes Organisation of care: asthma-related ED visits or hospitalisations, costs, and other resource utilisation
Asthma control: % patients overusing rescue fast acting bronchodilators (beta2-agonists) (primary)
Asthma quality of life: score on the mini-AQLQ (primary)
Self-management: score on the Chronic Disease Self-Efficacy Scale, adherence to controller asthma medica-
tions
Acceptability and attitudes toward the web portal: score on the Technology Acceptance Model (TAM) ques-
tionnaire, the number of minutes patients spent logged into the system/week, the number of days/week and
times that patients logged in, and features of the system used including number of messages sent to the asthma
nurse
Starting date March 2010
Contact information Sara Ahmed, School of Physical and Occupational Therapy, McGill University, Montreal, Canada
sara.ahmed@mcgill.ca
Notes controlled-trials.com identifier: ISRCTN34326236
AQLQ: Asthma Quality of Life Questionnaire
Arguel 2013
Trial name or title Internet Intervention called Healthy.me to Improve Asthma Management
Methods Design: randomised controlled trial with a 2-group parallel design
Setting: Australia
Participants Adults (aged 18 years or above) with a doctor diagnosis of asthma, living in Australia at the time of the study
and with easy access to the Internet and e-mail on a regular basis
Interventions Intervention group: a web-based personally controlled health management system (PCHMS) called Healthy.
me supports consumers with asthma to encourage the uptake and use of a personal written asthma action
plan, and to proactively seek self-management advice and schedule planned general practitioner visits before
experiencing an asthma exacerbation. It features a Personal Health Record (PHR) and pillbox allowing for
self-recording of medical test results, health measurements, current medications and medication adherence,
a schedule or to-do lists or reminders, consumer-specific care pathways, social communication spaces which
supports interaction across the continuum of care between participants and clinicians, and an online appoint-
ment booking service
Control group: usual care (with access to a static webpage, without PCHMS features or any interactive
component, with links to Australian information websites about asthma)
Duration: 12 months
Outcomes Organisation of care: number of planned and unplanned visits to healthcare providers for asthma issues
Process: % patients with an asthma action plan (new or revised) (primary), usage patterns of Healthy.me and
attrition rates
Quality of life: competing demands on health and asthma
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Asthma symptoms and activity levels: score on ACQ, score on the Asthma Exacerbation Questionnaire, days
lost from work
Self-management: adherence to the asthma action plan
Starting date March 1, 2013
Contact information Amae l Arguel, Centre for Health Informatics, Australian Institute of Health Innovation, University of New
South Wales, Sydney, Australia
a.arguel@unsw.edu.au
Notes Australian New Zealand Clinical Trials Registry CTRN12612000716864
ACQ: Asthma Control Questionnaire
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D A T A A N D A N A L Y S E S
Comparison 1. Chronic disease management programme versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Asthma-specific quality of
life score (post intervention
measurements)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 RCTs 8 1627 Std. Mean Difference (IV, Random, 95% CI) 0.22 [0.08, 0.37]
1.2 NRCT 1 413 Std. Mean Difference (IV, Random, 95% CI) 0.46 [0.27, 0.66]
2 Subgroup analysis
asthma-specific quality of
life score according to the
comprehensiveness of the
intervention (≥ 8 / < 8
components)
8 1627 Std. Mean Difference (IV, Random, 95% CI) 0.22 [0.08, 0.37]
2.1 Comprehensive
intervention (≥ 8 components)
6 1349 Std. Mean Difference (IV, Random, 95% CI) 0.17 [0.04, 0.29]
2.2 Less comprehensive
intervention (< 8 components)
2 278 Std. Mean Difference (IV, Random, 95% CI) 0.44 [0.12, 0.77]
3 Subgroup analysis
asthma-specific quality of
life score according to the
dominant component of the
intervention
8 1627 Std. Mean Difference (IV, Random, 95% CI) 0.22 [0.08, 0.37]
3.1 Education and/or
self-management support
4 698 Std. Mean Difference (IV, Random, 95% CI) 0.20 [-0.11, 0.51]
3.2 Mixed 4 929 Std. Mean Difference (IV, Random, 95% CI) 0.26 [0.12, 0.39]
4 Subgroup analysis
asthma-specific quality of life
score according to the presence
of limited CDM components
in the control group
8 1627 Std. Mean Difference (IV, Random, 95% CI) 0.22 [0.08, 0.37]
4.1 Control group without
limited CDM components
4 629 Std. Mean Difference (IV, Random, 95% CI) 0.28 [0.05, 0.51]
4.2 Control group with
limited CDM components
4 998 Std. Mean Difference (IV, Random, 95% CI) 0.17 [-0.03, 0.37]
5 Subgroup analysis
asthma-specific quality of life
score according to QOL scale
8 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 AQLQ - overall score 7 1543 Mean Difference (IV, Random, 95% CI) 0.32 [0.12, 0.52]
5.2 LWAQ - overall score 1 84 Mean Difference (IV, Random, 95% CI) 0.02 [-0.16, 0.20]
6 Sensitivity analysis
asthma-specific quality of
life (change from baseline
measurements)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 RCTs 7 1547 Std. Mean Difference (IV, Random, 95% CI) 0.30 [0.18, 0.43]
6.2 NRCT 1 413 Std. Mean Difference (IV, Random, 95% CI) 0.37 [0.18, 0.57]
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7 Self-efficacy score (post
intervention measurements)
5 642 Std. Mean Difference (IV, Random, 95% CI) 0.51 [-0.08, 1.11]
8 Asthma severity score (post
intervention measurements)
7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 RCTs 6 1330 Std. Mean Difference (IV, Random, 95% CI) 0.18 [0.05, 0.30]
8.2 NRCT 1 409 Std. Mean Difference (IV, Random, 95% CI) 0.47 [0.27, 0.66]
9 Lung function (FEV1 and
PEF) (post intervention
measurements)
8 1559 Std. Mean Difference (IV, Random, 95% CI) 0.19 [0.09, 0.30]
9.1 FEV1 (% predicted) 6 1279 Std. Mean Difference (IV, Random, 95% CI) 0.16 [0.05, 0.27]
9.2 PEF (L/min) 1 224 Std. Mean Difference (IV, Random, 95% CI) 0.30 [0.03, 0.56]
9.3 PEF (% predicted) 1 56 Std. Mean Difference (IV, Random, 95% CI) 0.53 [-0.01, 1.06]
10 FEV1 (% predicted) (post
intervention measurements)
6 1279 Mean Difference (IV, Random, 95% CI) 2.81 [0.99, 4.64]
11 PEF (L/min) (post intervention
measurements)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 RCTs 2 372 Mean Difference (IV, Random, 95% CI) 33.52 [11.38, 55.65]
11.2 NRCT 1 409 Mean Difference (IV, Random, 95% CI) 30.52 [7.46, 53.58]
12 PEF (% predicted) (post
intervention measurements)
2 307 Mean Difference (IV, Random, 95% CI) 8.68 [3.73, 13.63]
13 Subgroup analysis lung
function according to the
comprehensiveness of the
intervention (≥ 8 / < 8
components)
8 1559 Std. Mean Difference (IV, Random, 95% CI) 0.19 [0.09, 0.30]
13.1 Comprehensive
intervention (≥ 8 components)
5 1133 Std. Mean Difference (IV, Random, 95% CI) 0.19 [0.07, 0.31]
13.2 Less comprehensive
intervention (< 8 components)
3 426 Std. Mean Difference (IV, Random, 95% CI) 0.21 [0.01, 0.40]
14 Subgroup analysis lung
function according to the
dominant component of the
intervention
8 1559 Std. Mean Difference (IV, Random, 95% CI) 0.19 [0.09, 0.30]
14.1 Education and/or
self-management support
4 675 Std. Mean Difference (IV, Random, 95% CI) 0.19 [0.04, 0.35]
14.2 Organisation component
targeting healthcare system
1 56 Std. Mean Difference (IV, Random, 95% CI) 0.53 [-0.01, 1.06]
14.3 Mixed 3 828 Std. Mean Difference (IV, Random, 95% CI) 0.17 [0.03, 0.32]
15 Subgroup analysis lung
function according to the
presence of limited CDM
components in the control
group
8 1559 Std. Mean Difference (IV, Random, 95% CI) 0.19 [0.09, 0.30]
15.1 Control group without
limited CDM components
4 585 Std. Mean Difference (IV, Random, 95% CI) 0.21 [0.02, 0.39]
15.2 Control group with
limited CDM components
4 974 Std. Mean Difference (IV, Random, 95% CI) 0.19 [0.06, 0.32]
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Analysis 1.1. Comparison 1 Chronic disease management programme versus usual care, Outcome 1
Asthma-specific quality of life score (post intervention measurements).
Review: Chronic disease management programmes for adults with asthma
Comparison: 1 Chronic disease management programme versus usual care
Outcome: 1 Asthma-specific quality of life score (post intervention measurements)
Study or subgroup Intervention Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 RCTs
Armour 2007 (1) 155 -3.81 (1.51) 181 -3.8 (1.37) 19.2 % -0.01 [ -0.22, 0.21 ]
Castro 2003 33 4 (1.3) 33 3.9 (1.5) 7.2 % 0.07 [ -0.41, 0.55 ]
Couturaud 2002 (2) 26 5.28 (1.3) 28 5.03 (1.35) 6.1 % 0.19 [ -0.35, 0.72 ]
Galbreath 2008 174 4.73 (1.45) 93 4.43 (1.43) 16.6 % 0.21 [ -0.05, 0.46 ]
McLean 2003 (3) 119 5.13 (1.3) 105 4.4 (1.35) 15.6 % 0.55 [ 0.28, 0.82 ]
Schatz 2006 30 5.8 (1.1) 15 5.3 (1.2) 4.7 % 0.43 [ -0.19, 1.06 ]
Smith 2005 42 -1.02 (0.45) 42 -1.04 (0.4) 8.6 % 0.05 [ -0.38, 0.47 ]
Wilson 2010 362 5.42 (1.16) 189 5.07 (1.25) 22.0 % 0.29 [ 0.12, 0.47 ]
Subtotal (95% CI) 941 686 100.0 % 0.22 [ 0.08, 0.37 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 12.25, df = 7 (P = 0.09); I2 =43%
Test for overall effect: Z = 2.99 (P = 0.0028)
2 NRCT
Herborg 2001 209 -1.41 (0.38) 204 -1.6 (0.44) 100.0 % 0.46 [ 0.27, 0.66 ]
Subtotal (95% CI) 209 204 100.0 % 0.46 [ 0.27, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.63 (P < 0.00001)
-2 -1 0 1 2
Favours control Favours intervention
(1) sample size adjusted for design effect
(2) SD imputed from the mean SD of studies using the AQLQ or miniAQLQ (Armour 2007, Castro 2003, Galbreath 2008, Schatz 2006, Wilson 2010)
(3) SD imputed from the mean SD of studies using the AQLQ or miniAQLQ (Armour 2007, Castro 2003, Galbreath 2008, Schatz 2006, Wilson 2010)
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Analysis 1.2. Comparison 1 Chronic disease management programme versus usual care, Outcome 2
Subgroup analysis asthma-specific quality of life score according to the comprehensiveness of the intervention
(≥ 8 / < 8 components).
Review: Chronic disease management programmes for adults with asthma
Comparison: 1 Chronic disease management programme versus usual care
Outcome: 2 Subgroup analysis asthma-specific quality of life score according to the comprehensiveness of the intervention (≥ 8 / < 8 components)
Study or subgroup Intervention Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Comprehensive intervention (≥ 8 components)
Armour 2007 (1) 155 -3.81 (1.51) 181 -3.8 (1.37) 19.2 % -0.01 [ -0.22, 0.21 ]
Castro 2003 33 4 (1.3) 33 3.9 (1.5) 7.2 % 0.07 [ -0.41, 0.55 ]
Galbreath 2008 174 4.73 (1.45) 93 4.43 (1.43) 16.6 % 0.21 [ -0.05, 0.46 ]
Schatz 2006 30 5.8 (1.1) 15 5.3 (1.2) 4.7 % 0.43 [ -0.19, 1.06 ]
Smith 2005 42 -1.02 (0.45) 42 -1.04 (0.4) 8.6 % 0.05 [ -0.38, 0.47 ]
Wilson 2010 362 5.42 (1.16) 189 5.07 (1.25) 22.0 % 0.29 [ 0.12, 0.47 ]
Subtotal (95% CI) 796 553 78.3 % 0.17 [ 0.04, 0.29 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 5.73, df = 5 (P = 0.33); I2 =13%
Test for overall effect: Z = 2.66 (P = 0.0077)
2 Less comprehensive intervention (< 8 components)
Couturaud 2002 (2) 26 5.28 (1.3) 28 5.03 (1.35) 6.1 % 0.19 [ -0.35, 0.72 ]
McLean 2003 (3) 119 5.13 (1.3) 105 4.4 (1.35) 15.6 % 0.55 [ 0.28, 0.82 ]
Subtotal (95% CI) 145 133 21.7 % 0.44 [ 0.12, 0.77 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 1.42, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 2.70 (P = 0.0070)
Total (95% CI) 941 686 100.0 % 0.22 [ 0.08, 0.37 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 12.25, df = 7 (P = 0.09); I2 =43%
Test for overall effect: Z = 2.99 (P = 0.0028)
Test for subgroup differences: Chi2 = 2.44, df = 1 (P = 0.12), I2 =59%
-2 -1 0 1 2
Favours control Favours intervention
(1) sample size adjusted for design effect
(2) SD imputed from the mean SD of studies using the AQLQ or miniAQLQ (Armour 2007, Castro 2003, Galbreath 2008, Schatz 2006, Wilson 2010)
(3) SD imputed from the mean SD of studies using the AQLQ or miniAQLQ (Armour 2007, Castro 2003, Galbreath 2008, Schatz 2006, Wilson 2010)
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Analysis 1.3. Comparison 1 Chronic disease management programme versus usual care, Outcome 3
Subgroup analysis asthma-specific quality of life score according to the dominant component of the
intervention.
Review: Chronic disease management programmes for adults with asthma
Comparison: 1 Chronic disease management programme versus usual care
Outcome: 3 Subgroup analysis asthma-specific quality of life score according to the dominant component of the intervention
Study or subgroup Intervention Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Education and/or self-management support
Armour 2007 (1) 155 -3.81 (1.51) 181 -3.8 (1.37) 19.2 % -0.01 [ -0.22, 0.21 ]
Couturaud 2002 (2) 26 5.28 (1.3) 28 5.03 (1.35) 6.1 % 0.19 [ -0.35, 0.72 ]
McLean 2003 (3) 119 5.13 (1.3) 105 4.4 (1.35) 15.6 % 0.55 [ 0.28, 0.82 ]
Smith 2005 42 -1.02 (0.45) 42 -1.04 (0.4) 8.6 % 0.05 [ -0.38, 0.47 ]
Subtotal (95% CI) 342 356 49.5 % 0.20 [ -0.11, 0.51 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 10.62, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 1.26 (P = 0.21)
2 Mixed
Castro 2003 33 4 (1.3) 33 3.9 (1.5) 7.2 % 0.07 [ -0.41, 0.55 ]
Galbreath 2008 174 4.73 (1.45) 93 4.43 (1.43) 16.6 % 0.21 [ -0.05, 0.46 ]
Schatz 2006 30 5.8 (1.1) 15 5.3 (1.2) 4.7 % 0.43 [ -0.19, 1.06 ]
Wilson 2010 362 5.42 (1.16) 189 5.07 (1.25) 22.0 % 0.29 [ 0.12, 0.47 ]
Subtotal (95% CI) 599 330 50.5 % 0.26 [ 0.12, 0.39 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.19, df = 3 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 3.73 (P = 0.00019)
Total (95% CI) 941 686 100.0 % 0.22 [ 0.08, 0.37 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 12.25, df = 7 (P = 0.09); I2 =43%
Test for overall effect: Z = 2.99 (P = 0.0028)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
-2 -1 0 1 2
Favours control Favours intervention
(1) sample size adjusted for design effect
(2) SD imputed from the mean SD of studies using the AQLQ or miniAQLQ (Armour 2007, Castro 2003, Galbreath 2008, Schatz 2006, Wilson 2010)
(3) SD imputed from the mean SD of studies using the AQLQ or miniAQLQ (Armour 2007, Castro 2003, Galbreath 2008, Schatz 2006, Wilson 2010)
84Chronic disease management programmes for adults with asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.4. Comparison 1 Chronic disease management programme versus usual care, Outcome 4
Subgroup analysis asthma-specific quality of life score according to the presence of limited CDM components
in the control group.
Review: Chronic disease management programmes for adults with asthma
Comparison: 1 Chronic disease management programme versus usual care
Outcome: 4 Subgroup analysis asthma-specific quality of life score according to the presence of limited CDM components in the control group
Study or subgroup Intervention Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Control group without limited CDM components
Couturaud 2002 (1) 26 5.28 (1.3) 28 5.03 (1.35) 6.1 % 0.19 [ -0.35, 0.72 ]
Galbreath 2008 174 4.73 (1.45) 93 4.43 (1.43) 16.6 % 0.21 [ -0.05, 0.46 ]
McLean 2003 (2) 119 5.13 (1.3) 105 4.4 (1.35) 15.6 % 0.55 [ 0.28, 0.82 ]
Smith 2005 42 -1.02 (0.45) 42 -1.04 (0.4) 8.6 % 0.05 [ -0.38, 0.47 ]
Subtotal (95% CI) 361 268 46.9 % 0.28 [ 0.05, 0.51 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 5.38, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 2.42 (P = 0.015)
2 Control group with limited CDM components
Armour 2007 (3) 155 -3.81 (1.51) 181 -3.8 (1.37) 19.2 % -0.01 [ -0.22, 0.21 ]
Castro 2003 33 4 (1.3) 33 3.9 (1.5) 7.2 % 0.07 [ -0.41, 0.55 ]
Schatz 2006 30 5.8 (1.1) 15 5.3 (1.2) 4.7 % 0.43 [ -0.19, 1.06 ]
Wilson 2010 362 5.42 (1.16) 189 5.07 (1.25) 22.0 % 0.29 [ 0.12, 0.47 ]
Subtotal (95% CI) 580 418 53.1 % 0.17 [ -0.03, 0.37 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 5.32, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 1.63 (P = 0.10)
Total (95% CI) 941 686 100.0 % 0.22 [ 0.08, 0.37 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 12.25, df = 7 (P = 0.09); I2 =43%
Test for overall effect: Z = 2.99 (P = 0.0028)
Test for subgroup differences: Chi2 = 0.57, df = 1 (P = 0.45), I2 =0.0%
-2 -1 0 1 2
Favours control Favours intervention
(1) SD imputed from the mean SD of studies using the AQLQ or miniAQLQ (Armour 2007, Castro 2003, Galbreath 2008, Schatz 2006, Wilson 2010)
(2) SD imputed from the mean SD of studies using the AQLQ or miniAQLQ (Armour 2007, Castro 2003, Galbreath 2008, Schatz 2006, Wilson 2010)
(3) sample size adjusted for design effect
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Analysis 1.5. Comparison 1 Chronic disease management programme versus usual care, Outcome 5
Subgroup analysis asthma-specific quality of life score according to QOL scale.
Review: Chronic disease management programmes for adults with asthma
Comparison: 1 Chronic disease management programme versus usual care
Outcome: 5 Subgroup analysis asthma-specific quality of life score according to QOL scale
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 AQLQ - overall score
Armour 2007 (1) 155 -3.81 (1.51) 181 -3.8 (1.37) 19.6 % -0.01 [ -0.32, 0.30 ]
Castro 2003 33 4 (1.3) 33 3.9 (1.5) 7.1 % 0.10 [ -0.58, 0.78 ]
Couturaud 2002 (2) 26 5.28 (1.3) 28 5.03 (1.35) 6.6 % 0.25 [ -0.46, 0.96 ]
Galbreath 2008 174 4.73 (1.45) 93 4.43 (1.43) 16.8 % 0.30 [ -0.06, 0.66 ]
McLean 2003 (3) 119 5.13 (1.3) 105 4.4 (1.35) 17.5 % 0.73 [ 0.38, 1.08 ]
Schatz 2006 30 5.8 (1.1) 15 5.3 (1.2) 6.4 % 0.50 [ -0.22, 1.22 ]
Wilson 2010 362 5.42 (1.16) 189 5.07 (1.25) 26.0 % 0.35 [ 0.14, 0.56 ]
Subtotal (95% CI) 899 644 100.0 % 0.32 [ 0.12, 0.52 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 10.43, df = 6 (P = 0.11); I2 =42%
Test for overall effect: Z = 3.15 (P = 0.0016)
2 LWAQ - overall score
Smith 2005 42 -1.02 (0.45) 42 -1.04 (0.4) 100.0 % 0.02 [ -0.16, 0.20 ]
Subtotal (95% CI) 42 42 100.0 % 0.02 [ -0.16, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Chi2 = 4.79, df = 1 (P = 0.03), I2 =79%
-2 -1 0 1 2
Favours control Favours intervention
(1) sample size adjusted for design effect
(2) Mean score of the four dimensions of the scale. SD imputed from the mean SD of studies using the AQLQ or miniAQLQ (Armour 2007, Castro 2003, Galbreath
2008, Schatz 2006, Wilson 2010)
(3) SD imputed from the mean SD of studies using the AQLQ or miniAQLQ (Armour 2007, Castro 2003, Galbreath 2008, Schatz 2006, Wilson 2010)
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Analysis 1.6. Comparison 1 Chronic disease management programme versus usual care, Outcome 6
Sensitivity analysis asthma-specific quality of life (change from baseline measurements).
Review: Chronic disease management programmes for adults with asthma
Comparison: 1 Chronic disease management programme versus usual care
Outcome: 6 Sensitivity analysis asthma-specific quality of life (change from baseline measurements)
Study or subgroup Intervention Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 RCTs
Armour 2007 160 0.64 (1.23) 186 0.41 (0.97) 22.6 % 0.21 [ 0.00, 0.42 ]
Cambach 1997 22 3 (4) 21 0 (3) 3.9 % 0.83 [ 0.20, 1.46 ]
Castro 2003 33 1.4 (1.2) 33 1.2 (1.3) 6.3 % 0.16 [ -0.33, 0.64 ]
Galbreath 2008 (1) 174 0.65 (1.2) 93 0.37 (1.2) 17.9 % 0.23 [ -0.02, 0.49 ]
Kokubu 2000 23 1.5 (2.9) 27 0.9 (1.6) 4.8 % 0.26 [ -0.30, 0.82 ]
McLean 2003 (2) 119 0.84 (1.2) 105 0.17 (1.2) 16.5 % 0.56 [ 0.29, 0.82 ]
Wilson 2010 362 0.98 (1.17) 189 0.68 (1.34) 27.9 % 0.24 [ 0.07, 0.42 ]
Subtotal (95% CI) 893 654 100.0 % 0.30 [ 0.18, 0.43 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 8.00, df = 6 (P = 0.24); I2 =25%
Test for overall effect: Z = 4.65 (P < 0.00001)
2 NRCT
Herborg 2001 209 0.17 (0.25) 204 0.08 (0.23) 100.0 % 0.37 [ 0.18, 0.57 ]
Subtotal (95% CI) 209 204 100.0 % 0.37 [ 0.18, 0.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.76 (P = 0.00017)
-2 -1 0 1 2
Favours control Favours intervention
(1) change-from-baseline SD imputed from the mean change-from-baseline SD of studies using the AQLQ or miniAQLQ (Armour 2007, Castro 2003, Wilson 2010)
(2) change-from-baseline SD imputed from the mean change-from-baseline SD of studies using the AQLQ or miniAQLQ (Armour 2007, Castro 2003, Wilson 2010)
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Analysis 1.7. Comparison 1 Chronic disease management programme versus usual care, Outcome 7 Self-
efficacy score (post intervention measurements).
Review: Chronic disease management programmes for adults with asthma
Comparison: 1 Chronic disease management programme versus usual care
Outcome: 7 Self-efficacy score (post intervention measurements)
Study or subgroup Intervention Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Armour 2007 (1) 149 -23.43 (5.68) 171 -23.83 (5.18) 22.0 % 0.07 [ -0.15, 0.29 ]
Couturaud 2002 (2) 26 5.2 (3.82) 28 3.4 (3.61) 19.1 % 0.48 [ -0.06, 1.02 ]
Huang 2009 98 20.88 (2.43) 50 17.08 (2.63) 20.8 % 1.51 [ 1.13, 1.90 ]
Martin 2009 18 4.14 (0.64) 18 3.81 (0.73) 17.7 % 0.47 [ -0.19, 1.13 ]
Smith 2005 42 38.81 (6.54) 42 38.54 (5.89) 20.3 % 0.04 [ -0.38, 0.47 ]
Total (95% CI) 333 309 100.0 % 0.51 [ -0.08, 1.11 ]
Heterogeneity: Tau2 = 0.41; Chi2 = 43.69, df = 4 (P<0.00001); I2 =91%
Test for overall effect: Z = 1.68 (P = 0.092)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours control Favours intervention
(1) sample size adjusted for design effect
(2) SD imputed from the mean SD of the other studies (Armour 2007, Huang 2009, Martin 2009, Smith 2005)
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Analysis 1.8. Comparison 1 Chronic disease management programme versus usual care, Outcome 8
Asthma severity score (post intervention measurements).
Review: Chronic disease management programmes for adults with asthma
Comparison: 1 Chronic disease management programme versus usual care
Outcome: 8 Asthma severity score (post intervention measurements)
Study or subgroup Intervention Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 RCTs
Charrois 2006 36 -1.02 (0.87) 34 -1.58 (1.2) 6.4 % 0.53 [ 0.05, 1.01 ]
Galbreath 2008 168 -18.86 (6.8) 85 -19.54 (6.58) 19.2 % 0.10 [ -0.16, 0.36 ]
Huang 2009 98 3.37 (1.42) 50 3.36 (1.35) 12.1 % 0.01 [ -0.33, 0.35 ]
McLean 2003 (1) 119 -0.53 (2.37) 105 -0.93 (2.32) 19.0 % 0.17 [ -0.09, 0.43 ]
Smith 2005 42 -4.21 (3.5) 42 -4 (2.91) 7.9 % -0.06 [ -0.49, 0.36 ]
Wilson 2010 362 -0.58 (0.92) 189 -0.84 (1) 35.4 % 0.27 [ 0.10, 0.45 ]
Subtotal (95% CI) 825 505 100.0 % 0.18 [ 0.05, 0.30 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 5.76, df = 5 (P = 0.33); I2 =13%
Test for overall effect: Z = 2.81 (P = 0.0050)
2 NRCT
Herborg 2001 208 -1.52 (0.68) 201 -1.88 (0.85) 100.0 % 0.47 [ 0.27, 0.66 ]
Subtotal (95% CI) 208 201 100.0 % 0.47 [ 0.27, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.66 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.94, df = 1 (P = 0.01), I2 =83%
-2 -1 0 1 2
Favours control Favours intervention
(1) SD imputed from the mean SD of the other studies (Charrois 2006, Galbreath 2008, Herborg 2001, Huang 2009, Smith 2005, Wilson 2010)
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Analysis 1.9. Comparison 1 Chronic disease management programme versus usual care, Outcome 9 Lung
function (FEV1 and PEF) (post intervention measurements).
Review: Chronic disease management programmes for adults with asthma
Comparison: 1 Chronic disease management programme versus usual care
Outcome: 9 Lung function (FEV1 and PEF) (post intervention measurements)
Study or subgroup Intervention Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 FEV1 (% predicted)
Armour 2007 (1) 118 79.18 (22.7) 131 75.39 (21.7) 17.0 % 0.17 [ -0.08, 0.42 ]
Charrois 2006 36 84 (53.4) 34 80 (65.4) 4.8 % 0.07 [ -0.40, 0.54 ]
Couturaud 2002 (2) 26 84 (25.26) 28 85 (26.81) 3.7 % -0.04 [ -0.57, 0.50 ]
Galbreath 2008 167 79.83 (17.36) 84 78.2 (17.6) 15.4 % 0.09 [ -0.17, 0.36 ]
Huang 2009 98 55.3 (18.76) 50 52.48 (17.62) 9.1 % 0.15 [ -0.19, 0.49 ]
Wilson 2010 (3) 335 76.14 (14.07) 172 73.1 (11.71) 31.1 % 0.23 [ 0.04, 0.41 ]
Subtotal (95% CI) 780 499 81.1 % 0.16 [ 0.05, 0.27 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.46, df = 5 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.75 (P = 0.0060)
2 PEF (L/min)
McLean 2003 (4) 119 383.4 (100.38) 105 351.9 (110.7) 15.2 % 0.30 [ 0.03, 0.56 ]
Subtotal (95% CI) 119 105 15.2 % 0.30 [ 0.03, 0.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
3 PEF (% predicted)
Kokubu 2000 (5) 30 68.2 (21.25) 26 56.9 (21) 3.7 % 0.53 [ -0.01, 1.06 ]
Subtotal (95% CI) 30 26 3.7 % 0.53 [ -0.01, 1.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.053)
Total (95% CI) 929 630 100.0 % 0.19 [ 0.09, 0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.88, df = 7 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 3.71 (P = 0.00021)
Test for subgroup differences: Chi2 = 2.43, df = 2 (P = 0.30), I2 =18%
-2 -1 0 1 2
Favours control Favours intervention
(1) sample size adjusted for design effect
(2) SD imputed from the mean SD of the other studies (Armour 2007, Charrois 2006, Galbreath 2008, Huang 2009, Wilson 2010)
(3) SD estimated from graphic
(4) SD imputed from the SD of Huang 2009 (L/min)
(5) SD imputed from the SD of Galbreath 2008
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Analysis 1.10. Comparison 1 Chronic disease management programme versus usual care, Outcome 10
FEV1 (% predicted) (post intervention measurements).
Review: Chronic disease management programmes for adults with asthma
Comparison: 1 Chronic disease management programme versus usual care
Outcome: 10 FEV1 (% predicted) (post intervention measurements)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Armour 2007 (1) 118 79.18 (22.7) 131 75.39 (21.7) 10.9 % 3.79 [ -1.74, 9.32 ]
Charrois 2006 36 84 (53.4) 34 80 (65.4) 0.4 % 4.00 [ -24.06, 32.06 ]
Couturaud 2002 (2) 26 84 (25.26) 28 85 (26.81) 1.7 % -1.00 [ -14.89, 12.89 ]
Galbreath 2008 167 79.83 (17.36) 84 78.2 (17.6) 15.8 % 1.63 [ -2.96, 6.22 ]
Huang 2009 98 55.3 (18.76) 50 52.48 (17.62) 8.8 % 2.82 [ -3.32, 8.96 ]
Wilson 2010 335 76.14 (14.07) 172 73.1 (11.71) 62.4 % 3.04 [ 0.73, 5.35 ]
Total (95% CI) 780 499 100.0 % 2.81 [ 0.99, 4.64 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 5 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 3.02 (P = 0.0025)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours control Favours intervention
(1) sample size adjusted for design effect
(2) SD imputed from the mean SD of the other studies (Armour 2007, Charrois 2006, Galbreath 2008, Huang 2009, Wilson 2010)
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Analysis 1.11. Comparison 1 Chronic disease management programme versus usual care, Outcome 11 PEF
(L/min) (post intervention measurements).
Review: Chronic disease management programmes for adults with asthma
Comparison: 1 Chronic disease management programme versus usual care
Outcome: 11 PEF (L/min) (post intervention measurements)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 RCTs
Huang 2009 98 338 (100.38) 50 301 (110.7) 36.7 % 37.00 [ 0.44, 73.56 ]
McLean 2003 (1) 119 383.4 (100.38) 105 351.9 (110.7) 63.3 % 31.50 [ 3.69, 59.31 ]
Subtotal (95% CI) 217 155 100.0 % 33.52 [ 11.38, 55.65 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.97 (P = 0.0030)
2 NRCT
Herborg 2001 208 476.25 (114.22) 201 445.73 (123.34) 100.0 % 30.52 [ 7.46, 53.58 ]
Subtotal (95% CI) 208 201 100.0 % 30.52 [ 7.46, 53.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.59 (P = 0.0095)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.85), I2 =0.0%
-100 -50 0 50 100
Favours control Favours intervention
(1) SD imputed from the SD of Huang 2009
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Analysis 1.12. Comparison 1 Chronic disease management programme versus usual care, Outcome 12 PEF
(% predicted) (post intervention measurements).
Review: Chronic disease management programmes for adults with asthma
Comparison: 1 Chronic disease management programme versus usual care
Outcome: 12 PEF (% predicted) (post intervention measurements)
Study or subgroup Favours control Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Galbreath 2008 167 82.73 (21.25) 84 74.7 (21) 80.1 % 8.03 [ 2.50, 13.56 ]
Kokubu 2000 (1) 30 68.2 (21.25) 26 56.9 (21) 19.9 % 11.30 [ 0.21, 22.39 ]
Total (95% CI) 197 110 100.0 % 8.68 [ 3.73, 13.63 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.44 (P = 0.00058)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours control Favours intervention
(1) SD imputed from the SD of Galbreath 2008
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Analysis 1.13. Comparison 1 Chronic disease management programme versus usual care, Outcome 13
Subgroup analysis lung function according to the comprehensiveness of the intervention (≥ 8 / < 8
components).
Review: Chronic disease management programmes for adults with asthma
Comparison: 1 Chronic disease management programme versus usual care
Outcome: 13 Subgroup analysis lung function according to the comprehensiveness of the intervention (≥ 8 / < 8 components)
Study or subgroup Intervention Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Comprehensive intervention (≥ 8 components)
Armour 2007 (1) 118 79.18 (22.7) 131 75.39 (21.7) 17.0 % 0.17 [ -0.08, 0.42 ]
Charrois 2006 36 84 (53.4) 34 80 (65.4) 4.8 % 0.07 [ -0.40, 0.54 ]
Galbreath 2008 167 79.83 (17.36) 84 78.2 (17.6) 15.4 % 0.09 [ -0.17, 0.36 ]
Kokubu 2000 (2) 30 68.2 (21.25) 26 56.9 (21) 3.7 % 0.53 [ -0.01, 1.06 ]
Wilson 2010 335 76.14 (14.07) 172 73.1 (11.71) 31.1 % 0.23 [ 0.04, 0.41 ]
Subtotal (95% CI) 686 447 72.0 % 0.19 [ 0.07, 0.31 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.50, df = 4 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 3.08 (P = 0.0021)
2 Less comprehensive intervention (< 8 components)
Couturaud 2002 (3) 26 84 (25.26) 28 85 (26.81) 3.7 % -0.04 [ -0.57, 0.50 ]
Huang 2009 98 55.3 (18.76) 50 52.48 (17.62) 9.1 % 0.15 [ -0.19, 0.49 ]
McLean 2003 (4) 119 383.4 (100.38) 105 351.9 (110.7) 15.2 % 0.30 [ 0.03, 0.56 ]
Subtotal (95% CI) 243 183 28.0 % 0.21 [ 0.01, 0.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.36, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.038)
Total (95% CI) 929 630 100.0 % 0.19 [ 0.09, 0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.88, df = 7 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 3.71 (P = 0.00021)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
-2 -1 0 1 2
Favours control Favours intervention
(1) sample size adjusted for design effect
(2) SD imputed from the SD of Galbreath 2008
(3) SD imputed from the mean SD of the other studies (Armour 2007, Charrois 2006, Galbreath 2008, Huang 2009, Wilson 2010)
(4) SD imputed from the SD of Huang 2009
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Analysis 1.14. Comparison 1 Chronic disease management programme versus usual care, Outcome 14
Subgroup analysis lung function according to the dominant component of the intervention.
Review: Chronic disease management programmes for adults with asthma
Comparison: 1 Chronic disease management programme versus usual care
Outcome: 14 Subgroup analysis lung function according to the dominant component of the intervention
Study or subgroup Intervention Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Education and/or self-management support
Armour 2007 (1) 118 79.18 (22.7) 131 75.39 (21.7) 17.0 % 0.17 [ -0.08, 0.42 ]
Couturaud 2002 (2) 26 84 (25.26) 28 85 (26.81) 3.7 % -0.04 [ -0.57, 0.50 ]
Huang 2009 98 55.3 (18.76) 50 52.48 (17.62) 9.1 % 0.15 [ -0.19, 0.49 ]
McLean 2003 (3) 119 383.4 (100.38) 105 351.9 (110.7) 15.2 % 0.30 [ 0.03, 0.56 ]
Subtotal (95% CI) 361 314 45.0 % 0.19 [ 0.04, 0.35 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.41, df = 3 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
2 Organisation component targeting healthcare system
Kokubu 2000 (4) 30 68.2 (21.25) 26 56.9 (21) 3.7 % 0.53 [ -0.01, 1.06 ]
Subtotal (95% CI) 30 26 3.7 % 0.53 [ -0.01, 1.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.053)
3 Mixed
Charrois 2006 36 84 (53.4) 34 80 (65.4) 4.8 % 0.07 [ -0.40, 0.54 ]
Galbreath 2008 167 79.83 (17.36) 84 78.2 (17.6) 15.4 % 0.09 [ -0.17, 0.36 ]
Wilson 2010 335 76.14 (14.07) 172 73.1 (11.71) 31.1 % 0.23 [ 0.04, 0.41 ]
Subtotal (95% CI) 538 290 51.3 % 0.17 [ 0.03, 0.32 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.89, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
Total (95% CI) 929 630 100.0 % 0.19 [ 0.09, 0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.88, df = 7 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 3.71 (P = 0.00021)
Test for subgroup differences: Chi2 = 1.58, df = 2 (P = 0.45), I2 =0.0%
-2 -1 0 1 2
Favours control Favours intervention
(1) sample size adjusted for design effect
(2) SD imputed from the mean SD of the other studies (Armour 2007, Charrois 2006, Galbreath 2008, Huang 2009, Wilson 2010)
(3) SD imputed from the SD of Huang 2009
(4) SD imputed from the SD of Galbreath 2008
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Analysis 1.15. Comparison 1 Chronic disease management programme versus usual care, Outcome 15
Subgroup analysis lung function according to the presence of limited CDM components in the control group.
Review: Chronic disease management programmes for adults with asthma
Comparison: 1 Chronic disease management programme versus usual care
Outcome: 15 Subgroup analysis lung function according to the presence of limited CDM components in the control group
Study or subgroup Intervention Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Control group without limited CDM components
Couturaud 2002 (1) 26 84 (25.26) 28 85 (26.81) 3.7 % -0.04 [ -0.57, 0.50 ]
Galbreath 2008 167 79.83 (17.36) 84 78.2 (17.6) 15.4 % 0.09 [ -0.17, 0.36 ]
Kokubu 2000 (2) 30 68.2 (21.25) 26 56.9 (21) 3.7 % 0.53 [ -0.01, 1.06 ]
McLean 2003 (3) 119 383.4 (100.38) 105 351.9 (110.7) 15.2 % 0.30 [ 0.03, 0.56 ]
Subtotal (95% CI) 342 243 38.0 % 0.21 [ 0.02, 0.39 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 3.36, df = 3 (P = 0.34); I2 =11%
Test for overall effect: Z = 2.22 (P = 0.026)
2 Control group with limited CDM components
Armour 2007 (4) 118 79.18 (22.7) 131 75.39 (21.7) 17.0 % 0.17 [ -0.08, 0.42 ]
Charrois 2006 36 84 (53.4) 34 80 (65.4) 4.8 % 0.07 [ -0.40, 0.54 ]
Huang 2009 98 55.3 (18.76) 50 52.48 (17.62) 9.1 % 0.15 [ -0.19, 0.49 ]
Wilson 2010 335 76.14 (14.07) 172 73.1 (11.71) 31.1 % 0.23 [ 0.04, 0.41 ]
Subtotal (95% CI) 587 387 62.0 % 0.19 [ 0.06, 0.32 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.50, df = 3 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.83 (P = 0.0046)
Total (95% CI) 929 630 100.0 % 0.19 [ 0.09, 0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.88, df = 7 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 3.71 (P = 0.00021)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
-2 -1 0 1 2
Favours control Favours intervention
(1) SD imputed from the mean SD of the other studies (Armour 2007, Charrois 2006, Galbreath 2008, Huang 2009, Wilson 2010)
(2) SD imputed from the SD of Galbreath 2008
(3) SD imputed from the SD of Huang 2009
(4) sample size adjusted for design effect
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A D D I T I O N A L T A B L E S
Table 1. Overview of characteristics of included studies
Study ID Design (alloca-
tion)
Country and
setting
Interven-
tion name, du-
ration, number
of components,
dominant com-
ponent
Pa-
tients in inter-
vention group
Patients in con-
trol group
Number
of reported out-
comes
RCTs
Armour 2007 C-RCT
(pharmacy)
Australia
rural and urban
pharmacies
Pharmacy
Asthma Care
Program
6 months
components: 8
dominant com-
ponent: EDU
N = 160
women: 67.5%
mean age: 47.5
moderate-severe
asthma
N = 186
women: 60.5%
mean age: 50.4
moderate-severe
asthma
Org: 1
Process: 6
QOL: 1
Symptoms/
activity: 2
Self-care: 5
Lung function: 2
Cambach 1997 RCT Netherlands
local physiother-
apy
practices
Rehabilitation
programme
3 months
components: 6
dominant com-
ponent: ORG
PT
N = 22
women: 81.8%
mean age: 40
mild-moderate
asthma
N = 21
women: 66.7%
mean age: 53
mild-moderate
asthma
QOL: 1
Symptoms/
activity: 3
Castro 2003 RCT USA
inpatients and
outpatients
in a hospital
Use of an asthma
nurse special-
ist to provide a
multifaceted ap-
proach to
asthma care for
“high-risk” inpa-
tients
6 months
components: 10
dominant com-
ponent: mixed
N = 50
women: 80%
mean age: 35
moderate-severe
asthma
N = 46
women: 85%
mean age: 38
mod-severe
asthma
HC use: 8
QOL: 1
Charrois 2006 RCT Canada
community rural
pharmacies and
PCPs
Better Res-
piratory Educa-
tion and Asthma
Treat-
ment in Hin-
ton and Edson
(BREATHE)
6 months
components: 11
dominant com-
N = 36
women: 53%
mean age: 35.7
moderate-severe
asthma
N = 34
women: 53%
mean age: 38.7
moderate-severe
asthma
Org: 1
Process: 3
HC use: 1
Symptoms/
activity: 2
Lung function: 1
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Table 1. Overview of characteristics of included studies (Continued)
ponent: mixed
Couturaud 2002 RCT France
outpatient clinic
of two university
hospitals
Educational pro-
gramme in asth-
matic pa-
tients following
treatment read-
justment
12 months
components: 7
dominant com-
ponent: EDU
N = 26
women: 69.4%
mean age: 37.8
moderate-severe
asthma
N = 28
women: 66.7%
mean age: 38.1
moderate-severe
asthma
HC use: 1
QOL:1
Symptoms/
activity: 3
Self-care: 3
Lung function: 1
Galbreath 2008 RCT USA
University Med-
ical Center
and PCP
The South Texas
Asthma Man-
agement Project
(STAMP)
6 months
components: 9
dominant com-
ponent: mixed
N = 262
women: 77.6%
mean age: 42.3
moderate-severe
asthma
N = 124
women: 77.6%
mean age: 43.7
moderate-severe
asthma
Org: 1
Process: 2
HC use: 4
QOL: 1
Symptoms/
activity: 2
Lung function: 3
Huang 2009 RCT Taiwan
outpatient chest
department
of hospital
Individualised
self-care educa-
tion programme
6 months
components: 6
dominant com-
ponent: EDU
N = 98
women: 29.5%
mean age: na
moderate-severe
asthma
N = 50
women: 22%
mean age: na
moderate-severe
asthma
Process: 1
HC use: 1
Symptoms/
activity: 2
Self-care: 3
Lung function: 4
Kokubu 2000 RCT Japan
hospital and pa-
tients’ home
Asthma
telemedicine sys-
tem
6 months
components: 8
dominant com-
ponent: ORG
HC
N = 32
women: 62%
mean age: 49.9
asthma severity
na
N = 34
women: 56%
mean age: 47.3
asthma severity
na
HC use: 4
Pt satis: 1
QOL: 1
Symptoms/
activity: 3
Self-care: 3
Lung function: 1
Martin 2009 RCT USA
PCPs
A community-
based interven-
tion to improve
asthma self-effi-
cacy in African
American adults
designed by
the Chicago Ini-
tiative to Raise
Asthma
N = 19
women: 60%
mean age: 33
asthma severity
na
N = 18
women: 77%
mean age: 37
asthma severity
na
Org: 1
Process: 2
QOL: 1
Symptoms/
activity: 3
Self-care: 3
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Table 1. Overview of characteristics of included studies (Continued)
Health Equity
(CHIRAH)
3 months
components: 7
dominant com-
ponent: EDU
Mayo 1990 RCT USA
outpatient chest
clinic of a hospi-
tal
Outpatient pro-
gramme de-
signed to reduce
readmissions for
asthma exacerba-
tions
8 months
components: 6
dominant com-
ponent: EDU
N = 47
women: 70.2%
mean age: 42
moderate-severe
asthma
N = 57
women: 57.9%
mean age: 42
moderate-severe
asthma
HC use: 1
Symptoms/
activity: 1
McLean 2003 RCT Canada
community
pharmacies
The British
Columbia phar-
macy asthma
study
incorporating an
asthma care
protocol
provided by spe-
cially
trained commu-
nity pharmacists
12 months
components: 7
dominant com-
ponent: EDU
N = 119
women: 63%
mean age: na
asthma severity
na
N = 105
women: 62.9%
mean age: na
asthma severity
na
HC use: 4
Pt satis: 1
QOL: 1
Symptoms/
activity: 4
Self-care: 1
Lung function: 1
Petro 2005 C-RCT
(provider)
Germany PCPs A disease man-
agement
programme with
a case manager
12 months
components: 7
dominant com-
ponent: ORG
HC
N = 56
women: 54.2%
mean age: 57.3
moderate-severe
asthma
N = 55
women: 44%
mean age: 55
moderate-severe
asthma
HC use: 2
QOL: 3
Symptoms/
activity: 1
Lung function: 2
Schatz 2006 RCT USA
Kaiser Per-
manente Medi-
cal Care program
Regu-
lar care manager
and intensive in-
dividualised ed-
ucational visit
N = 30
women: 32.3%
mean age: 45
moderate-severe
asthma
N = 15
women: 54.8%
mean age: 45.4
moderate-severe
asthma
Process: 1
HC use: 1
QOL: 1
Symptoms/
activity: 2
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Table 1. Overview of characteristics of included studies (Continued)
12 months
components: 11
dominant com-
ponent: mixed
Self-care: 1
Smith 2005 RCT UK
outpatient
asthma clinics of
a hospital and
PCPs
The Cop-
ing with Asthma
Study (a home
based, nurse led
psychoeduca-
tional
intervention for
adults at risk of
adverse asthma
outcomes)
6 months
components: 15
dominant com-
ponent: EDU
N = 42
women: 62%
mean age: 38.2
moderate-severe
asthma
N = 42
women: 84%
mean age: 34.7
moderate-severe
asthma
QOL: 6
Symptoms/
activity: 1
Self-care: 6
Wilson 2010 RCT USA
Kaiser Perma-
nente clinics
The Better Out-
comes of Asthma
Treatment
(BOAT) study
9 months
components: 9
dominant com-
ponent: mixed
N = 362
women: 56.2%
mean age: 46.3
moderate-severe
asthma
N = 189
women: 57.4%
mean age: 45.1
moderate-severe
asthma
Process: 1
HC use: 2
QOL: 1
Symptoms/
activity: 5
Lung function: 2
NRCT
Herborg 2001 C-NRCT
(pharmacy)
Denmark
community
pharmacies
Therapeutic out-
comes monitor-
ing (TOM) pro-
gramme
12 months
components: 9
dominant com-
ponent: ORG
PT
N = 209
women: 57.6%
mean age: 38.8
moderate-severe
asthma
N = 204
women: 54.7%
mean age: 42.4
moderate-severe
asthma
Org : 3
HC use: 7
Pt satis: 1
QOL: 2
Symptoms/
activity: 4
Self-care: 1
Lung function: 1
CBAs
Feifer 2004 CBA USA
PCPs in a re-
gion covered by a
health insurance
company
Population-
based asthma
disease manage-
ment
programme us-
ing broad-based
N = 35,450
women: 56%
mean age: na
asthma severity
na
N = 35,450
women: 56%
mean age: na
asthma severity
na
Process: 3
HC use: 3
QOL: 1
Symptoms/
activity: 4
Self-care: 3
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Table 1. Overview of characteristics of included studies (Continued)
educational in-
terventions
12 months
components: 7
dominant com-
ponent: mixed
Landon 2000 CBA USA
community
health centres
Health Dispar-
ities Collabora-
tives disseminat-
ing quality im-
provement tech-
niques
54 months
components: ≥
11
dominant com-
ponent: ORG
HC
N = 1696 (total/
2)
women: 63.5%
mean age: 28.4
asthma severity
na
N = 1696 (total/
2)
women: 67.6%
mean age: 34.4
asthma severity
na
Process: 7
HC use: 1
Symptoms/
activity: 1
Weng 2005 CBA Taiwan
outpatient clin-
ics of a
hospital and
PCPs
A government-
sponsored
outpatient-based
disease manage-
ment
programme
12 months
components: 8
dominant com-
ponent: EDU
N = 854
women: 44.5%
mean age: na
asthma severity
na
N = 3188
women: 43%
mean age: na
asthma severity
na
Pro satis: 1
HC use: 4
Windt 2010 CBA Germany
PCPs
Na-
tionwide asthma
disease manage-
ment
programme
> 12 months
components: ≥
5
dominant com-
ponent: ORG
HC
N=317
women: 48.6%
mean age: 36.5
asthma severity
na
N=317
women: 44.2%
mean age: 36.5
asthma severity
na
Process: 8
HC use: 2
RCT: randomised controlled trial, NRCT: non-randomised controlled trial, CBA: controlled before-after study, C-: cluster, PCP:
primary care practice, EDU: educational and self-management support component, ORG˙PAT: organisational component targeting
patients; ORG˙HC organisational component targeting healthcare professionals or the healthcare system, na: not available, HC:
healthcare, QOL: quality of life, Org: organisational, Pt satis: patient satisfaction, Pro satis: healthcare professionals’ satisfaction
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A P P E N D I C E S
Appendix 1. MEDLINE strategies 2014
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Present>
RCT search
Search date: June 13, 2014
1 exp Asthma/ (105750)
2 asthma$.ti. or wheez$.ti,ab. (81128)
3 (asthmatic? or (asthma$ adj2 (chronic$ or patient?))).ab. (37283)
4 Bronchial Hyperreactivity/ (6788)
5 bronchial$ hyperreactivit$.ti,ab. (1957)
6 lung diseases, obstructive/ (17975)
7 (obstructive adj (lung disease or lung diseases)).ti. (1966)
8 or/1-7 [Asthma] (139414)
9 chronic disease management.ti,ab. (1112)
10 (asthma adj3 (program or programs or programme or programme)).ti. (414)
11 exp Patient Care Team/ (54559)
12 (care adj2 team$).ti,ab. (8290)
13 or/11-12 [Patient Care Team] (60111)
14 Disease management/ (11729)
15 ((disease adj2 management) or (chronic adj2 management)).ti,ab. (18495)
16 or/14-15 [Disease Management] (27904)
17 Patient Care Management/ or Patient-Centered Care/ or ”Continuity of Patient Care“/ or Comprehensive Health Care/ (32517)
18 comprehensive health care.ti,ab. (679)
19 (care adj2 management).ti,ab. (8132)
20 (patient centred or patient centered or (continuity adj2 care)).ti,ab. (12492)
21 or/17-20 [Care Management/continuity] (47989)
22 patient care planning/ or case management/ or critical pathways/ (45209)
23 ((care adj2 (algorithm? or pathway? or plan)) or CRITICAL pathway?).ti,ab. (7764)
24 (((written or action) adj3 plan?) or (planning adj2 care)).ti,ab. (9719)
25 or/22-24 [Care Planning/Pathway] (59358)
26 ”Delivery of Health Care, Integrated“/ (8391)
27 (integrat$ adj2 (care or healthcare)).ti,ab. (5974)
28 or/26-27 [Integrated Care] (12868)
29 ”length of stay“/ or patient readmission/ (64055)
30 (”length of stay“ or readmission?).ti. (4613)
31 ((reduc$ or shorten or lower$) adj3 (hospitali?ation? or ”length of stay“ or readmiss$ or readmit$)).ab. (6951)
32 or/29-31 [Length of Stay/Readmissions] (69373)
33 *hospitalization/ and (management or program? or programme or programmes or model? or reduc$ or impact or intervention or
improving).ti. (2353)
34 patient discharge/ and ((chronic or plan? or planning or team? or collaborat$ or intervention?).ti. or (planning or team? or collaborat$
or (chronic adj3 (disease or model?))).ab.) (3383)
35 or/33-34 [Discharge/reduce, manage hospitalizations] (5717)
36 Managed Care Programs/ (23447)
37 ((care or healthcare) adj3 (model? or program? or programme or programmes)).ti,ab. (27884)
38 or/36-37 [Managed Care] (50315)
39 home care services/ or home care services, hospital-based/ or home nursing/ (36216)
40 (home adj2 (service or services or care or healthcare or visit?)).ti,ab. (25334)
41 or/39-40 [Home Care] (49205)
42 community health services/ or community health nursing/ or community networks/ or community pharmacy services/ or counseling/
(79125)
43 ((community adj3 (nursing or nurse or nurses or care or healthcare)) or community-based).ti,ab. (52960)
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44 or/42-43 [Community Care] (121322)
45 Occupational Health Services/ and ((primary adj2 care) or disease management or specialist? or chronic disease? or chronic care or
chronic condition?).ti,ab. (349)
46 (School Health Services/ not (child/ or child, preschool/ or exp infant/)) and (chronic or disease management).ti,ab. (48)
47 school health services/ and adolescent/ and (chronic or disease management).ti,ab. (116)
48 (((mobile or preventive or preventative or clinic?) adj2 (clinic? or service or services or health or health care or care or model?)) and
(chronic or disease management)).ti,ab. (17833)
49 early medical intervention/ (712)
50 or/45-49 [Misc Health Service] (19002)
51 exp Telemedicine/ or telenursing/ or remote consultation/ (15741)
52 ((telemedicine or telehealth$ or telenurs$ or tele-medicin$ or tele-health$ or tele-nurs$ or ehealth or e-health or remote consult$)
adj10 chronic).ti,ab. or telephone.ti. (4984)
53 (PDA or hand-held? or Iphone? or ipad? or i-phone? or i-pad? or blackberry or personal digital assistant? or webbased or web-based
web2$ or computeri?ed).ti,ab. (75884)
54 or/51-53 [Telemed/Tech Terms] (95571)
55 Patient Education as Topic/ or health education/ or consumer health information/ or health literacy/ or health fairs/ (123583)
56 Patient Participation/ or Self care/ or Self administration/ or consumer participation/ (64052)
57 (patient? adj3 (participation or motivating)).ti,ab. (3762)
58 (patient? adj3 (education$ or educating or educate?)).ti,ab. (23517)
59 (self-care or self-manag$).ti,ab. (18430)
60 or/55-59 [Patient Education/Self Care] (199836)
61 education, continuing/ or education, medical, continuing/ or education, nursing, continuing/ or education, pharmacy, continuing/
or education, professional, retraining/ or exp inservice training/ (69860)
62 ((continuing adj3 education$) or (CME adj3 (program$ or session? or meeting?)) or inservice? or workshop? or professional
development).ti,ab. (46492)
63 ((physician? adj2 behavio?r?) or (upskill$ or up-skill$)).ti,ab. (1818)
64 or/61-63 [Continuing Education] (105728)
65 Nurse’s Role/ or Physician’s Role/ or Professional Role/ (66788)
66 ((role or roles) adj2 (chang$ or expand$ or extend$ or revision or revised or revising or nurse or nurse’s or nursing or physician?
)).ti,ab. (18920)
67 or/65-66 [Professional Roles] (81662)
68 medical staff/ or exp medical staff, hospital/ or exp nurses/ or exp nursing staff/ or exp pharmacists/ or exp physicians/ (230078)
69 Primary Nursing/ or Nurse Clinicians/ or Nurse Practitioners/ or Community Health Nursing/ or Physician Assistants/ (44157)
70 nursing care/ or emergency nursing/ or holistic nursing/ or home nursing/ or nursing, practical/ or occupational health nursing/ or
primary nursing/ or rehabilitation nursing/ (53149)
71 (nurse-led or ((nurse or nurses or nursing) adj3 (primary adj2 (care or healthcare)))).ti,ab. (4079)
72 exp Allied Health Personnel/ (41633)
73 (allied health or physiotherapist? or physical therapist? or exercise therap$).ti,ab. (13910)
74 (nurse clinician? or nurse practitioner? or physician? Assistant?).ti,ab. (10377)
75 (”nurse-led“ or (nurse? adj2 (led or managed or coordinat$ or co-ordinat$))).ti,ab. (3291)
76 or/68-75 [General Medical Practitioners] (345435)
77 respiratory therapy department, hospital/ (382)
78 physical therapy department, hospital/ (310)
79 ((pulmonary or respiratory or respirolog$ or pneumology) adj2 (practitioner? or physician? or specialist? or doctor? or medicine or
nurse or nurses)).ti,ab. (2911)
80 (pulmonologist? or respirologist? or pulmonology or respirology or pneumologist? or pneumology).ti,ab. (4427)
81 or/77-80 [Specialist practitioners/discipline] (7799)
82 Decision Support Systems, Clinical/ or Decision Making, Computer-Assisted/ or Medical Informatics Applications/ or Decision
Support Techniques/ or decision making, organizational/ (30860)
83 (shared decision$ or decision aid? or (decision$ adj2 model$) or (decision$ adj support?) or (decision making adj2 computer$) or
informatics).ti,ab. (23574)
84 ((clinical or clinician? or doctor? or medical or nurse or nurses or nursing or patient? or physician? or practitioner?) adj3 decision
making).ti,ab. (17727)
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85 or/82-84 [Decision Support/Making] (62742)
86 ”Referral and Consultation“/ or Gatekeeping/ (51835)
87 (Referral? adj3 (chronic or decreas$ or ((general or family) adj2 (doctor? or physician? or practitioner?)) or impact or improv$ or
increas$ or intervention or plan or plans or primary care or primary health$ or program$ or reduc$ or specialist?)).ti,ab. (6917)
88 or/86-87 [Referral] (55620)
89 Practice Guidelines as Topic/ or guidelines as topic/ or Guideline Adherence/ (122252)
90 (guideline? adj3 (implement$ or impact or adherence)).ti,ab. (8241)
91 Evidence-Based Medicine/ and (change or changing or chronic or ((patient or care or disease) adj2 management) or impact or
implement$ or influence or intervention? or model? or patient care or program? or programme or programmes or strategy or strategies
or translation).ti,ab,hw. (23555)
92 or/89-91 [Guidelines (topic/adherence)/ EBM] (144237)
93 Interdisciplinary Communication/ or Cooperative Behavior/ (36001)
94 (collaborat$ or ”cross-profession$“ or interdisciplin$ or inter-discipllin$ or intraprofession$ or intra-profession$ or interprofession$
or inter-profession$ or multidisciplin$ or multi-disciplin$ or crossdisciplin$ or cross-disciplin$ or team or teams or team-based or (skill
adj2 mix$)).ti,ab. (215885)
95 or/93-94 [Interdisciplinary/Collaboration] (237175)
96 ”Outcome Assessment (Health Care)“/ (48993)
97 outcome? Assessment?.ti,ab. (3731)
98 or/96-97 [Outcome Assessment] (51815)
99 health services administration/ or ”organization and administration“/ or efficiency, organizational/ or health facility administration/
or hospital administration/ (64124)
100 exp hospital restructuring/ or hospital shared services/ (9394)
101 centralized hospital services/ or pharmacy service, hospital/ or diagnostic services/ (12245)
102models, organizational/ ormulti-institutional systems/ or organizational culture/ or exp organizational innovation/ or organizational
objectives/ or institutional management teams/ (67611)
103 (organi?ational or restructuring or (organi?ation$ adj3 (change? or changing or initiat$ or structur$ or restrict$ or model?))).ti,ab.
(56245)
104 or/99-103 [Organisations/Org services/Org Admin] (186973)
105 total quality management/ or ”quality of health care“/ or quality assurance, health care/ or benchmarking/ or quality improvement/
or Management Quality Circles/ or Quality Assurance, Health Care/ or ”Quality of Health Care“/ or ”United States Agency for
Healthcare Research and Quality“/ (129088)
106 (quality adj2 (assessment? or assurance or circle? or implement$ or increase$ or improvement? or management or measure$ or
outcome? or total)).ti,ab. (73012)
107 Peer Review, Health Care/ or Peer Review/ (7528)
108 or/105-107 [Quality Improvement/Quality Care] (183213)
109 Physician Incentive Plans/ or reimbursement, incentive/ [ML] (4857)
110 ((physician? or practitioner? or doctor? or nurse or nurses) adj4 incentive? plan?).ti,ab. (33)
111 exp Health Personnel/ and (incentiv$ adj2 (economic or financial or monetar$ or payment? or reimburs$)).ti,ab. (561)
112 or/109-111 [Incentives] (5278)
113 (insurance, health, reimbursement/ or reimbursement mechanisms/ or fee-for-service plans/ or ”physician payment review commis-
sion“/ or medicare payment advisory commission/ or reimbursement, disproportionate share/ or relative value scales/) and chronic.ti,ab.
(429)
114 (insurance, health, reimbursement/ or reimbursement mechanisms/ or fee-for-service plans/ or ”physician payment review com-
mission“/ or medicare payment advisory commission/ or reimbursement, disproportionate share/ or relative value scales/) and (change
or changes or changing or chronic or effectiveness or impact or implement$ or intervention).ti,ab. (4959)
115 ”fees and charges“/ or capitation fee/ or fee-for-service plans/ or fees, medical/ or fees, pharmaceutical/ or prescription fees/ or ”rate
setting and review“/ [ML] (22973)
116 (gainshar$ or payer-provider? or payer-patient?).ti,ab. (139)
117 (”pay for compliance“ or ”pay for participation“ or ”pay for performance“ or ”performance pay$“ or P4P or ”pay for quality
improvement?“ or P4QI or ”fee-for service?“).ti,ab. (5057)
118 (payment? adj (blend$ or ”blue cross“ or bonus$ or capped or ”episode of care“ or fixed or government$ or insurance or insurer?
or level? or linear or medicaid or medicare or non-linear or per-patient or per-episode or per-visit or performance or prospectiv$ or
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retroactiv$ or retrospectiv$ or reward$ or schedule? or system? or target$ or third-part$ or threshold? or uncap$ or shared or variable
or per-visit?)).ti,ab. (3007)
119 or/113-118 [Financial] (32314)
120 adult/ or exp aged/ or middle aged/ or young adult/ (5564077)
121 adult?.ti,ab,hw. or middle aged.ti,ab. (4481427)
122 or/120-121 [Adults] (5977532)
123 exp child/ or adolescent/ (2408162)
124 (adolescent? or baby or babies or child$ or infant? or neonate? or neo-nate? or p?ediatric$).ti. (886816)
125 *pediatrics/ or *neonatology/ or *perinatology/ (31200)
126 (infant? or toddler? or child$ or adolescent? or neonate? or neo-nate? or (p?ediatric$ adj2 (patient? or inpatient?))).ab. (992901)
127 or/123-126 [Child/Pediatrics] (2938570)
128 (randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or clinical trials as topic.sh. or
randomly.ab. or trial.ti. (908159)
129 exp animals/ not humans.sh. (3949551)
130 128 not 129 [Cochrane RCT Filter 6.4.d Sens/Precision Maximizing] (838022)
131 (8 and 9 and 122) or ((8 and 9) not 127) [Screen all; do not add filter] (41)
132 ((10 and 122) or (10 not 127)) not 131 [Keyword results; do not add filter] (212)
133 ((8 and 13 and 122) or ((8 and 13) not 127)) and 130 [Set 1] (21)
134 ((8 and 16 and 122) or ((8 and 16) not 127)) and 130 [Set 1a] (120)
135 ((8 and 21 and 122) or ((8 and 21) not 127)) and 130 [Set 1b] (40)
136 ((8 and 25 and 122) or ((8 and 25) not 127)) and 130 [Set 1bc] (90)
137 ((8 and 28 and 122) or ((8 and 28) not 127)) and 130 [Set 2] (6)
138 ((8 and 32 and 122) or ((8 and 32) not 127)) and 130 [Set 2a] (107)
139 ((8 and 35 and 122) or ((8 and 35) not 127)) and 130 [Set 2c] (7)
140 ((8 and 38 and 122) or ((8 and 38) not 127)) and 130 [Set 3] (57)
141 ((8 and 41 and 122) or ((8 and 41) not 127)) and 130 [Set 4] (77)
142 ((8 and 44 and 122) or ((8 and 44) not 127)) and 130 [Set 5] (94)
143 ((8 and 50 and 122) or ((8 and 50) not 127)) and 130 [Set 6] (90)
144 ((8 and 54 and 122) or ((8 and 54) not 127)) and 130 [Set 7] (101)
145 ((8 and 60 and 122) or ((8 and 60) not 127)) and 130 [Set 8] (490)
146 ((8 and 64 and 122) or ((8 and 64) not 127)) and 130 [Set 9] (47)
147 ((8 and 67 and 122) or ((8 and 67) not 127)) and 130 [Set 10] (16)
148 ((8 and 76 and 122) or ((8 and 76) not 127)) and 130 [Set 11] (137)
149 ((8 and 81 and 122) or ((8 and 81) not 127)) and 130 [Set 12] (92)
150 ((8 and 85 and 122) or ((8 and 85) not 127)) and 130 [Set 13] (31)
151 ((8 and 88 and 122) or ((8 and 88) not 127)) and 130 [Set 14] (28)
152 ((8 and 92 and 122) or ((8 and 92) not 127)) and 130 [Set 15] (216)
153 ((8 and 95 and 122) or ((8 and 95) not 127)) and 130 [Set 16] (107)
154 ((8 and 98 and 122) or ((8 and 98) not 127)) and 130 [Set 17] (89)
155 ((8 and 104 and 122) or ((8 and 104) not 127)) and 130 [Set 18] (17)
156 ((8 and 108 and 122) or ((8 and 108) not 127)) and 130 [Set 19] (179)
157 ((8 and 112 and 122) or ((8 and 112) not 127)) and 130 [Set 20] (3)
158 ((8 and 119 and 122) or ((8 and 119) not 127)) and 130 [Set 21] (7)
159 13 or 16 or 21 or 25 or 28 or 32 or 35 or 38 or 41 or 44 or 50 or 54 or 60 or 64 or 67 or 76 or 81 or 85 or 88 or 92 or 95 or 98
or 104 or 108 or 112 or 119 (1661114)
160 (((8 and 159 and 122) or ((8 and 159) not 127)) and 130) not (or/131-132) [RCT Results ] (1375)
161 (or/133-158) not (or/131-132) (1375)
162 (201211$ or 2013$ or 2014$).ep,ed,yr. [2012-2014 Limits] (1965302)
163 161 and 162 [2014 RCT results] (103)
164 132 and 162 [2014 KW results] (21)
Non-RCT search (using EPOC non-RCT study designs filter)
Search date: June 18, 2014
1 asthma/ (103892)
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2 (asthma$ or wheez$).ti. (76459)
3 (asthma$ adj3 (sever$ or chronic$ or primary or major)).ab. (17035)
4 or/1-3 [Asthma] (113631)
5 (chronic adj4 (model or management)).ti,ab. (23279)
6 (asthma adj3 (model? or program or programs or programme or programmes)).ti,ab. (4446)
7 (disease adj2 management adj5 (model? or program? or programme or programmes)).ti,ab. (1965)
8 (comprehensive health care or ((continuity or continu$) adj3 (care or healthcare))).ti,ab. (14246)
9 (care adj2 model?).ti,ab. (7996)
10 (patient centred or patient centered).ti,ab. (8330)
11 ((care adj2 (algorithm? or pathway? or plan)) or CRITICAL pathway?).ti,ab. (7779)
12 (((written or action) adj3 plan?) or (planning adj2 care)).ti,ab. (9739)
13 (integrat$ adj2 (care or healthcare)).ti,ab. (5980)
14 ((fewer or reduc$ or lower$ or shorten$) adj3 (”length of stay“ or hospitali?ation? or readmission? or readmit$ or admission?)).ti,ab.
(11818)
15 (hospitali?ation?.ti,hw. and (program? or programme or programmes or model? or reduc$ or impact or intervention or improving
or reduc$ or lower$ or fewer).ti.) or (hospitali?ation? adj4 (reduc$ or fewer or lower)).ab. (11438)
16 (patient? discharg$ or discharge plan$).ti,hw. and ((impact or improv$ or initiativ$ or quality or chronic or plan?).ti. or (planning
or team? or collaborat$ or intervention?).ti,ab.) (5689)
17 ((patient admission? or hospital$ admission? or readmission? or readmit$).ti,hw. and (fewer or reduc$ or lower$ or shorten$).ti.) or
((patient admission? or hospital$ admission? or readmission? or readmit$) adj4 (fewer or reduc$ or lower$)).ab. (3221)
18 ((community adj3 (nursing or nurse or nurses or care or healthcare)) or community-based).ti,ab. (53018)
19 ((telephone? or telephoning or phone? or phoning or telemedicine or telehealth$ or telenurs$ or tele-medicin$ or tele-health$ or
tele-nurs$ or ehealth or e-health or remote consult$) and chronic and (care or diseas$ or condition?)).ti,ab. (2822)
20 (PDA or Iphone? or ipad? or i-phone? or i-pad? or blackberry or personal digital assistant? or handheld or ((webbased or web-based
web2$ or computeri?ed) adj5 ((chronic or diseas$) adj2 (care or manag$ or diseas$ or condition$)))).ti,ab. (10507)
21 (patient? adj3 (participation or physician?)).ti,ab. (37380)
22 (patient? adj3 (education$ or educating or educate?) adj4 (part or intervention? or complex or program? or model or multifacet$ or
multimod$ or combin$ or ”in addition“ or package or suite)).ti,ab. (2497)
23 ((self-care or self-manag$) adj4 (part or intervention? or complex or program? or model or multifacet$ or multimod$ or combin$
or ”in addition“ or package or suite)).ti,ab. (2831)
24 ((continuing adj3 education$) or (CME adj3 (program$ or session? or meeting?)) or inservice? or workshop? or professional
development).ti,ab. (46525)
25 ((physician? adj2 behavio?r?) or (upskill$ or up-skill$)).ti,ab. (1819)
26 ((role or roles) adj2 (chang$ or expand$ or extend$ or revision or revised or revising or nurse or nurse’s or nursing or physician?
)).ti,ab. (18937)
27 (((nurse or nurses or nursing) adj3 (primary adj2 (care or healthcare))) and specialist?).ti,ab. (162)
28 ((allied health or physiotherapist? or therapist?) adj7 (specialist? or partner$)).ti,ab. (575)
29 (nurse clinician? or nurse practitioner? or physician? Assistant?).ti,ab. (10382)
30 (”nurse-led“ or (nurse? adj2 (led or managed or coordinat$ or co-ordinat$))).ti,ab. (3296)
31 (shared decision$ or decision aid? or (decision$ adj2 model$) or (decision$ adj support?) or (decision making adj2 computer$) or
informatics).ti,ab. (23600)
32 ((clinical or clinician? or doctor? or medical or nurse or nurses or nursing or patient? or physician? or practitioner?) adj3 decision
making).ti,ab. (17757)
33 (Referral? adj3 (chronic or decreas$ or ((general or family) adj2 (doctor? or physician? or practitioner?)) or impact or improv$ or
increas$ or intervention or plan or plans or primary care or primary health$ or program$ or reduc$ or specialist?)).ti,ab. (6930)
34 (guideline? adj3 (implement$ or impact or ((improv$ or increas$) adj2 adherence))).ti,ab. (5788)
35 (collaborat$ or ”cross-profession$“ or interdisciplin$ or inter-discipllin$ or intraprofession$ or intra-profession$ or interprofession$
or inter-profession$ or multidisciplin$ or multi-disciplin$ or crossdisciplin$ or cross-disciplin$ or team or teams or team-based or (skill
adj2 mix$)).ti,ab. (216209)
36 (patient? adj2 outcome? adj3 (improv$ or increas$)).ti,ab. (13202)
37 ((organi?ation$ adj2 (change or changes or culture or intervention? or model?)) or multi-institution$ or innovat$).ti,ab. (74359)
38 restructuring.ti,ab. (6341)
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39 (quality adj2 (assessment? or assurance or circle? or implement$ or increase$ or improvement? or management or measure$ or
outcome? or total)).ti,ab. (73102)
40 ((nurse or nurses or provider? or practitioner? or physician?) adj3 incentiv$).ti,ab. (1025)
41 (insurance or reimbursement or ”fee-for-service?“ or medicare or medicaid).ti,hw. and (change or changes or changing or chronic
or effectiveness or impact or implement$ or intervention$).ti. (8394)
42 (gainshar$ or payer-provider? or payer-patient?).ti,ab. (139)
43 (”pay for compliance“ or ”pay for participation“ or ”pay for performance“ or ”performance pay$“ or P4P or ”pay for quality
improvement?“ or P4QI or ”fee-for service?“).ti,ab. (5064)
44 (payment? adj (blend$ or ”blue cross“ or bonus$ or capped or ”episode of care“ or fixed or government$ or insurance or insurer?
or level? or linear or medicaid or medicare or non-linear or per-patient or per-episode or per-visit or performance or prospectiv$ or
retroactiv$ or retrospectiv$ or reward$ or schedule? or system? or target$ or third-part$ or threshold? or uncap$ or shared or variable
or per-visit?)).ti,ab. (3010)
45 *”health care quality“/ and (improv$ or increas$ or decreas$ or reduc$ or outcome?).ti. (3701)
46 (practice pattern? or ((physician? or pharmacist?) adj2 led)).ti,ab. (5481)
47 (”cross-profession$“ or interdisciplin$ or inter-discipllin$ or intraprofession$ or intra-profession$ or interprofession$ or inter-
profession$ ormultidisciplin$ ormulti-disciplin$ or crossdisciplin$ or cross-disciplin$ or team-based or (skill adj2mix$)).ti,ab. (74309)
48 management.ti. (264199)
49 or/5-48 [Intervention terms] (882410)
50 intervention?.ti. or (intervention? adj6 (clinician? or collaborat$ or community or complex or DESIGN$ or doctor? or educational
or family doctor? or family physician? or family practitioner? or financial or GP or general practice? or hospital? or impact? or improv$
or individuali?e? or individuali?ing or interdisciplin$ or multicomponent or multi-component or multidisciplin$ or multi-disciplin$ or
multifacet$ or multi-facet$ or multimodal$ or multi-modal$ or personali?e? or personali?ing or pharmacies or pharmacist? or pharmacy
or physician? or practitioner? or prescrib$ or prescription? or primary care or professional$ or provider? or regulatory or regulatory or
tailor$ or target$ or team$ or usual care)).ab. (163873)
51 (pre-intervention? or preintervention? or ”pre intervention?“ or post-intervention? or postintervention? or ”post intervention?“).ti,ab.
[added 2.4] (10398)
52 (hospital$ or patient?).hw. and (study or studies or care or health$ or practitioner? or provider? or physician? or nurse? or nursing
or doctor?).ti,hw. (721142)
53 demonstration project?.ti,ab. (1963)
54 (pre-post or ”pre test$“ or pretest$ or posttest$ or ”post test$“ or (pre adj5 post)).ti,ab. (66412)
55 (pre-workshop or post-workshop or (before adj3 workshop) or (after adj3 workshop)).ti,ab. (621)
56 trial.ti. or ((study adj3 aim?) or ”our study“).ab. (637598)
57 (before adj10 (after or during)).ti,ab. (359155)
58 (”quasi-experiment$“ or quasiexperiment$ or ”quasi random$“ or quasirandom$ or ”quasi control$“ or quasicontrol$ or ((quasi$
or experimental) adj3 (method$ or study or trial or design$))).ti,ab,hw. (102099)
59 (”time series“ adj2 interrupt$).ti,ab,hw. (1070)
60 (time points adj3 (over or multiple or three or four or five or six or seven or eight or nine or ten or eleven or twelve or month$ or
hour? or day? or ”more than“)).ab. (9239)
61 pilot.ti. (40150)
62 Pilot projects/ (82634)
63 (clinical trial or controlled clinical trial or multicenter study).pt. (628551)
64 (multicentre or multicenter or multi-centre or multi-center).ti. (29237)
65 random$.ti,ab. or controlled.ti. (761933)
66 (control adj3 (area or cohort? or compare? or condition or design or group? or intervention? or participant? or study)).ab. not
(controlled clinical trial or randomized controlled trial).pt. (413376)
67 ”comment on“.cm. or review.ti,pt. or randomized controlled trial.pt. (2934047)
68 (rat or rats or cow or cows or chicken? or horse or horses or mice or mouse or bovine or animal?).ti. (1345613)
69 exp animals/ not humans.sh. (3949551)
70 (or/50-66) not (or/67-69) [EPOCMethods Filter 2.4 Medline] (2157067)
71 exp adult/ or adult?.ti. or (adult? adj3 asthma$).ab. (5639003)
72 exp child/ or adolescent/ (2408162)
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73 (child or children or infant or neonat$ or pre-school or baby or babies or p?ediatric$ or perinat$ or teen$ or ”school-age?“ or toddler?
).ti,ab,hw. (2416343)
74 (adolescent? or adolescence).ti. (105354)
75 or/72-74 [Child/Pediatrics] (3218406)
76 exp air pollution/ or dust/ or Antigens, Dermatophagoides/ or (dust? or mites or pollution or pollutant?).ti. (79218)
77 (and/4,49,71) not (or/73,76) (2136)
78 (and/4,49) not (or/75-76) (6607)
79 70 and (or/77-78) [Results EPOC Filter all years] (1442)
80 (201211$ or 2013$ or 2014$).ep,ed,yr. [2012-2014 Limits] (1980315)
81 79 and 80 [EPOC 2014 results] (170)
Appendix 2. EMBASE strategy 2014
Embase <1947 to 2014 June 17> OVID
Search date: June 18, 2014
1 exp *asthma/ (134484)
2 (asthma$ or wheez$).ti. (101147)
3 (asthma$ adj3 (sever$ or chronic$ or primary or major)).ab. (23848)
4 or/1-3 [Asthma] (145506)
5 (exp asthma/ or bronchus hyperreactivity/) and chronic disease? management.ti,ab. (90)
6 4 and chronic disease? manag$.ti,ab. (58)
7 or/5-6 [Focussed Key Terms] (92)
8 chronic disease management.ti,ab. (1409)
9 (asthma adj3 (model? or program or programs or programme or programmes)).ti,ab. (5828)
10 (care adj2 team$).ti,ab. (11602)
11 (disease adj2 management adj5 (model? or program? or programme or programmes)).ti,ab. (2840)
12 comprehensive health care.ti,ab. (903)
13 (care adj2 (model? or management)).ti,ab. (20461)
14 (patient centred or patient centered or (continuity adj2 care)).ti,ab. (15904)
15 ((care adj2 (algorithm? or pathway? or plan)) or CRITICAL pathway?).ti,ab. (11010)
16 (((written or action) adj3 plan?) or (planning adj2 care)).ti,ab. (12743)
17 (integrat$ adj2 (care or healthcare)).ti,ab. (7802)
18 ((fewer or reduc$ or lower$ or shorten$) adj3 (”length of stay“ or hospitali?ation? or readmission? or readmit$ or admission?)).ti,ab.
(17645)
19 hospitali?ation?.ti,hw. and (management or program? or programme or programmes or model? or reduc$ or impact or intervention
or improving).ti. (22501)
20 (patient? discharg$ or discharge plan$).ti,hw. and ((improv$ or quality or chronic or plan?).ti. or (planning or team? or collaborat$
or intervention?).ti,ab.) (1165)
21 ((care or healthcare) adj3 (model? or program? or programme or programmes)).ti,ab. (35859)
22 (home adj2 (service or services or care or healthcare or visit?)).ti,ab. (30388)
23 ((community adj3 (nursing or nurse or nurses or care or healthcare)) or community-based).ti,ab. (62459)
24 (((mobile or preventive or preventative or clinic?) and (clinic? or service or services or health or health care or care or model?) and
chronic) or ((mobile or preventive or preventative or clinic?) adj3 (clinic? or service or services or health or health care or care or model?
) adj5 chronic)).ti. (1555)
25 ((telephone? or telephoning or phone? or phoning or telemedicine or telehealth$ or telenurs$ or tele-medicin$ or tele-health$ or
tele-nurs$ or ehealth or e-health or remote consult$) adj7 chronic).ti,ab. (453)
26 (PDA or Iphone? or ipad? or i-phone? or i-pad? or blackberry or personal digital assistant? or handheld or ((webbased or web-based
web2$ or computeri?ed) adj5 ((chronic or diseas$) adj2 (care or manag$ or diseas$ or condition$)))).ti,ab. (14824)
27 (patient? adj3 (participation or physician?)).ti,ab. (50452)
28 (patient? adj3 (education$ or educating or educate?) adj4 (part or intervention? or complex or program? or model or multifacet$ or
multimod$ or combin$ or ”in addition“ or package or suite)).ti,ab. (3545)
108Chronic disease management programmes for adults with asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
29 ((self-care or self-manag$) adj4 (part or intervention? or complex or program? or model or multifacet$ or multimod$ or combin$
or ”in addition“ or package or suite)).ti,ab. (3604)
30 ((continuing adj3 education$) or (CME adj3 (program$ or session? or meeting?)) or inservice? or workshop? or professional
development).ti,ab. (60692)
31 ((physician? adj2 behavio?r?) or (upskill$ or up-skill$)).ti,ab. (2227)
32 ((role or roles) adj2 (chang$ or expand$ or extend$ or revision or revised or revising or nurse or nurse’s or nursing or physician?
)).ti,ab. (21418)
33 ((nurse or nurses or nursing) adj3 (primary adj2 (care or healthcare))).ti,ab. (2517)
34 ((allied health or physiotherapist? or physical therapist? or exercise therap$) adj4 (team? or team-based or partner$ or collab$ or
intervention?)).ti,ab. (833)
35 (nurse clinician? or nurse practitioner? or physician? Assistant?).ti,ab. (12375)
36 (”nurse-led“ or (nurse? adj2 (led or managed or coordinat$ or co-ordinat$))).ti,ab. (4666)
37 (shared decision$ or decision aid? or (decision$ adj2 model$) or (decision$ adj support?) or (decision making adj2 computer$) or
informatics).ti,ab. (29827)
38 ((clinical or clinician? or doctor? or medical or nurse or nurses or nursing or patient? or physician? or practitioner?) adj3 decision
making).ti,ab. (22539)
39 (Referral? adj3 (chronic or decreas$ or ((general or family) adj2 (doctor? or physician? or practitioner?)) or impact or improv$ or
increas$ or intervention or plan or plans or primary care or primary health$ or program$ or reduc$ or specialist?)).ti,ab. (9726)
40 (guideline? adj3 (implement$ or impact or ((improv$ or increas$) adj2 adherence))).ti,ab. (7943)
41 (collaborat$ or ”cross-profession$“ or interdisciplin$ or inter-discipllin$ or intraprofession$ or intra-profession$ or interprofession$
or inter-profession$ or multidisciplin$ or multi-disciplin$ or crossdisciplin$ or cross-disciplin$ or team or teams or team-based or (skill
adj2 mix$)).ti,ab. (302243)
42 (patient? adj2 outcome? adj3 (improv$ or increas$)).ti,ab. (18908)
43 ((organi?ation$ adj2 (change or changes or culture or intervention? or model?)) or multi-institution$ or innovat$).ti,ab. (97271)
44 restructuring.ti,ab. (7406)
45 (quality adj2 (assessment? or assurance or circle? or implement$ or increase$ or improvement? or management or measure$ or
outcome? or total)).ti,ab. (98681)
46 ((nurse or nurses or provider? or practitioner? or physician?) adj3 incentiv$).ti,ab. (1151)
47 (insurance or reimbursement or ”fee-for-service?“ or medicare or medicaid).ti,hw. and (change or changes or changing or chronic
or effectiveness or impact or implement$ or intervention$).ti,ab. (48460)
48 (gainshar$ or payer-provider? or payer-patient?).ti,ab. (159)
49 (”pay for compliance“ or ”pay for participation“ or ”pay for performance“ or ”performance pay$“ or P4P or ”pay for quality
improvement?“ or P4QI or ”fee-for service?“).ti,ab. (5970)
50 (payment? adj (blend$ or ”blue cross“ or bonus$ or capped or ”episode of care“ or fixed or government$ or insurance or insurer?
or level? or linear or medicaid or medicare or non-linear or per-patient or per-episode or per-visit or performance or prospectiv$ or
retroactiv$ or retrospectiv$ or reward$ or schedule? or system? or target$ or third-part$ or threshold? or uncap$ or shared or variable
or per-visit?)).ti,ab. (3453)
51 (chronic adj3 manag$).ti,ab. (17404)
52 (collaborat$ or coordinat$ or co-ordinat$ or (care team or (manag$ adj3 care) or interdisciplin$ or inter-disciplin$ or multidisciplin$
or multi-disciplin$ or (continuing adj2 education$) or eduational or action plan? or written plan? or quality improv$)).ti,ab. (461425)
53 *”health care quality“/ (61091)
54 (practice pattern? or ((physician? or pharmacist?) adj2 led)).ti,ab. (7501)
55 ((primary care or nurse or nurses or nursing or pulmonologist? or respirologist? or pulmonology or respirology or pneumologist? or
pneumology) adj5 team?).ti,ab. (8454)
56 (”cross-profession$“ or interdisciplin$ or inter-discipllin$ or intraprofession$ or intra-profession$ or interprofession$ or inter-
profession$ or multidisciplin$ or multi-disciplin$ or crossdisciplin$ or cross-disciplin$ or team-based or (skill adj2 mix$)).ti,ab.
(106638)
57 (community or integrat$).ti. (178686)
58 management.ti. (341735)
59 or/8-58 (1540362)
60 adult?.ti,hw. or (adult? adj3 asthma$).ab. (4694320)
61 (child or children or infant or neonat$ or pre-school or baby or babies or p?ediatric$ or perinat$).ti,ab,hw. (2659040)
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62 intervention?.ti. or (intervention? adj6 (clinician? or collaborat$ or community or complex or DESIGN$ or doctor? or educational
or family doctor? or family physician? or family practitioner? or financial or GP or general practice? or hospital? or impact? or improv$
or individuali?e? or individuali?ing or interdisciplin$ or multicomponent or multi-component or multidisciplin$ or multi-disciplin$ or
multifacet$ or multi-facet$ or multimodal$ or multi-modal$ or personali?e? or personali?ing or pharmacies or pharmacist? or pharmacy
or physician? or practitioner? or prescrib$ or prescription? or primary care or professional$ or provider? or regulatory or regulatory or
tailor$ or target$ or team$ or usual care)).ab. (211159)
63 (pre-intervention? or preintervention? or ”pre intervention?“ or post-intervention? or postintervention? or ”post intervention?“).ti,ab.
[added 2.4] (13867)
64 (hospital$ or patient?).hw. and (study or studies or care or health$ or practitioner? or provider? or physician? or nurse? or nursing
or doctor?).ti,hw. (1742418)
65 demonstration project?.ti,ab. (2399)
66 (pre-post or ”pre test$“ or pretest$ or posttest$ or ”post test$“ or (pre adj5 post)).ti,ab. (100690)
67 (pre-workshop or post-workshop or (before adj3 workshop) or (after adj3 workshop)).ti,ab. (887)
68 trial.ti. or ((study adj3 aim?) or ”our study“).ab. (888019)
69 (before adj10 (after or during)).ti,ab. (479749)
70 (time points adj3 (over or multiple or three or four or five or six or seven or eight or nine or ten or eleven or twelve or month$ or
hour? or day? or ”more than“)).ab. (12588)
71 pilot.ti. (51773)
72 (multicentre or multicenter or multi-centre or multi-center).ti. (40570)
73 random$.ti,ab. or controlled.ti. (955245)
74 review.ti. (317768)
75 (animal$ not human$).sh,hw. (3762097)
76 *experimental design/ or *pilot study/ or quasi experimental study/ (8561)
77 (”quasi-experiment$“ or quasiexperiment$ or ”quasi random$“ or quasirandom$ or ”quasi control$“ or quasicontrol$ or ((quasi$
or experimental) adj3 (method$ or study or trial or design$))).ti,ab. (128543)
78 (”time series“ adj2 interrupt$).ti,ab. (1188)
79 (or/62-73,76-78) not (or/74-75) [EPOC Methods Filter 2.4 EMBASE] (3478848)
80 controlled clinical trial/ or controlled study/ or randomized controlled trial/ [EM] (4410611)
81 (book or conference paper or editorial or letter or review).pt. not randomized controlled trial/ [Per BMJ Clinical Evidence filter]
(3983119)
82 (random sampl$ or random digit$ or random effect$ or random survey or random regression).ti,ab. not randomized controlled
trial/ [Per BMJ Clinical Evidence filter] (56912)
83 (animal$ not human$).sh,hw. (3762097)
84 80 not (or/81-83) [Trial filter per BMJ CLinical Evidence] (2912054)
85 (2007$ or 2008$ or 2009$ or 201$).em. [Embase entry week] (8395693)
86 (2007$ or 2008$ or 2009$ or 201$).yr. (8212115)
87 ((and/4,59) not 61) or ((and/4,59) and 60) [Results before filters] (11993)
88 87 and 84 [RCT Results all years] (1895)
89 (and/79,87) not 88 [EPOC FIlter results all years] (3378)
90 88 and (or/85-86) [RCT 2007-Nov 22-2012] (930)
91 89 and (or/85-86) [EPOC 2007-Nov-22-2012] (1922)
92 7 not (or/90-91) [KW results all years] (74)
93 (201211$ or 2013$ or 2014$).em,yr,dp. (2361234)
94 88 and 93 [RCT 2012-2014] (164)
95 89 and 93 [EPOC 2012-2014] (585)
96 (92 and 93) not (94 or 95) [KW 2012-2014]
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Appendix 3. CINAHL strategy 2012
CINAHL EBSCOhost (search date
November 26, 2012)
# Query Limiters/Expanders Results
S63 (s27 and s52) not s62 [EPOC Filter Re-
sults]
Limiters - Published Date from:
20070101-20121131
Expanders - Apply related words
Search modes - Boolean/Phrase
76
S62 s27 and s61 [Trial Filter Results] Limiters - Published Date from:
20070101-20121131
Expanders - Apply related words
Search modes - Boolean/Phrase
54
S61 S53 OR S54 OR S55 OR S56 OR S57
OR S58 OR S59 OR S60 [Trial Filter]
Expanders - Apply related words
Search modes - Boolean/Phrase
137,122
S60 TI controlled AND TI ( trial or trials or
study or experiment* or intervention )
Expanders - Apply related words
Search modes - Boolean/Phrase
15,818
S59 AB ( (multicent* n2 design*) or (multi-
cent* n2 study) or (multicent* n2 stud-
ies) or (multicent* n2 trial*) ) or AB (
(multi-cent* n2 design*) or (multi-cent*
n2 study) or (multi-cent* n2 studies) or
(multi-cent* n2 trial*) )
Expanders - Apply related words
Search modes - Boolean/Phrase
5,864
S58 TI multicentre or multicenter or multi-
centre or multi-center
Expanders - Apply related words
Search modes - Boolean/Phrase
3,870
S57 TI ( cluster N2 trial* or cluster N2 study
or cluster N2 group or cluster N2 groups
or cluster N2 cohort or clusterN2 design
or cluster N2 experiment* ) OR AB (
cluster N2 trial* or cluster N2 study or
cluster N2 group or cluster N2 groups or
cluster N2 cohort or cluster N2 design
or cluster N2 experiment* )
Expanders - Apply related words
Search modes - Boolean/Phrase
1,442
S56 TI ( control group or control groups OR
control* experiment* or control* design
or controlled study ) OR AB ( control
group OR control groups or control*
cohort* or controlled experiment* con-
trolled design or controlled study)
Expanders - Apply related words
Search modes - Boolean/Phrase
44,611
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(Continued)
S55 TI random* or AB random* Expanders - Apply related words
Search modes - Boolean/Phrase
97,503
S54 TI ( “clinical study” or “clinical studies” )
or AB ( “clinical study” or “clinical stud-
ies” )
Expanders - Apply related words
Search modes - Boolean/Phrase
6,286
S53 (MM ”Clinical Trials+“) Expanders - Apply related words
Search modes - Boolean/Phrase
7,536
S52 S28 or S29 or S30 or S31 or S32 or S33
or S34 or S35 or S36 or S37 or S38 or
S39 or S40 or S41 or S42 or S43 or S44
or S45 or S46 or S47 or S48 or S49 or
S50 or S51 [EPOC Filter]
Expanders - Apply related words
Search modes - Boolean/Phrase
379,913
S51 TI ( (time points n3 over) or (time points
n3 multiple) or (time points n3 three)
or (time points n3 four) or (time points
n3 five) or (time points n3 six) or (time
points n3 seven) or (time points n3 eight)
or (time points n3 nine) or (time points
n3 ten) or (time points n3 eleven) or
(time points n3 twelve) or (time points
n3 month*) or (time points n3 hour*)
or (time points n3 day*) or (time points
n3 ”more than“) ) or AB ( (time points
n3 over) or (time points n3 multiple) or
(time points n3 three) or (time points n3
four) or (time points n3 five) or (time
points n3 six) or (time points n3 seven)
or (time points n3 eight) or (time points
n3 nine) or (time points n3 ten) or (time
points n3 eleven) or (time points n3
twelve) or (time points n3 month*) or
(time points n3 hour*) or (time points
n3 day*) or (time points n3 ”more than“)
)
Expanders - Apply related words
Search modes - Boolean/Phrase
1,348
S50 TI ( (control w3 area) or (control w3
cohort*) or (control w3 compar*) or
(control w3 condition) or (control w3
group*) or (control w3 intervention*) or
(control w3 participant*) or (control w3
study) ) orAB ( (control w3 area) or (con-
trol w3 cohort*) or (control w3 compar*)
or (control w3 condition) or (control w3
group*) or (control w3 intervention*) or
(control w3 participant*) or (control w3
Expanders - Apply related words
Search modes - Boolean/Phrase
41,291
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(Continued)
study) )
S49 TI ( multicentre or multicenter or multi-
centre or multi-center ) or AB random*
Expanders - Apply related words
Search modes - Boolean/Phrase
88,433
S48 TI random* OR controlled Expanders - Apply related words
Search modes - Boolean/Phrase
30,082
S47 TI ( trial or (study n3 aim) or ”our study“
) or AB ( (study n3 aim) or ”our study“ )
Expanders - Apply related words
Search modes - Boolean/Phrase
73,597
S46 TI ( pre-workshop or preworkshop or
post-workshop or postworkshop or (be-
fore n3 workshop) or (after n3 work-
shop) ) or AB ( pre-workshop or pre-
workshop or post-workshop or post-
workshop or (before n3 workshop) or
(after n3 workshop) )
Expanders - Apply related words
Search modes - Boolean/Phrase
285
S45 TI ( demonstration project OR demon-
stration projects OR preimplement* or
pre-implement* or post-implement* or
postimplement* ) or AB ( demonstra-
tion project OR demonstration projects
OR preimplement* or pre-implement*
or post-implement* or postimplement*
)
Expanders - Apply related words
Search modes - Boolean/Phrase
1,193
S44 (intervention? n6 clinician*) or (inter-
vention? n6 community) or (interven-
tion? n6 complex) or (intervention? n6
design*) or (intervention? n6 doctor*)
or (intervention? n6 educational) or (in-
tervention? n6 family doctor*) or (inter-
vention? n6 family physician*) or (in-
tervention? n6 family practitioner*) or
(intervention? n6 financial) or (inter-
vention? n6 GP) or (intervention? n6
general practice*) Or (intervention? n6
hospital*) or (intervention? n6 impact*)
Or (intervention? n6 improv*) or (in-
tervention? n6 individualize*) Or (in-
tervention? n6 individualis*) or (inter-
vention? n6 individualizi*) or (interven-
tion? n6 interdisciplin*) or (interven-
tion? n6 multicomponent) or (interven-
tion? n6 multi-component) or (inter-
vention? n6 multidisciplin*) or (inter-
vention? n6 multi-disciplin*) or (inter-
Expanders - Apply related words
Search modes - Boolean/Phrase
18,639
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(Continued)
vention? n6 multifacet*) or (interven-
tion? n6 multi-facet*) or (intervention?
n6 multimodal*) or (intervention? n6
multi-modal*) or (intervention? n6 per-
sonalize*) or(intervention? n6 person-
alise*) or (intervention? n6 personaliz-
ing) or (intervention? n6 personalising)
or (intervention? n6 pharmaci*) or (in-
tervention? n6 pharmacist*) or (inter-
vention? n6 pharmacy) or (intervention?
n6 prescrib*) or (intervention? n6 pre-
scription*) or (intervention? n6 primary
care) or (intervention? n6 professional*)
or (intervention? n6 provider*) or (inter-
vention? n6 regulatory) or (intervention?
n6 regulatory) or (intervention? n6 tai-
lor*) or (intervention? n6 target*) or (in-
tervention? n6 team*) or (intervention?
n6 usual care)
S43 TI ( collaborativ* or collaboration* or
tailored or personalised or personalized )
or AB ( collaborativ* or collaboration* or
tailored or personalised or personalized )
Expanders - Apply related words
Search modes - Boolean/Phrase
33,831
S42 TI pilot Expanders - Apply related words
Search modes - Boolean/Phrase
10,322
S41 (MH ”Pilot Studies“) Expanders - Apply related words
Search modes - Boolean/Phrase
26,636
S40 AB ”before-and-after“ Expanders - Apply related words
Search modes - Boolean/Phrase
15,322
S39 AB time series Expanders - Apply related words
Search modes - Boolean/Phrase
1,571
S38 TI time series Expanders - Apply related words
Search modes - Boolean/Phrase
218
S37 AB ( before* n10 during or before n10
after ) or AU ( before* n10 during or
before n10 after )
Expanders - Apply related words
Search modes - Boolean/Phrase
29,065
S36 TI ( (time point*) or (period* n4 inter-
rupted) or (period* n4 multiple) or (pe-
riod* n4 time) or (period* n4 various)
or (period* n4 varying) or (period* n4
week*) or (period* n4 month*) or (pe-
riod* n4 year*) ) or AB ( (time point*)
Expanders - Apply related words
Search modes - Boolean/Phrase
44,227
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(Continued)
or (period* n4 interrupted) or (period*
n4 multiple) or (period* n4 time) or (pe-
riod* n4 various) or (period* n4 vary-
ing) or (period* n4 week*) or (period*
n4 month*) or (period* n4 year*) )
S35 TI ( ( quasi-experiment* or quasiexper-
iment* or quasi-random* or quasiran-
dom* or quasi control* or quasicontrol*
or quasi* W3 method* or quasi* W3
study or quasi* W3 studies or quasi*
W3 trial or quasi* W3 design* or ex-
perimental W3 method* or experimen-
talW3 study or experimentalW3 studies
or experimental W3 trial or experimen-
tal W3 design* ) ) or AB ( ( quasi-experi-
ment* or quasiexperiment* or quasi-ran-
dom* or quasirandom* or quasi control*
or quasicontrol* or quasi* W3 method*
or quasi* W3 study or quasi* W3 studies
or quasi* W3 trial or quasi* W3 design*
or experimental W3 method* or exper-
imental W3 study or experimental W3
studies or experimental W3 trial or ex-
perimental W3 design* ) )
Expanders - Apply related words
Search modes - Boolean/Phrase
10,908
S34 TI pre w7 post or AB pre w7 post Expanders - Apply related words
Search modes - Boolean/Phrase
8,035
S33 MH ”Multiple Time Series“ or MH
”Time Series“
Expanders - Apply related words
Search modes - Boolean/Phrase
1,205
S32 TI ( (comparative N2 study) or (compar-
ative N2 studies) or evaluation study or
evaluation studies ) or AB ( (comparative
N2 study) or (comparative N2 studies)
or evaluation study or evaluation studies
)
Expanders - Apply related words
Search modes - Boolean/Phrase
Display
S31 MH Experimental Studies or Commu-
nity Trials or Community Trials or
Pretest-Posttest Design + or Quasi-Ex-
perimental Studies + Pilot Studies or Pol-
icy Studies + Multicenter Studies
Expanders - Apply related words
Search modes - Boolean/Phrase
Display
S30 TI ( pre-test* or pretest* or posttest* or
post-test* ) orAB ( pre-test* or pretest* or
posttest* or ”post test* ) OR TI ( preim-
plement*“ or pre-implement* ) or AB (
Expanders - Apply related words
Search modes - Boolean/Phrase
Display
115Chronic disease management programmes for adults with asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
pre-implement* or preimplement* )
S29 TI ( intervention* or multiintervention*
or multi-intervention* or postinterven-
tion* or post-intervention* or preinter-
vention* or pre-intervention* ) or AB
( intervention* or multiintervention*
or multi-intervention* or postinterven-
tion* or post-intervention* or preinter-
vention* or pre-intervention* )
Expanders - Apply related words
Search modes - Boolean/Phrase
Display
S28 (MH ”Quasi-Experimental Studies“) Expanders - Apply related words
Search modes - Boolean/Phrase
Display
S27 s25 or s26 Expanders - Apply related words
Search modes - Boolean/Phrase
1,146
S26 s24 not (s17 or s18 or s19) Expanders - Apply related words
Search modes - Boolean/Phrase
932
S25 s24 and s21 Expanders - Apply related words
Search modes - Boolean/Phrase
549
S24 s7 or s8 or s23 Expanders - Apply related words
Search modes - Boolean/Phrase
1,676
S23 (s1 or s3) and (s9 or s10 or s11 or s12 or
s13 or s14 or s15 or s16 )
Expanders - Apply related words
Search modes - Boolean/Phrase
677
S22 MJ adult Expanders - Apply related words
Search modes - Boolean/Phrase
1,356
S21 (MH ”Adult+“) OR TI ( adult or adults
or adulthood ) OR AB (adult* n3
asthma*)
Expanders - Apply related words
Search modes - Boolean/Phrase
643,434
S20 s17 or s18 or s19 Expanders - Apply related words
Search modes - Boolean/Phrase
330,205
S19 TI ( pediatric* or paediatric* or child?
? or children or children? or infant or
infants or neonate or neonates or baby
or babies or baby?? or neo-nate or neo-
nates or adolescent or adolescents ) OR
AB ( pediatric* or paediatric* or child?
? or children or children? or infant or
infants or neonate or neonates or baby or
babies or baby?? or neo-nate or neo-nates
) OR MW ( pediatric* or paediatric* )
Expanders - Apply related words
Search modes - Boolean/Phrase
207,448
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(Continued)
S18 (MH ”Hospitals, Pediatric“) OR (MH
”Pediatric Physical Therapy“) OR (MH
”Intensive Care Units, Pediatric“) OR
(MH ”Pediatric Occupational Ther-
apy“) OR (MH ”Association of Pediatric
Oncology Nurses“) OR (MH ”Rehabil-
itation, Pediatric“) OR (MH ”National
Association of Pediatric Nurse Associates
and Practitioners“) OR (MH ”Pediatric
Critical Care Nursing“)
Expanders - Apply related words
Search modes - Boolean/Phrase
9,442
S17 (MH ”Child+“) Expanders - Apply related words
Search modes - Boolean/Phrase
266,981
S16 TI ( ”pay for compliance“ or ”pay for
participation“ or ”pay for performance“
or ”perfomance pay*“ or P4P or ”pay for
quality improvement*“ or P4QI or ”fee-
for-service“ or physician* incentiv* ) OR
TI ( ”pay for compliance“ or ”pay for
participation“ or ”pay for performance“
or ”perfomance pay*“ or P4P or ”pay for
quality improvement*“ or P4QI or ”fee-
for-service“ or physician* incentiv* )
Expanders - Apply related words
Search modes - Boolean/Phrase
944
S15 (MH ”Education, Medical, Continu-
ing“) OR (MH ”Education, Nursing,
Continuing“)
Expanders - Apply related words
Search modes - Boolean/Phrase
11,745
S14 TI ( continuing medical education* or
professional development* or inservice
or inservices ) OR AB ( continuing med-
ical education* or professional develop-
ment* or inservice or inservices ) OR (TI
patient? n3 education*) or (AB patient?
n3 education*)
Expanders - Apply related words
Search modes - Boolean/Phrase
10,829
S13 TI ( (improv* AND patient* AND out-
come*) ) OR AB (improv* patient* out-
come*) or TI (chang* n3 (practice* or
physician* or nurse or nurses or nursing)
) or AB (chang* n3 (practice* or physi-
cian* or nurse or nurses or nursing) )
Expanders - Apply related words
Search modes - Boolean/Phrase
16,264
S12 TI ( (reduce* or reducing or decreas*)
n3 (”length of stay“ or ”hospital stay“ or
hospitali*ation*) ) OR AB ( (reduce* or
reducing or decreas*) n3 (”length of stay“
or ”hospital stay“ or hospitali*ation*) )
Expanders - Apply related words
Search modes - Boolean/Phrase
2,319
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(Continued)
S11 TI ( (reduce* or reducing or reduction or
lower or fewer) n3 (admission* or read-
mission*) ) OR AB ( (reduce* or reduc-
ing or reduction or lower or fewer) n3
(admission* or readmission*) ) or TI (or-
gani?ational n3 (change or changes or
changing or structure or structures or
model or models)) or AB (organi?ational
n3 (change or changes or changing or
structure or structures or model or mod-
els))
Expanders - Apply related words
Search modes - Boolean/Phrase
4,283
S10 TI ( care n3 (integrated ormodel ormod-
els or innovat* or pathway* or protocol*
or guideline*) ) OR AB ( care n3 (inte-
grated or model or models or innovat* or
pathway* or protocol* or guideline*) )
Expanders - Apply related words
Search modes - Boolean/Phrase
14,895
S9 TI ( care n3 (team or teambased or teams
or collaborat* or interdisciplin* or inter-
disciplin* or multidisciplin* or multi-
disciplin* or crossdisciplin* or cross dis-
ciplin* or community) ) ORAB ( care n3
(team or teambased or teams or collabo-
rat* or interdisciplin* or inter-disciplin*
or multidisciplin* or multi-disciplin* or
crossdisciplin* or cross disciplin* or com-
munity) )
Expanders - Apply related words
Search modes - Boolean/Phrase
16,913
S8 (S1 or S3) AND (S4 or S5 or S6) Expanders - Apply related words
Search modes - Boolean/Phrase
451
S7 (S1 AND S2) Expanders - Apply related words
Search modes - Boolean/Phrase
744
S6 (MH ”Disease Management“) Expanders - Apply related words
Search modes - Boolean/Phrase
5,184
S5 TI chronic disease management OR AB
chronic disease management
Expanders - Apply related words
Search modes - Boolean/Phrase
1,498
S4 TI ( care n2 (model or models) ) OR AB
( care n2 (model or models) )
Expanders - Apply related words
Search modes - Boolean/Phrase
6,074
S3 AB ( asthma* n3 (chronic or serious) )
OR TI ( asthma* or wheez* )
Expanders - Apply related words
Search modes - Boolean/Phrase
12,793
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(Continued)
S2 (MH ”Chronic Disease“) Expanders - Apply related words
Search modes - Boolean/Phrase
25,532
S1 (MH ”Asthma“) Expanders - Apply related words
Search modes - Boolean/Phrase
16,955
Appendix 4. PsycINFO strategy 2014
PsycINFO <1806 to June Week 2 2014> OVID
Search date: June 18, 2014
1 asthma/ (3697)
2 asthma$.ti. or wheez$.ti,ab. (3309)
3 (asthma$ adj2 (chronic$ or sever$ or patient?)).ab. (1414)
4 or/1-3 [Asthma] (4246)
5 chronic disease management.ti,ab,id. (312)
6 (asthma adj3 (program or programs or programme or programme)).ti. (60)
7 (care adj2 team$).ti,ab. (2252)
8 Disease management/ (4013)
9 ((disease adj2 management) or (chronic adj2 management)).ti,ab. (3018)
10 comprehensive health care.ti,ab. (147)
11 (care adj2 management).ti,ab. (1845)
12 (patient centred or patient centered or (continuity adj2 care)).ti,ab. (4083)
13 patient care planning/ or case management/ or critical pathways/ (6411)
14 ((care adj2 (algorithm? or pathway? or plan)) or CRITICAL pathway?).ti,ab. (1616)
15 (((written or action) adj3 plan?) or (planning adj2 care)).ti,ab. (3796)
16 (integrat$ adj2 (care or healthcare)).ti,ab. (1852)
17 (”length of stay“ or readmission?).ti. (820)
18 ((reduc$ or shorten or lower$) adj3 (hospitali?ation? or ”length of stay“ or readmiss$ or readmit$)).ab. (929)
19 ((care or healthcare) adj3 (model? or program? or programme or programmes)).ti,ab. (10259)
20 (home adj2 (service or services or care or healthcare or visit?)).ti,ab. (8362)
21 ((community adj3 (nursing or nurse or nurses or care or healthcare)) or community-based).ti,ab. (24785)
22 (((mobile or preventive or preventative or clinic?) adj2 (clinic? or service or services or health or health care or care or model?)) and
(chronic or disease management)).ti,ab. (3325)
23 ((telemedicine or telehealth$ or telenurs$ or tele-medicin$ or tele-health$ or tele-nurs$ or ehealth or e-health or remote consult$)
adj10 chronic).ti,ab. or telephone.ti. (2194)
24 (PDA or hand-held? or Iphone? or ipad? or i-phone? or i-pad? or blackberry or personal digital assistant? or webbased or web-based
web2$ or computeri?ed).ti,ab. (15173)
25 (patient? adj3 (participation or motivating)).ti,ab. (1389)
26 (patient? adj3 (education$ or educating or educate?)).ti,ab. (4909)
27 (self-care or self-manag$).ti,ab. (10951)
28 ((continuing adj3 education$) or (CME adj3 (program$ or session? or meeting?)) or inservice? or workshop? or professional
development).ti,ab. (26654)
29 ((physician? adj2 behavio?r?) or (upskill$ or up-skill$)).ti,ab. (694)
30 ((role or roles) adj2 (chang$ or expand$ or extend$ or revision or revised or revising or nurse or nurse’s or nursing or physician?
)).ti,ab. (6779)
31 (nurse-led or ((nurse or nurses or nursing) adj3 (primary adj2 (care or healthcare)))).ti,ab. (935)
32 (allied health or physiotherapist? or physical therapist? or exercise therap$).ti,ab. (3078)
33 (nurse clinician? or nurse practitioner? or physician? Assistant?).ti,ab. (1915)
34 (”nurse-led“ or (nurse? adj2 (led or managed or coordinat$ or co-ordinat$))).ti,ab. (668)
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35 (shared decision$ or decision aid? or (decision$ adj2 model$) or (decision$ adj support?) or (decision making adj2 computer$) or
informatics).ti,ab. (7901)
36 ((clinical or clinician? or doctor? or medical or nurse or nurses or nursing or patient? or physician? or practitioner?) adj3 decision
making).ti,ab. (4864)
37 (Referral? adj3 (chronic or decreas$ or ((general or family) adj2 (doctor? or physician? or practitioner?)) or impact or improv$ or
increas$ or intervention or plan or plans or primary care or primary health$ or program$ or reduc$ or specialist?)).ti,ab. (2200)
38 (guideline? adj3 (implement$ or impact or adherence)).ti,ab. (1581)
39 Evidence-Based Medicine/ and (change or changing or chronic or ((patient or care or disease) adj2 management) or impact or
implement$ or influence or intervention? or model? or patient care or program? or programme or programmes or strategy or strategies
or translation).ti,ab,hw. (7811)
40 (collaborat$ or ”cross-profession$“ or interdisciplin$ or inter-discipllin$ or intraprofession$ or intra-profession$ or interprofession$
or inter-profession$ or multidisciplin$ or multi-disciplin$ or crossdisciplin$ or cross-disciplin$ or team or teams or team-based or (skill
adj2 mix$)).ti,ab. (115493)
41 outcome? Assessment?.ti,ab. (1195)
42 (organi?ational or restructuring or (organi?ation$ adj3 (change? or changing or initiat$ or structur$ or restrict$ or model?))).ti,ab.
(82564)
43 (quality adj2 (assessment? or assurance or circle? or implement$ or increase$ or improvement? or management or measure$ or
outcome? or total)).ti,ab. (13754)
44 exp Health Personnel/ and (incentiv$ adj2 (economic or financial or monetar$ or payment? or reimburs$)).ti,ab. (181)
45 (gainshar$ or payer-provider? or payer-patient?).ti,ab. (61)
46 (”pay for compliance“ or ”pay for participation“ or ”pay for performance“ or ”performance pay$“ or P4P or ”pay for quality
improvement?“ or P4QI or ”fee-for service?“).ti,ab. (1177)
47 (payment? adj (blend$ or ”blue cross“ or bonus$ or capped or ”episode of care“ or fixed or government$ or insurance or insurer?
or level? or linear or medicaid or medicare or non-linear or per-patient or per-episode or per-visit or performance or prospectiv$ or
retroactiv$ or retrospectiv$ or reward$ or schedule? or system? or target$ or third-part$ or threshold? or uncap$ or shared or variable
or per-visit?)).ti,ab. (397)
48 telemedicine/ (2494)
49 client education/ (3023)
50 exp managed care/ or health care delivery/ or health maintenance organizations/ or exp case management/ or ”cost containment“/
or disease management/ or fee for service/ or health care costs/ or exp health care services/ or exp health insurance/ or ”quality of care“/
or exp treatment planning/ or utilization reviews/ (111636)
51 treatment duration/ (3265)
52 hospital discharge/ or facility discharge/ (1695)
53 discharge planning/ or hospital admission/ (2010)
54 community services/ or community welfare services/ or home visiting programs/ or public health services/ or exp community
facilities/ or integrated services/ or outreach programs/ or exp self help techniques/ (38344)
55 Health Promotion/ or Self Care Skills/ or Self Management/ (22686)
56 client participation/ (1363)
57 continuing education/ or exp inservice training/ or professional development/ (15709)
58 inservice training/ or on the job training/ (955)
59 adult learning/ (994)
60 health care policy/ or policy making/ or health care reform/ or clinical governance/ or government policy making/ or exp health
care administration/ (36306)
61 peer evaluation/ (2123)
62 (exp health personnel/ or exp allied health personnel/ or exp medical personnel/ or exp mental health personnel/ or counselors/ or
exp social workers/ or exp therapists/) and (((chang$ or improv$) adj3 (care or patient outcome? or practice? or model?)) or incentive?
).ti. (494)
63 (((chang$ or improv$) adj3 (care or patient outcome? or practice? or model?)) or incentive?).ti. (6090)
64 chronic illness/ (7996)
65 or/6-63 [Intervetion terms] (469196)
66 limit 65 to (100 childhood <birth to age 12 yrs> or 120 neonatal <birth to age 1 mo> or 140 infancy <age 2 to 23 mo> or 160
preschool age <age 2 to 5 yrs> or 180 school age <age 6 to 12 yrs> or 200 adolescence <age 13 to 17 yrs>) [Limit not valid in PsycINFO;
records were retained] (60936)
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67 limit 65 to (”300 adulthood <age 18 yrs and older>“ or 320 young adulthood <age 18 to 29 yrs> or 340 thirties <age 30 to 39 yrs>
or 360 middle age <age 40 to 64 yrs> or ”380 aged <age 65 yrs and older>“ or ”390 very old <age 85 yrs and older>“) (219146)
68 adult?.ti,hw. or (asthma$ adj3 adult?).ab. (89638)
69 (adolescent? or baby or babies or child$ or infant? or neonate? or neo-nate? or p?ediatric$ or toddler?).ti,ab,id. (675528)
70 pediatricians/ or pediatrics/ (16025)
71 3 and 5 [Asthma & Chronic Disease] (3)
72 3 and 65 [Asthma & CDM terms] (433)
73 72 and 68 [Asthma & Adult KW] (72)
74 72 not (or/69-70) [Asthma not Child/Pediatrics] (266)
75 limit 72 to (”300 adulthood <age 18 yrs and older>“ or 320 young adulthood <age 18 to 29 yrs> or 340 thirties <age 30 to 39 yrs>
or 360 middle age <age 40 to 64 yrs> or ”380 aged <age 65 yrs and older>“ or ”390 very old <age 85 yrs and older>“) (264)
76 limit 72 to (100 childhood <birth to age 12 yrs> or 120 neonatal <birth to age 1 mo> or 140 infancy <age 2 to 23 mo> or 160
preschool age <age 2 to 5 yrs> or 180 school age <age 6 to 12 yrs> or 200 adolescence <age 13 to 17 yrs>) [Limit not valid in PsycINFO;
records were retained] (172)
77 72 not 76 (261)
78 71 or 73 or 74 or 75 or 77 (361)
79 78 not child$.ti. (324)
80 79 not p?ediatric$.ti. (310)
81 78 and (child$ and adult?).ti. (4)
82 80 or 81 (314)
83 limit 82 to yr=”2007 - 2012“ (141)
84 limit 82 to yr=”2012-2014“ (46)
Appendix 5. Cochrane Library strategy 2014
EBMReviews - Cochrane Central Register of Controlled Trials <May 2014>, EBMReviews - Cochrane Database of Systematic Reviews
<2005 to May 2014>, EBM Reviews - Database of Abstracts of Reviews of Effects <2nd Quarter 2014>
Search date: June 18, 2014
1 exp Asthma/ (8558)
2 asthma$.ti. or wheez$.ti,ab. (16581)
3 (asthma$ adj2 (chronic$ or sever$ or patient?)).ab. (5481)
4 or/1-3 [Asthma] (18899)
5 chronic disease management.ti,ab. (94)
6 (asthma adj3 (program or programs or programme or programme)).ti. (236)
7 exp Patient Care Team/ (1121)
8 (care adj2 team$).ti,ab. (487)
9 Disease management/ (404)
10 ((disease adj2 management) or (chronic adj2 management)).ti,ab. (2033)
11 Patient Care Management/ or Patient-Centered Care/ or ”Continuity of Patient Care“/ or Comprehensive Health Care/ (748)
12 comprehensive health care.ti,ab. (6)
13 (care adj2 management).ti,ab. (984)
14 (patient centred or patient centered or (continuity adj2 care)).ti,ab. (627)
15 patient care planning/ or case management/ or critical pathways/ (946)
16 ((care adj2 (algorithm? or pathway? or plan)) or CRITICAL pathway?).ti,ab. (403)
17 (((written or action) adj3 plan?) or (planning adj2 care)).ti,ab. (465)
18 ”Delivery of Health Care, Integrated“/ (155)
19 (integrat$ adj2 (care or healthcare)).ti,ab. (403)
20 ”length of stay“/ or patient readmission/ (5103)
21 (”length of stay“ or readmission?).ti. (305)
22 ((reduc$ or shorten or lower$) adj3 (hospitali?ation? or ”length of stay“ or readmiss$ or readmit$)).ab. (1562)
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23 *hospitalization/ and (management or program? or programme or programmes or model? or reduc$ or impact or intervention or
improving).ti. (0)
24 patient discharge/ and ((chronic or plan? or planning or team? or collaborat$ or intervention?).ti. or (planning or team? or collaborat$
or (chronic adj3 (disease or model?))).ab.) (225)
25 Managed Care Programs/ (198)
26 ((care or healthcare) adj3 (model? or program? or programme or programmes)).ti,ab. (2769)
27 home care services/ or home care services, hospital-based/ or home nursing/ (1556)
28 (home adj2 (service or services or care or healthcare or visit?)).ti,ab. (2221)
29 community health services/ or community health nursing/ or community networks/ or community pharmacy services/ or counseling/
(3591)
30 ((community adj3 (nursing or nurse or nurses or care or healthcare)) or community-based).ti,ab. (3947)
31 Occupational Health Services/ and ((primary adj2 care) or disease management or specialist? or chronic disease? or chronic care or
chronic condition?).ti,ab. (19)
32 (School Health Services/ not (child/ or child, preschool/ or exp infant/)) and (chronic or disease management).ti,ab. (3)
33 school health services/ and adolescent/ and (chronic or disease management).ti,ab. (5)
34 (((mobile or preventive or preventative or clinic?) adj2 (clinic? or service or services or health or health care or care or model?)) and
(chronic or disease management)).ti,ab. (1391)
35 early medical intervention/ (54)
36 exp Telemedicine/ or telenursing/ or remote consultation/ (880)
37 ((telemedicine or telehealth$ or telenurs$ or tele-medicin$ or tele-health$ or tele-nurs$ or ehealth or e-health or remote consult$)
adj10 chronic).ti,ab. or telephone.ti. (1145)
38 (PDA or hand-held? or Iphone? or ipad? or i-phone? or i-pad? or blackberry or personal digital assistant? or webbased or web-based
web2$ or computeri?ed).ti,ab. (4209)
39 Patient Education as Topic/ or health education/ or consumer health information/ or health literacy/ or health fairs/ (8363)
40 Patient Participation/ or Self care/ or Self administration/ or consumer participation/ (3730)
41 (patient? adj3 (participation or motivating)).ti,ab. (582)
42 (patient? adj3 (education$ or educating or educate?)).ti,ab. (2451)
43 (self-care or self-manag$).ti,ab. (2733)
44 education, continuing/ or education, medical, continuing/ or education, nursing, continuing/ or education, pharmacy, continuing/
or education, professional, retraining/ or exp inservice training/ (1275)
45 ((continuing adj3 education$) or (CME adj3 (program$ or session? or meeting?)) or inservice? or workshop? or professional
development).ti,ab. (1344)
46 ((physician? adj2 behavio?r?) or (upskill$ or up-skill$)).ti,ab. (8268)
47 Nurse’s Role/ or Physician’s Role/ or Professional Role/ (467)
48 ((role or roles) adj2 (chang$ or expand$ or extend$ or revision or revised or revising or nurse or nurse’s or nursing or physician?
)).ti,ab. (412)
49 medical staff/ or exp medical staff, hospital/ or exp nurses/ or exp nursing staff/ or exp pharmacists/ or exp physicians/ (2613)
50 Primary Nursing/ or Nurse Clinicians/ or Nurse Practitioners/ or Community Health Nursing/ or Physician Assistants/ (758)
51 nursing care/ or emergency nursing/ or holistic nursing/ or home nursing/ or nursing, practical/ or occupational health nursing/ or
primary nursing/ or rehabilitation nursing/ (538)
52 (nurse-led or ((nurse or nurses or nursing) adj3 (primary adj2 (care or healthcare)))).ti,ab. (688)
53 exp Allied Health Personnel/ (610)
54 (allied health or physiotherapist? or physical therapist? or exercise therap$).ti,ab. (1734)
55 (nurse clinician? or nurse practitioner? or physician? Assistant?).ti,ab. (383)
56 (”nurse-led“ or (nurse? adj2 (led or managed or coordinat$ or co-ordinat$))).ti,ab. (656)
57 respiratory therapy department, hospital/ (3)
58 physical therapy department, hospital/ (17)
59 Decision Support Systems, Clinical/ or Decision Making, Computer-Assisted/ or Medical Informatics Applications/ or Decision
Support Techniques/ or decision making, organizational/ (668)
60 (shared decision$ or decision aid? or (decision$ adj2 model$) or (decision$ adj support?) or (decision making adj2 computer$) or
informatics).ti,ab. (1151)
61 ((clinical or clinician? or doctor? or medical or nurse or nurses or nursing or patient? or physician? or practitioner?) adj3 decision
making).ti,ab. (735)
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62 ”Referral and Consultation“/ or Gatekeeping/ (1185)
63 (Referral? adj3 (chronic or decreas$ or ((general or family) adj2 (doctor? or physician? or practitioner?)) or impact or improv$ or
increas$ or intervention or plan or plans or primary care or primary health$ or program$ or reduc$ or specialist?)).ti,ab. (679)
64 Practice Guidelines as Topic/ or guidelines as topic/ or Guideline Adherence/ (1513)
65 (guideline? adj3 (implement$ or impact or adherence)).ti,ab. (728)
66 Evidence-Based Medicine/ and (change or changing or chronic or ((patient or care or disease) adj2 management) or impact or
implement$ or influence or intervention? or model? or patient care or program? or programme or programmes or strategy or strategies
or translation).ti,ab,hw. (498)
67 Interdisciplinary Communication/ or Cooperative Behavior/ (653)
68 (collaborat$ or ”cross-profession$“ or interdisciplin$ or inter-discipllin$ or intraprofession$ or intra-profession$ or interprofession$
or inter-profession$ or multidisciplin$ or multi-disciplin$ or crossdisciplin$ or cross-disciplin$ or team or teams or team-based or (skill
adj2 mix$)).ti,ab. (7984)
69 ”Outcome Assessment (Health Care)“/ (3808)
70 outcome? Assessment?.ti,ab. (630)
71 health services administration/ or ”organization and administration“/ or efficiency, organizational/ or health facility administration/
or hospital administration/ (105)
72 exp hospital restructuring/ or hospital shared services/ (7)
73 centralized hospital services/ or pharmacy service, hospital/ or diagnostic services/ (104)
74 models, organizational/ or multi-institutional systems/ or organizational culture/ or exp organizational innovation/ or organizational
objectives/ or institutional management teams/ (277)
75 (organi?ational or restructuring or (organi?ation$ adj3 (change? or changing or initiat$ or structur$ or restrict$ or model?))).ti,ab.
(1069)
76 total quality management/ or ”quality of health care“/ or quality assurance, health care/ or benchmarking/ or quality improvement/
or Management Quality Circles/ or Quality Assurance, Health Care/ or ”Quality of Health Care“/ or ”United States Agency for
Healthcare Research and Quality“/ (1373)
77 (quality adj2 (assessment? or assurance or circle? or implement$ or increase$ or improvement? or management or measure$ or
outcome? or total)).ti,ab. (7952)
78 Peer Review, Health Care/ or Peer Review/ (60)
79 Physician Incentive Plans/ or reimbursement, incentive/ [ML] (45)
80 ((physician? or practitioner? or doctor? or nurse or nurses) adj4 incentive? plan?).ti,ab. (1)
81 exp Health Personnel/ and (incentiv$ adj2 (economic or financial or monetar$ or payment? or reimburs$)).ti,ab. (16)
82 (insurance, health, reimbursement/ or reimbursement mechanisms/ or fee-for-service plans/ or ”physician payment review commis-
sion“/ or medicare payment advisory commission/ or reimbursement, disproportionate share/ or relative value scales/) and chronic.ti,ab.
(11)
83 (insurance, health, reimbursement/ or reimbursement mechanisms/ or fee-for-service plans/ or ”physician payment review commis-
sion“/ or medicare payment advisory commission/ or reimbursement, disproportionate share/ or relative value scales/) and (change or
changes or changing or chronic or effectiveness or impact or implement$ or intervention).ti,ab. (61)
84 ”fees and charges“/ or capitation fee/ or fee-for-service plans/ or fees, medical/ or fees, pharmaceutical/ or prescription fees/ or ”rate
setting and review“/ [ML] (138)
85 (gainshar$ or payer-provider? or payer-patient?).ti,ab. (7)
86 (”pay for compliance“ or ”pay for participation“ or ”pay for performance“ or ”performance pay$“ or P4P or ”pay for quality
improvement?“ or P4QI or ”fee-for service?“).ti,ab. (195)
87 (payment? adj (blend$ or ”blue cross“ or bonus$ or capped or ”episode of care“ or fixed or government$ or insurance or insurer?
or level? or linear or medicaid or medicare or non-linear or per-patient or per-episode or per-visit or performance or prospectiv$ or
retroactiv$ or retrospectiv$ or reward$ or schedule? or system? or target$ or third-part$ or threshold? or uncap$ or shared or variable
or per-visit?)).ti,ab. (71)
88 or/5-87 [Interventions] (67311)
89 adult/ or exp aged/ or middle aged/ (333136)
90 adult?.ti,hw. or (asthma$ adj3 adult?).ab. (304183)
91 or/89-90 [Adult] (388755)
92 exp child/ or adolescent/ (95058)
93 exp pediatrics/ or neonatology/ or perinatology/ (441)
94 (adolescent? or baby or babies or child$ or infant? or neonate? or neo-nate? or p?ediatric$ or toddler?).ti,ab,hw,kw. (149042)
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95 or/92-94 [Child] (149048)
96 (and/4,88) not 95 [Asthma not child/pediatrics] (755)
97 (and/4,88) and 91 [Asthma & Adult] (784)
98 or/96-97 (1121)
99 limit 98 to yr=”2007 - 2012“ [Limit not valid in DARE; records were retained] (349)
100 limit 98 to yr=”2012-2014“ [Limit not valid in DARE; records were retained] (128)
101 from 100 keep 1-108 (108) [Cochrane Central Database of Controlled Trials]
102 from 100 keep 109-118 (10) [Cochrane Database of Systematic Reviews]
103 from 100 keep 119-128 (10) [Database of Abstracts of Reviews of Effects]
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We planned in the protocol to perform subgroup analysis on the duration of the intervention and the disease severity. This was not
possible due to the lack of relevant data. We added one subgroup analysis on the presence of limited CDM components in the control
group to further explore clinical heterogeneity.
The search strategies published in the protocol were revised to improve the sensitivity of the search terms and to comply with EPOC
and Cochrane Collaboration search methodologies.
We did not include ITS studies. If this was the case, results and analyses would have been expressed and run separately from other
designs, according to guidance found on the EPOCReview Group website (EPOC-specific resources for review authors/ITS analyses).
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Disease Management; Asthma [∗therapy]; Chronic Disease; Hospitalization; Quality of Life; Randomized Controlled Trials as Topic;
Self Care [methods]
MeSH check words
Adolescent; Adult; Female; Humans; Male
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